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 Preamble
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies as they are introduced and tested in the
detection, management, or prevention of disease states. Rig-
orous and expert analysis of the available data documenting
absolute and relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve the
effectiveness of care, optimize patient outcomes, and favor-
ably affect the overall cost of care by focusing resources on
the most effective strategies.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
engaged in the production of such guidelines in the area of
cardiovascular disease since 1980. The American College of
Cardiology (ACC)/AHA Task Force on Practice Guidelines,
whose charge is to develop, update, or revise practice
guidelines for important cardiovascular diseases and proce-
dures, directs this effort. Writing committees are charged with
the task of performing an assessment of the evidence and
acting as an independent group of authors to develop, update,
or revise written recommendations for clinical practice.
Experts in the subject under consideration have been
selected from both organizations to examine subject-specific
data and write guidelines. The process includes additional
representatives from other medical practitioner and specialty
groups when appropriate. Writing committees are specifically
charged to perform a formal literature review, weigh the
strength of evidence for or against a particular treatment or
procedure, and include estimates of expected health outcomes
where data exist. Patient-specific modifiers and comorbidities
and issues of patient preference that may influence the choice
of particular tests or therapies are considered, as well as
frequency of follow-up and cost-effectiveness. When avail-
able, information from studies on cost will be considered;
however, review of data on efficacy and clinical outcomes
will constitute the primary basis for preparing recommenda-
tions in these guidelines.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual, potential, or perceived
conflicts of interest that may arise as a result of an industry
relationship or personal interest of the writing committee.
Specifically, all members of the writing committee, as well as
peer reviewers of the document, were asked to provide
disclosure statements of all such relationships that may be
perceived as real or potential conflicts of interest. Writing
committee members are also strongly encouraged to declare a
previous relationship with industry that may be perceived as
relevant to guideline development. If a writing committee
member develops a new relationship with industry during his
or her tenure, he or she is required to notify guideline staff in
writing. The continued participation of the writing committee
member will be reviewed. These statements are reviewed by
the parent task force, reported orally to all members of the
writing committee at each meeting, and updated and reviewed
by the writing committee as changes occur. Please refer to the
methodology manual for ACC/AHA guideline writing com-
mittees for further description of the relationships withindustry policy.1 See Appendix 1 for author relationships
with industry and Appendix 2 for peer reviewer relationships
with industry that are pertinent to this guideline.
These practice guidelines are intended to assist health care
providers in clinical decision making by describing a range of
generally acceptable approaches for the diagnosis, manage-
ment, and prevention of specific diseases or conditions.
Clinical decision making should consider the quality and
availability of expertise in the area where care is provided.
These guidelines attempt to define practices that meet the
needs of most patients in most circumstances. These guide-
line recommendations reflect a consensus of expert opinion
after a thorough review of the available current scientific
evidence and are intended to improve patient care.
Patient adherence to prescribed and agreed upon medical
regimens and lifestyles is an important aspect of treatment.
Prescribed courses of treatment in accordance with these
recommendations will only be effective if they are followed.
Because lack of patient understanding and adherence may
adversely affect treatment outcomes, physicians and other
health care providers should make every effort to engage the
patient in active participation with prescribed medical regi-
mens and lifestyles.
If these guidelines are used as the basis for regulatory or payer
decisions, the ultimate goal is quality of care and serving the
patient’s best interests. The ultimate judgment regarding care of
a particular patient must be made by the health care provider and
the patient in light of all of the circumstances presented by that
patient. There are circumstances in which deviations from these
guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/
AHA Task Force on Practice Guidelines and will be consid-
ered current unless they are updated, revised, or sunsetted and
withdrawn from distribution. The executive summary and
recommendations are published in the May 27, 2008, issue of
the Journal of the American College of Cardiology, May 27,
2008, issue of Circulation, and the June 2008 issue of Heart
Rhythm. The full-text guidelines are e-published in the same
issue of the journals noted above, as well as posted on the
ACC (www.acc.org), AHA (http://my.americanheart.org),
and Heart Rhythm Society (HRS) (www.hrsonline.org) Web
sites. Copies of the full-text and the executive summary are
available from each organization.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Organization of Committee
This revision of the “ACC/AHA/NASPE Guidelines for
Implantation of Cardiac Pacemakers and Antiarrhythmia
Devices” updates the previous versions published in 1984,
1991, 1998, and 2002. Revision of the statement was deemed
necessary for multiple reasons: 1) Major studies have been
reported that have advanced our knowledge of the natural
history of bradyarrhythmias and tachyarrhythmias, which
may be treated optimally with device therapy; 2) there have
been tremendous changes in the management of heart failure
that involve both drug and device therapy; and 3) major
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 advances in the technology of devices to treat, delay, and
even prevent morbidity and mortality from bradyarrhythmias,
tachyarrhythmias, and heart failure have occurred.
The committee to revise the “ACC/AHA/NASPE Guide-
lines for Implantation of Cardiac Pacemakers and Antiar-
rhythmia Devices” was composed of physicians who are
experts in the areas of device therapy and follow-up and
senior clinicians skilled in cardiovascular care, internal med-
icine, cardiovascular surgery, ethics, and socioeconomics.
The committee included representatives of the American
Association for Thoracic Surgery, Heart Failure Society of
America, and Society of Thoracic Surgeons.
1.2. Document Review and Approval
The document was reviewed by 2 official reviewers nomi-
nated by each of the ACC, AHA, and HRS and by 11
additional peer reviewers. Of the total 17 peer reviewers, 10
had no significant relevant relationships with industry. In
addition, this document has been reviewed and approved by
the governing bodies of the ACC, AHA, and HRS, which
include 19 ACC Board of Trustees members (none of whom
had any significant relevant relationships with industry), 15
AHA Science Advisory Coordinating Committee members
(none of whom had any significant relevant relationships with
industry), and 14 HRS Board of Trustees members (6 of
whom had no significant relevant relationships with industry).
All guideline recommendations underwent a formal, blinded
writing committee vote. Writing committee members were
required to recuse themselves if they had a significant
relevant relationship with industry. The guideline recommen-
dations were unanimously approved by all members of the
writing committee who were eligible to vote. The section
“Pacing in Children and Adolescents” was reviewed by
additional reviewers with special expertise in pediatric elec-
trophysiology. The committee thanks all the reviewers for
their comments. Many of their suggestions were incorporated
into the final document.
1.3. Methodology and Evidence
The recommendations listed in this document are, whenever
possible, evidence based. An extensive literature survey was
conducted that led to the incorporation of 527 references.
Searches were limited to studies, reviews, and other evidence
conducted in human subjects and published in English. Key
search words included but were not limited to antiarrhythmic,
antibradycardia, atrial fibrillation, bradyarrhythmia, cardiac,
CRT, defibrillator, device therapy, devices, dual chamber,
heart, heart failure, ICD, implantable defibrillator, device
implantation, long-QT syndrome, medical therapy, pace-
maker, pacing, quality-of-life, resynchronization, rhythm,
sinus node dysfunction, sleep apnea, sudden cardiac death,
syncope, tachyarrhythmia, terminal care, and transplantation.
Additionally, the committee reviewed documents related to
the subject matter previously published by the ACC, AHA,
and HRS. References selected and published in this document
are representative and not all-inclusive.
The committee reviewed and ranked evidence supporting
current recommendations, with the weight of evidence ranked
as Level A if the data were derived from multiple randomizedclinical trials that involved a large number of individuals. The
committee ranked available evidence as Level B when data
were derived either from a limited number of trials that
involved a comparatively small number of patients or from
well-designed data analyses of nonrandomized studies or
observational data registries. Evidence was ranked as Level C
when the consensus of experts was the primary source of the
recommendation. In the narrative portions of these guide-
lines, evidence is generally presented in chronological order
of development. Studies are identified as observational, ran-
domized, prospective, or retrospective. The committee em-
phasizes that for certain conditions for which no other therapy
is available, the indications for device therapy are based on
expert consensus and years of clinical experience and are thus
well supported, even though the evidence was ranked as
Level C. An analogous example is the use of penicillin in
pneumococcal pneumonia, for which there are no randomized
trials and only clinical experience. When indications at Level
C are supported by historical clinical data, appropriate refer-
ences (e.g., case reports and clinical reviews) are cited if
available. When Level C indications are based strictly on
committee consensus, no references are cited. In areas where
sparse data were available (e.g., pacing in children and
adolescents), a survey of current practices of major centers in
North America was conducted to determine whether there
was a consensus regarding specific pacing indications. The
schema for classification of recommendations and level of
evidence is summarized in Table 1, which also illustrates how
the grading system provides an estimate of the size of the
treatment effect and an estimate of the certainty of the
treatment effect.
The focus of these guidelines is the appropriate use of heart
pacing devices (e.g., pacemakers for bradyarrhythmias and
heart failure management, cardiac resynchronization, and
implantable cardioverter-defibrillators [ICDs]), not the treat-
ment of cardiac arrhythmias. The fact that the use of a device
for treatment of a particular condition is listed as a Class I
indication (beneficial, useful, and effective) does not preclude
the use of other therapeutic modalities that may be equally
effective. As with all clinical practice guidelines, the recom-
mendations in this document focus on treatment of an average
patient with a specific disorder and may be modified by patient
comorbidities, limitation of life expectancy because of coexist-
ing diseases, and other situations that only the primary treating
physician may evaluate appropriately.
These guidelines include sections on selection of pacemak-
ers and ICDs, optimization of technology, cost, and follow-up
of implanted devices. Although the section on follow-up is
relatively brief, its importance cannot be overemphasized:
First, optimal results from an implanted device can be
obtained only if the device is adjusted to changing clinical
conditions; second, recent advisories and recalls serve as
warnings that devices are not infallible, and failure of
electronics, batteries, and leads can occur.2,3
The committee considered including a section on extrac-
tion of failed/unused leads, a topic of current interest, but
elected not to do so in the absence of convincing evidence to
support specific criteria for timing and methods of lead
extraction. A policy statement on lead extraction from the
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 North American Society of Pacing and Electrophysiology
(now the HRS) provides information on this topic.4 Similarly,
the issue of when to discontinue long-term cardiac pacing or
defibrillator therapy has not been studied sufficiently to allow
formulation of appropriate guidelines5; however, the question
is of such importance that this topic is addressed to emphasize
the importance of patient-family-physician discussion and
ethical principles.
The text that accompanies the listed indications should be
read carefully, because it includes the rationale and support-
Table 1. Applying Classification of Recommendations and Leveling evidence for many of the indications, and in severalinstances, it includes a discussion of alternative acceptable
therapies. Many of the indications are modified by the term
“potentially reversible.” This term is used to indicate abnor-
mal pathophysiology (e.g., complete heart block) that may be
the result of reversible factors. Examples include complete
heart block due to drug toxicity (digitalis), electrolyte abnor-
malities, diseases with periatrioventricular node inflammation
(Lyme disease), and transient injury to the conduction system
at the time of open heart surgery. When faced with a
potentially reversible situation, the treating physician must
enceof Eviddecide how long of a waiting period is justified before device
Epstein et al ACC/AHA/HRS Guidelines for Device-Based Therapy e355
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 therapy is begun. The committee recognizes that this state-
ment does not address the issue of length of hospital stay
vis-à-vis managed-care regulations. It is emphasized that
these guidelines are not intended to address this issue, which
falls strictly within the purview of the treating physician.
The term “symptomatic bradycardia” is used in this docu-
ment. Symptomatic bradycardia is defined as a documented
bradyarrhythmia that is directly responsible for development
of the clinical manifestations of syncope or near syncope,
transient dizziness or lightheadedness, or confusional states
resulting from cerebral hypoperfusion attributable to slow
heart rate. Fatigue, exercise intolerance, and congestive heart
failure may also result from bradycardia. These symptoms
may occur at rest or with exertion. Definite correlation of
symptoms with a bradyarrhythmia is required to fulfill the
criteria that define symptomatic bradycardia. Caution should
be exercised not to confuse physiological sinus bradycardia
(as occurs in highly trained athletes) with pathological bra-
dyarrhythmias. Occasionally, symptoms may become appar-
ent only in retrospect after antibradycardia pacing. Neverthe-
less, the universal application of pacing therapy to treat a
specific heart rate cannot be recommended except in specific
circumstances, as detailed subsequently.
In these guidelines, the terms “persistent,” “transient,” and
“not expected to resolve” are used but not specifically defined
because the time element varies in different clinical condi-
tions. The treating physician must use appropriate clinical
judgment and available data in deciding when a condition is
persistent or when it can be expected to be transient. Section
2.1.4, “Pacing for Atrioventricular Block Associated With
Acute Myocardial Infarction,” overlaps with the “ACC/AHA
Guidelines for the Management of Patients With ST-
Elevation Myocardial Infarction”6 and includes expanded
indications and stylistic changes. The statement “incidental
finding at electrophysiological study” is used several times in
this document and does not mean that such a study is
indicated. Appropriate indications for electrophysiological
studies have been published.7
The section on indications for ICDs has been updated to
reflect the numerous new developments in this field and the
voluminous literature related to the efficacy of these devices
in the treatment and prophylaxis of sudden cardiac death
(SCD) and malignant ventricular arrhythmias. As previously
noted, indications for ICDs, cardiac resynchronization ther-
apy (CRT) devices, and combined ICDs and CRT devices
(hereafter called CRT-Ds) are continuously changing and can
be expected to change further as new trials are reported.
Indeed, it is inevitable that the indications for device therapy
will be refined with respect to both expanded use and the
identification of patients expected to benefit the most from
these therapies. Furthermore, it is emphasized that when a
patient has an indication for both a pacemaker (whether it be
single-chamber, dual-chamber, or biventricular) and an ICD,
a combined device with appropriate programming is indi-
cated.
In this document, the term “mortality” is used to indicate
all-cause mortality unless otherwise specified. The committee
elected to use all-cause mortality because of the variable
definition of sudden death and the developing consensus touse all-cause mortality as the most appropriate end point of
clinical trials.8,9
These guidelines are not designed to specify training or
credentials required for physicians to use device therapy.
Nevertheless, in view of the complexity of both the cognitive
and technical aspects of device therapy, only appropriately
trained physicians should use device therapy. Appropriate
training guidelines for physicians have been published previ-
ously.10–13
The 2008 revision reflects what the committee believes are
the most relevant and significant advances in pacemaker/ICD
therapy since the publication of these guidelines in the
Journal of the American College of Cardiology and Circula-
tion in 2002.14,15
All recommendations assume that patients are treated with
optimal medical therapy according to published guidelines, as
had been required in all the randomized controlled clinical
trials on which these guidelines are based, and that human
issues related to individual patients are addressed. The
committee believes that comorbidities, life expectancy, and
quality-of-life (QOL) issues must be addressed forthrightly
with patients and their families. We have repeatedly used the
phrase “reasonable expectation of survival with a good
functional status for more than 1 year” to emphasize this
integration of factors in decision-making. Even when physi-
cians believe that the anticipated benefits warrant device
implantation, patients have the option to decline intervention
after having been provided with a full explanation of the
potential risks and benefits of device therapy. Finally, the
committee is aware that other guideline/expert groups have
interpreted the same data differently.16–19
In preparing this revision, the committee was guided by the
following principles:
1. Changes in recommendations and levels of evidence were
made either because of new randomized trials or because
of the accumulation of new clinical evidence and the
development of clinical consensus.
2. The committee was cognizant of the health care, logistic,
and financial implications of recent trials and factored in
these considerations to arrive at the classification of
certain recommendations.
3. For recommendations taken from other guidelines, word-
ing changes were made to render some of the original
recommendations more precise.
4. The committee would like to reemphasize that the recom-
mendations in this guideline apply to most patients but
may require modification because of existing situations
that only the primary treating physician can evaluate
properly.
5. All of the listed recommendations for implantation of a
device presume the absence of inciting causes that may be
eliminated without detriment to the patient (e.g., nones-
sential drug therapy).
6. The committee endeavored to maintain consistency of
recommendations in this and other previously published
guidelines. In the section on atrioventricular (AV) block
associated with acute myocardial infarction (AMI), the
recommendations follow closely those in the “ACC/AHA
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 Guidelines for the Management of Patients With ST-
Elevation Myocardial Infarction.”6 However, because of
the rapid evolution of pacemaker/ICD science, it has not
always been possible to maintain consistency with other
published guidelines.
2. Indications for Pacing
2.1. Pacing for Bradycardia Due to Sinus and
Atrioventricular Node Dysfunction
In some patients, bradycardia is the consequence of essential
long-term drug therapy of a type and dose for which there is
no acceptable alternative. In these patients, pacing therapy is
necessary to allow maintenance of ongoing medical treat-
ment.
2.1.1. Sinus Node Dysfunction
Sinus node dysfunction (SND) was first described as a
clinical entity in 1968,20 although Wenckebach reported the
electrocardiographic (ECG) manifestation of SND in 1923.
SND refers to a broad array of abnormalities in sinus node
and atrial impulse formation and propagation. These include
persistent sinus bradycardia and chronotropic incompetence
without identifiable causes, paroxysmal or persistent sinus
arrest with replacement by subsidiary escape rhythms in the
atrium, AV junction, or ventricular myocardium. The fre-
quent association of paroxysmal atrial fibrillation (AF) and
sinus bradycardia or sinus bradyarrhythmias, which may
oscillate suddenly from one to the other, usually accompanied
by symptoms, is termed “tachy-brady syndrome.”
SND is primarily a disease of the elderly and is presumed
to be due to senescence of the sinus node and atrial muscle.
Collected data from 28 different studies on atrial pacing for
SND showed a median annual incidence of complete AV
block of 0.6% (range 0% to 4.5%) with a total prevalence of
2.1% (range 0% to 11.9%).21 This suggests that the degen-
erative process also affects the specialized conduction system,
although the rate of progression is slow and does not
dominate the clinical course of disease.21 SND is typically
diagnosed in the seventh and eighth decades of life, which is
also the average age at enrollment in clinical trials of
pacemaker therapy for SND.22,23 Identical clinical manifes-
tations may occur at any age as a secondary phenomenon of
any condition that results in destruction of sinus node cells, such
as ischemia or infarction, infiltrative disease, collagen vascular
disease, surgical trauma, endocrinologic abnormalities, auto-
nomic insufficiency, and others.24
The clinical manifestations of SND are diverse, reflecting
the range of typical sinoatrial rhythm disturbances. The most
dramatic presentation is syncope. The mechanism of syncope
is a sudden pause in sinus impulse formation or sinus exit
block, either spontaneously or after the termination of an
atrial tachyarrhythmia, that causes cerebral hypoperfusion.
The pause in sinus node activity is frequently accompanied
by an inadequate, delayed, or absent response of subsidiary
escape pacemakers in the AV junction or ventricular myo-
cardium, which aggravates the hemodynamic consequences.
However, in many patients, the clinical manifestations of
SND are more insidious and relate to an inadequate heart rateresponse to activities of daily living that can be difficult to
diagnose.25 The term “chronotropic incompetence” is used to
denote an inadequate heart rate response to physical activity.
Although many experienced clinicians claim to recognize
chronotropic incompetence in individual patients, no single
metric has been established as a diagnostic standard upon
which therapeutic decisions can be based. The most obvious
example of chronotropic incompetence is a monotonic daily
heart rate profile in an ambulatory patient. Various protocols
have been proposed to quantify subphysiological heart rate
responses to exercise,26,27 and many clinicians would con-
sider failure to achieve 80% of the maximum predicted heart
rate (220 minus age) at peak exercise as evidence of a blunted
heart rate response.28,29 However, none of these approaches
have been validated clinically, and it is likely that the
appropriate heart rate response to exercise in individual
patients is too idiosyncratic for standardized testing.
The natural history of untreated SND may be highly
variable. The majority of patients who have experienced
syncope because of a sinus pause or marked sinus bradycar-
dia will have recurrent syncope.30 Not uncommonly, the
natural history of SND is interrupted by other necessary
medical therapies that aggravate the underlying tendency to
bradycardia.24 MOST (Mode Selection Trial) included symp-
tomatic pauses greater than or equal to 3 seconds or sinus
bradycardia with rates greater than 50 bpm, which restricted
the use of indicated long-term medical therapy. Supraventric-
ular tachycardia (SVT) including AF was present in 47% and
53% of patients, respectively, enrolled in a large randomized
clinical trial of pacing mode selection in SND.22,31 The
incidence of sudden death is extremely low, and SND does
not appear to affect survival whether untreated30 or treated
with pacemaker therapy.32,33
The only effective treatment for symptomatic bradycardia
is permanent cardiac pacing. The decision to implant a
pacemaker for SND is often accompanied by uncertainty that
arises from incomplete linkage between sporadic symptoms
and ECG evidence of coexisting bradycardia. It is crucial to
distinguish between physiological bradycardia due to auto-
nomic conditions or training effects and circumstantially
inappropriate bradycardia that requires permanent cardiac
pacing. For example, sinus bradycardia is accepted as a
physiological finding that does not require cardiac pacing in
trained athletes. Such individuals may have heart rates of 40
to 50 bpm while at rest and awake and may have a sleeping
rate as slow as 30 bpm, with sinus pauses or progressive sinus
slowing accompanied by AV conduction delay (PR prolon-
gation), sometimes culminating in type I second-degree AV
block.34,35 The basis of the distinction between physiological
and pathological bradycardia, which may overlap in ECG
presentation, therefore pivots on correlation of episodic
bradycardia with symptoms compatible with cerebral hypo-
perfusion. Intermittent ECG monitoring with Holter monitors
and event recorders may be helpful,36,37 although the duration
of monitoring required to capture such evidence may be very
long.38 The use of insertable loop recorders offers the advan-
tages of compliance and convenience during very long-term
monitoring efforts.39
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 The optimal pacing system for prevention of symptomatic
bradycardia in SND is unknown. Recent evidence suggests
that ventricular desynchronization due to right ventricular
apical (RVA) pacing may have adverse effects on left
ventricular (LV) and left atrial structure and function.40–47
These adverse effects likely explain the association of RVA
pacing, independent of AV synchrony, with increased risks of
AF and heart failure in randomized clinical trials of pace-
maker therapy45,48,49 and, additionally, ventricular arrhyth-
mias and death during ICD therapy.50,51 Likewise, although
simulation of the normal sinus node response to exercise in
bradycardia patients with pacemaker sensors seems logical, a
clinical benefit on a population scale has not been demon-
strated in large randomized controlled trials of pacemaker
therapy.52 These rapidly evolving areas of clinical investiga-
tion should inform the choice of pacing system in SND (see
Section 2.6, “Selection of Pacemaker Device”).
Recommendations for Permanent Pacing in Sinus Node
Dysfunction
Class I
1. Permanent pacemaker implantation is indicated for SND
with documented symptomatic bradycardia, including fre-
quent sinus pauses that produce symptoms. (Level of
Evidence: C)53–55
2. Permanent pacemaker implantation is indicated for symp-
tomatic chronotropic incompetence. (Level of Evidence:
C)53–57
3. Permanent pacemaker implantation is indicated for symp-
tomatic sinus bradycardia that results from required drug
therapy for medical conditions. (Level of Evidence: C)
Class IIa
1. Permanent pacemaker implantation is reasonable for SND
with heart rate less than 40 bpm when a clear association
between significant symptoms consistent with bradycardia
and the actual presence of bradycardia has not been
documented. (Level of Evidence: C)53–55,58–60
2. Permanent pacemaker implantation is reasonable for syn-
cope of unexplained origin when clinically significant
abnormalities of sinus node function are discovered or
provoked in electrophysiological studies. (Level of Evi-
dence: C)61,62
Class IIb
1. Permanent pacemaker implantation may be considered in
minimally symptomatic patients with chronic heart rate less
than 40 bpm while awake. (Level of Evidence: C)53,55,56,58–60
Class III
1. Permanent pacemaker implantation is not indicated for
SND in asymptomatic patients. (Level of Evidence: C)
2. Permanent pacemaker implantation is not indicated for
SND in patients for whom the symptoms suggestive of
bradycardia have been clearly documented to occur in the
absence of bradycardia. (Level of Evidence: C)3. Permanent pacemaker implantation is not indicated for
SND with symptomatic bradycardia due to nonessential
drug therapy. (Level of Evidence: C)
2.1.2. Acquired Atrioventricular Block in Adults
AV block is classified as first-, second-, or third-degree
(complete) block; anatomically, it is defined as supra-, intra-,
or infra-His. First-degree AV block is defined as abnormal
prolongation of the PR interval (greater than 0.20 seconds).
Second-degree AV block is subclassified as type I and type II.
Type I second-degree AV block is characterized by progres-
sive prolongation of the interval between the onset of atrial (P
wave) and ventricular (R wave) conduction (PR) before a
nonconducted beat and is usually seen in conjunction with
QRS. Type I second-degree AV block is characterized by
progressive prolongation of the PR interval before a noncon-
ducted beat and a shorter PR interval after the blocked beat.
Type II second-degree AV block is characterized by fixed PR
intervals before and after blocked beats and is usually
associated with a wide QRS complex. When AV conduction
occurs in a 2:1 pattern, block cannot be classified unequivo-
cally as type I or type II, although the width of the QRS can
be suggestive, as just described. Advanced second-degree AV
block refers to the blocking of 2 or more consecutive P waves
with some conducted beats, which indicates some preserva-
tion of AV conduction. In the setting of AF, a prolonged
pause (e.g., greater than 5 seconds) should be considered to
be due to advanced second-degree AV block. Third-degree
AV block (complete heart block) is defined as absence of AV
conduction.
Patients with abnormalities of AV conduction may be
asymptomatic or may experience serious symptoms related to
bradycardia, ventricular arrhythmias, or both. Decisions re-
garding the need for a pacemaker are importantly influenced
by the presence or absence of symptoms directly attributable
to bradycardia. Furthermore, many of the indications for
pacing have evolved over the past 40 years on the basis of
experience without the benefit of comparative randomized
clinical trials, in part because no acceptable alternative
options exist to treat most bradycardias.
Nonrandomized studies strongly suggest that permanent
pacing does improve survival in patients with third-degree
AV block, especially if syncope has occurred.63–68 Although
there is little evidence to suggest that pacemakers improve
survival in patients with isolated first-degree AV block,69 it is
now recognized that marked (PR more than 300 milliseconds)
first-degree AV block can lead to symptoms even in the
absence of higher degrees of AV block.70 When marked
first-degree AV block for any reason causes atrial systole in
close proximity to the preceding ventricular systole and
produces hemodynamic consequences usually associated
with retrograde (ventriculoatrial) conduction, signs and
symptoms similar to the pacemaker syndrome may occur.71
With marked first-degree AV block, atrial contraction occurs
before complete atrial filling, ventricular filling is compro-
mised, and an increase in pulmonary capillary wedge pressure
and a decrease in cardiac output follow. Small uncontrolled
trials have suggested some symptomatic and functional im-
provement by pacing of patients with PR intervals more than
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 0.30 seconds by decreasing the time for AV conduction.70
Finally, a long PR interval may identify a subgroup of
patients with LV dysfunction, some of whom may benefit
from dual-chamber pacing with a short(er) AV delay.72 These
same principles also may be applied to patients with type I
second-degree AV block who experience hemodynamic com-
promise due to loss of AV synchrony, even without brady-
cardia. Although echocardiographic or invasive techniques
may be used to assess hemodynamic improvement before
permanent pacemaker implantation, such studies are not
required.
Type I second-degree AV block is usually due to delay in
the AV node irrespective of QRS width. Because progression
to advanced AV block in this situation is uncommon,73–75
pacing is usually not indicated unless the patient is symptom-
atic. Although controversy exists, pacemaker implantation is
supported for this finding.76–78 Type II second-degree AV
block is usually infranodal (either intra- or infra-His), espe-
cially when the QRS is wide. In these patients, symptoms are
frequent, prognosis is compromised, and progression to
third-degree AV block is common and sudden.73,75,79 Thus,
type II second-degree AV block with a wide QRS typically
indicates diffuse conduction system disease and constitutes an
indication for pacing even in the absence of symptoms.
However, it is not always possible to determine the site of AV
block without electrophysiological evaluation, because type I
second-degree AV block can be infranodal even when the
QRS is narrow.80 If type I second-degree AV block with a
narrow or wide QRS is found to be intra- or infra-Hisian at
electrophysiological study, pacing should be considered.
Because it may be difficult for both patients and their
physicians to attribute ambiguous symptoms such as fatigue
to bradycardia, special vigilance must be exercised to ac-
knowledge the patient’s concerns about symptoms that may
be caused by a slow heart rate. In a patient with third-degree
AV block, permanent pacing should be strongly considered
even when the ventricular rate is more than 40 bpm, because
the choice of a 40 bpm cutoff in these guidelines was not
determined from clinical trial data. Indeed, it is not the escape
rate that is necessarily critical for safety but rather the site of
origin of the escape rhythm (i.e., in the AV node, the His
bundle, or infra-His).
AV block can sometimes be provoked by exercise. If not
secondary to myocardial ischemia, AV block in this circum-
stance usually is due to disease in the His-Purkinje system
and is associated with a poor prognosis; thus, pacing is
indicated.81,82 Long sinus pauses and AV block can also
occur during sleep apnea. In the absence of symptoms,
these abnormalities are reversible and do not require
pacing.83 If symptoms are present, pacing is indicated as in
other conditions.
Recommendations for permanent pacemaker implantation
in patients with AV block in AMI, congenital AV block, and
AV block associated with enhanced vagal tone are discussed
in separate sections. Neurocardiogenic causes in young pa-
tients with AV block should be assessed before proceeding
with permanent pacing. Physiological AV block in the
presence of supraventricular tachyarrhythmias does not con-stitute an indication for pacemaker implantation except as
specifically defined in the recommendations that follow.
In general, the decision regarding implantation of a pace-
maker must be considered with respect to whether AV block will
be permanent. Reversible causes of AV block, such as electro-
lyte abnormalities, should be corrected first. Some diseases may
follow a natural history to resolution (e.g., Lyme disease), and
some AV block can be expected to reverse (e.g., hypervagotonia
due to recognizable and avoidable physiological factors, periop-
erative AV block due to hypothermia, or inflammation near the
AV conduction system after surgery in this region). Conversely,
some conditions may warrant pacemaker implantation because
of the possibility of disease progression even if the AV block
reverses transiently (e.g., sarcoidosis, amyloidosis, and neuro-
muscular diseases). Finally, permanent pacing for AV block
after valve surgery follows a variable natural history; therefore,
the decision for permanent pacing is at the physician’s
discretion.84
Recommendations for Acquired Atrioventricular Block
in Adults
Class I
1. Permanent pacemaker implantation is indicated for third-
degree and advanced second-degree AV block at any ana-
tomic level associated with bradycardia with symptoms
(including heart failure) or ventricular arrhythmias presumed
to be due to AV block. (Level of Evidence: C)59,63,76,85
2. Permanent pacemaker implantation is indicated for third-
degree and advanced second-degree AV block at any
anatomic level associated with arrhythmias and other
medical conditions that require drug therapy that results in
symptomatic bradycardia. (Level of Evidence: C)59,63,76,85
3. Permanent pacemaker implantation is indicated for third-
degree and advanced second-degree AV block at any
anatomic level in awake, symptom-free patients in sinus
rhythm, with documented periods of asystole greater than
or equal to 3.0 seconds86 or any escape rate less than 40
bpm, or with an escape rhythm that is below the AV node.
(Level of Evidence: C)53,58
4. Permanent pacemaker implantation is indicated for third-
degree and advanced second-degree AV block at any ana-
tomic level in awake, symptom-free patients with AF and
bradycardia with 1 or more pauses of at least 5 seconds or
longer. (Level of Evidence: C)
5. Permanent pacemaker implantation is indicated for third-
degree and advanced second-degree AV block at any ana-
tomic level after catheter ablation of the AV junction. (Level
of Evidence: C)87,88
6. Permanent pacemaker implantation is indicated for third-
degree and advanced second-degree AV block at any ana-
tomic level associated with postoperative AV block that is
not expected to resolve after cardiac surgery. (Level of
Evidence: C)84,85,89,90
7. Permanent pacemaker implantation is indicated for third-
degree and advanced second-degree AV block at any ana-
tomic level associated with neuromuscular diseases with AV
block, such as myotonic muscular dystrophy, Kearns-Sayre
syndrome, Erb dystrophy (limb-girdle muscular dystrophy),
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 and peroneal muscular atrophy, with or without symptoms.
(Level of Evidence: B)91–97
8. Permanent pacemaker implantation is indicated for
second-degree AV block with associated symptomatic
bradycardia regardless of type or site of block. (Level of
Evidence: B)74
9. Permanent pacemaker implantation is indicated for
asymptomatic persistent third-degree AV block at any
anatomic site with average awake ventricular rates of 40
bpm or faster if cardiomegaly or LV dysfunction is present
or if the site of block is below the AV node. (Level of
Evidence: B)76,78
10. Permanent pacemaker implantation is indicated for second-
or third-degree AV block during exercise in the absence of
myocardial ischemia. (Level of Evidence: C)81,82
Class IIa
1. Permanent pacemaker implantation is reasonable for persis-
tent third-degree AV block with an escape rate greater than
40 bpm in asymptomatic adult patients without cardiomeg-
aly. (Level of Evidence: C)59,63,64,76,82,85
2. Permanent pacemaker implantation is reasonable for
asymptomatic second-degree AV block at intra- or infra-
His levels found at electrophysiological study. (Level of
Evidence: B)74,76,78
3. Permanent pacemaker implantation is reasonable for first-
or second-degree AV block with symptoms similar to
those of pacemaker syndrome or hemodynamic compro-
mise. (Level of Evidence: B)70,71
4. Permanent pacemaker implantation is reasonable for
asymptomatic type II second-degree AV block with a
narrow QRS. When type II second-degree AV block
occurs with a wide QRS, including isolated right bundle-
branch block, pacing becomes a Class I recommendation.
(See Section 2.1.3, “Chronic Bifascicular Block.”) (Level
of Evidence: B)70,76,80,85
Class IIb
1. Permanent pacemaker implantation may be considered for
neuromuscular diseases such as myotonic muscular dys-
trophy, Erb dystrophy (limb-girdle muscular dystrophy),
and peroneal muscular atrophy with any degree of AV
block (including first-degree AV block), with or without
symptoms, because there may be unpredictable progres-
sion of AV conduction disease. (Level of Evidence: B)91–97
2. Permanent pacemaker implantation may be considered for
AV block in the setting of drug use and/or drug toxicity
when the block is expected to recur even after the drug is
withdrawn. (Level of Evidence: B)98,99
Class III
1. Permanent pacemaker implantation is not indicated for
asymptomatic first-degree AV block. (Level of Evidence:
B)69 (See Section 2.1.3, “Chronic Bifascicular Block.”)
2. Permanent pacemaker implantation is not indicated for
asymptomatic type I second-degree AV block at the
supra-His (AV node) level or that which is not known to
be intra- or infra-Hisian. (Level of Evidence: C)743. Permanent pacemaker implantation is not indicated for
AV block that is expected to resolve and is unlikely to
recur100 (e.g., drug toxicity, Lyme disease, or transient
increases in vagal tone or during hypoxia in sleep apnea
syndrome in the absence of symptoms). (Level of Evi-
dence: B)99,100
2.1.3. Chronic Bifascicular Block
Bifascicular block refers to ECG evidence of impaired conduc-
tion below the AV node in the right and left bundles. Alternating
bundle-branch block (also known as bilateral bundle-branch
block) refers to situations in which clear ECG evidence for block
in all 3 fascicles is manifested on successive ECGs. Examples
are right bundle-branch block and left bundle-branch block on
successive ECGs or right bundle-branch block with associated
left anterior fascicular block on 1 ECG and associated left
posterior fascicular block on another ECG. Patients with first-
degree AV block in association with bifascicular block and
symptomatic, advanced AV block have a high mortality rate and
a substantial incidence of sudden death.64,101 Although third-
degree AV block is most often preceded by bifascicular block,
there is evidence that the rate of progression of bifascicular block
to third-degree AV block is slow.102 Furthermore, no single
clinical or laboratory variable, including bifascicular block,
identifies patients at high risk of death due to a future brady-
arrhythmia caused by bundle-branch block.103
Syncope is common in patients with bifascicular block.
Although syncope may be recurrent, it is not associated with an
increased incidence of sudden death.73,102–112 Even though
pacing relieves the neurological symptoms, it does not reduce
the occurrence of sudden death.108 An electrophysiological
study may be helpful to evaluate and direct the treatment of
inducible ventricular arrhythmias113,114 that are common in
patients with bifascicular block. There is convincing evidence
that in the presence of permanent or transient third-degree AV
block, syncope is associated with an increased incidence of
sudden death regardless of the results of the electrophysiological
study.64,114,115 Finally, if the cause of syncope in the presence of
bifascicular block cannot be determined with certainty, or
if treatments used (such as drugs) may exacerbate AV
block, prophylactic permanent pacing is indicated, espe-
cially if syncope may have been due to transient third-
degree AV block.102–112,116
Of the many laboratory variables, the PR and HV intervals
have been identified as possible predictors of third-degree AV
block and sudden death. Although PR-interval prolongation is
common in patients with bifascicular block, the delay is often at
the level of the AV node. There is no correlation between the PR
and HV intervals or between the length of the PR interval,
progression to third-degree AV block, and sudden
death.107,109,116 Although most patients with chronic or intermit-
tent third-degree AV block demonstrate prolongation of the HV
interval during anterograde conduction, some investigators110,111
have suggested that asymptomatic patients with bifascicular
block and a prolonged HV interval should be considered for
permanent pacing, especially if the HV interval is greater than or
equal to 100 milliseconds.109 Although the prevalence of HV-
interval prolongation is high, the incidence of progression to
third-degree AV block is low. Because HV prolongation accom-
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 panies advanced cardiac disease and is associated with increased
mortality, death is often not sudden or due to AV block but
rather is due to the underlying heart disease itself and nonar-
rhythmic cardiac causes.102,103,108,109,111,114–117
Atrial pacing at electrophysiological study in asymptomatic
patients as a means of identifying patients at increased risk of
future high- or third-degree AV block is controversial. The
probability of inducing block distal to the AV node (i.e., intra- or
infra-His) with rapid atrial pacing is low.102,110,111,118–121 Failure
to induce distal block cannot be taken as evidence that the patient
will not develop third-degree AV block in the future. However,
if atrial pacing induces nonphysiological infra-His block, some
consider this an indication for pacing.118 Nevertheless, infra-His
block that occurs during either rapid atrial pacing or pro-
grammed stimulation at short coupling intervals may be physi-
ological and not pathological, simply reflecting disparity be-
tween refractoriness of the AV node and His-Purkinje
systems.122
Recommendations for Permanent Pacing in Chronic
Bifascicular Block
Class I
1. Permanent pacemaker implantation is indicated for ad-
vanced second-degree AV block or intermittent third-
degree AV block. (Level of Evidence: B)63–68,101
2. Permanent pacemaker implantation is indicated for type II
second-degree AV block. (Level of Evidence: B)73,75,79,123
3. Permanent pacemaker implantation is indicated for alter-
nating bundle-branch block. (Level of Evidence: C)124
Class IIa
1. Permanent pacemaker implantation is reasonable for syncope
not demonstrated to be due to AV block when other likely
causes have been excluded, specifically ventricular tachycar-
dia (VT). (Level of Evidence: B)102–111,113–119,123,125
2. Permanent pacemaker implantation is reasonable for an
incidental finding at electrophysiological study of a markedly
prolonged HV interval (greater than or equal to 100 millisec-
onds) in asymptomatic patients. (Level of Evidence: B)109
3. Permanent pacemaker implantation is reasonable for an
incidental finding at electrophysiological study of pacing-
induced infra-His block that is not physiological. (Level of
Evidence: B)118
Class IIb
1. Permanent pacemaker implantation may be considered in
the setting of neuromuscular diseases such as myotonic
muscular dystrophy, Erb dystrophy (limb-girdle muscular
dystrophy), and peroneal muscular atrophy with bifascicu-
lar block or any fascicular block, with or without symp-
toms. (Level of Evidence: C)91–97
Class III
1. Permanent pacemaker implantation is not indicated for
fascicular block without AV block or symptoms. (Level of
Evidence: B)103,107,109,1162. Permanent pacemaker implantation is not indicated for
fascicular block with first-degree AV block without symp-
toms. (Level of Evidence: B)103,107,109,116
2.1.4. Pacing for Atrioventricular Block Associated
With Acute Myocardial Infarction
Indications for permanent pacing after myocardial infarction
(MI) in patients experiencing AV block are related in large
measure to the presence of intraventricular conduction de-
fects. The criteria for patients with MI and AV block do not
necessarily depend on the presence of symptoms. Further-
more, the requirement for temporary pacing in AMI does not
by itself constitute an indication for permanent pacing (see
“ACC/AHA Guidelines for the Management of Patients With
ST-Elevation Myocardial Infarction.”6) The long-term prog-
nosis for survivors of AMI who have had AV block is related
primarily to the extent of myocardial injury and the character
of intraventricular conduction disturbances rather than the
AV block itself.66,126–130 Patients with AMI who have intra-
ventricular conduction defects, with the exception of isolated
left anterior fascicular block, have an unfavorable short- and
long-term prognosis and an increased risk of sudden
death.66,79,126,128,130 This unfavorable prognosis is not neces-
sarily due to development of high-grade AV block, although
the incidence of such block is higher in postinfarction patients
with abnormal intraventricular conduction.126,131,132
When AV or intraventricular conduction block complicates
AMI, the type of conduction disturbance, location of infarc-
tion, and relation of electrical disturbance to infarction must
be considered if permanent pacing is contemplated. Even
with data available, the decision is not always straightfor-
ward, because the reported incidence and significance of
various conduction disturbances vary widely.133 Despite the
use of thrombolytic therapy and primary angioplasty, which
have decreased the incidence of AV block in AMI, mortality
remains high if AV block occurs.130,134–137
Although more severe disturbances in conduction have
generally been associated with greater arrhythmic and non-
arrhythmic mortality,126–129,131,133 the impact of preexisting
bundle-branch block on mortality after AMI is controver-
sial.112,133 A particularly ominous prognosis is associated
with left bundle-branch block combined with advanced
second- or third-degree AV block and with right bundle-
branch block combined with left anterior or left posterior
fascicular block.105,112,127,129 Regardless of whether the in-
farction is anterior or inferior, the development of an intra-
ventricular conduction delay reflects extensive myocardial
damage rather than an electrical problem in isolation.129
Although AV block that occurs during inferior MI can be
associated with a favorable long-term clinical outcome,
in-hospital survival is impaired irrespective of temporary or
permanent pacing in this situation.134,135,138,139 Pacemakers
generally should not be implanted with inferior MI if the
peri-infarctional AV block is expected to resolve or is not
expected to negatively affect long-term prognosis.136 When
symptomatic high-degree or third-degree heart block compli-
cates inferior MI, even when the QRS is narrow, permanent
pacing may be considered if the block does not resolve. For
the patient with recent MI with a left ventricular ejection
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 fraction (LVEF) less than or equal to 35% and an indication
for permanent pacing, consideration may be given to use of
an ICD, a CRT device that provides pacing but not defibril-
lation capability (CRT-P), or a CRT device that incorporates
both pacing and defibrillation capabilities (CRT-D) when
improvement in LVEF is not anticipated.
Recommendations for Permanent Pacing After the
Acute Phase of Myocardial Infarction*
Class I
1. Permanent ventricular pacing is indicated for persistent
second-degree AV block in the His-Purkinje system with
alternating bundle-branch block or third-degree AV block
within or below the His-Purkinje system after ST-segment
elevation MI. (Level of Evidence: B)79,126–129,131
2. Permanent ventricular pacing is indicated for transient
advanced second- or third-degree infranodal AV block and
associated bundle-branch block. If the site of block is
uncertain, an electrophysiological study may be necessary.
(Level of Evidence: B)126,127
3. Permanent ventricular pacing is indicated for persistent
and symptomatic second- or third-degree AV block.
(Level of Evidence: C)
Class IIb
1. Permanent ventricular pacing may be considered for
persistent second- or third-degree AV block at the AV
node level, even in the absence of symptoms. (Level of
Evidence: B)58
Class III
1. Permanent ventricular pacing is not indicated for transient
AV block in the absence of intraventricular conduction
defects. (Level of Evidence: B)126
2. Permanent ventricular pacing is not indicated for transient
AV block in the presence of isolated left anterior fascic-
ular block. (Level of Evidence: B)128
3. Permanent ventricular pacing is not indicated for new
bundle-branch block or fascicular block in the absence of
AV block. (Level of Evidence: B)66,126
4. Permanent ventricular pacing is not indicated for persis-
tent asymptomatic first-degree AV block in the presence
of bundle-branch or fascicular block. (Level of Evidence:
B)126
2.1.5. Hypersensitive Carotid Sinus Syndrome and
Neurocardiogenic Syncope
The hypersensitive carotid sinus syndrome is defined as
syncope or presyncope resulting from an extreme reflex
response to carotid sinus stimulation. There are 2 components
of the reflex:
Cardioinhibitory, which results from increased parasympa-
thetic tone and is manifested by slowing of the sinus
*These recommendations are consistent with the “ACC/AHA Guidelines
for the Management of Patients With ST-Elevation Myocardial Infarc-
tion.”6rate or prolongation of the PR interval and advanced
AV block, alone or in combination.
Vasodepressor, which is secondary to a reduction in sympa-
thetic activity that results in loss of vascular tone and
hypotension. This effect is independent of heart rate
changes.
Before concluding that permanent pacing is clinically
indicated, the physician should determine the relative contri-
bution of the 2 components of carotid sinus stimulation to the
individual patient’s symptom complex. Hyperactive response
to carotid sinus stimulation is defined as asystole due to either
sinus arrest or AV block of more than 3 seconds, a substantial
symptomatic decrease in systolic blood pressure, or both.140
Pauses up to 3 seconds during carotid sinus massage are
considered to be within normal limits. Such heart rate and
hemodynamic responses may occur in normal subjects and
patients with coronary artery disease. The cause-and-effect
relation between the hypersensitive carotid sinus and the
patient’s symptoms must be drawn with great caution.141
Spontaneous syncope reproduced by carotid sinus stimulation
should alert the physician to the presence of this syndrome.
Minimal pressure on the carotid sinus in elderly patients may
result in marked changes in heart rate and blood pressure yet
may not be of clinical significance. Permanent pacing for
patients with an excessive cardioinhibitory response to ca-
rotid stimulation is effective in relieving symptoms.142,143
Because 10% to 20% of patients with this syndrome may
have an important vasodepressive component of their reflex
response, it is desirable that this component be defined before
one concludes that all symptoms are related to asystole alone.
Among patients whose reflex response includes both car-
dioinhibitory and vasodepressive components, attention to the
latter is essential for effective therapy in patients undergoing
pacing.
Carotid sinus hypersensitivity should be considered in
elderly patients who have had otherwise unexplained falls. In
1 study, 175 elderly patients who had fallen without loss of
consciousness and who had pauses of more than 3 seconds
during carotid sinus massage (thus fulfilling the diagnosis of
carotid sinus hypersensitivity) were randomized to pacing or
nonpacing therapy. The paced group had a significantly lower
likelihood of subsequent falling episodes during follow-up.144
Neurocardiogenic syncope and neurocardiogenic syn-
dromes refer to a variety of clinical scenarios in which
triggering of a neural reflex results in a usually self-limited
episode of systemic hypotension characterized by both bra-
dycardia and peripheral vasodilation.145,146 Neurocardiogenic
syncope accounts for an estimated 10% to 40% of syncope
episodes. Vasovagal syncope is a term used to denote one of
the most common clinical scenarios within the category of
neurocardiogenic syncopal syndromes. Patients classically
have a prodrome of nausea and diaphoresis (often absent in
the elderly), and there may be a positive family history of the
condition. Spells may be considered situational (e.g., they
may be triggered by pain, anxiety, stress, specific bodily
functions, or crowded conditions). Typically, no evidence of
structural heart disease is present. Other causes of syncope
such as LV outflow obstruction, bradyarrhythmias, and tachy-
e362 Circulation May 27, 2008
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 arrhythmias should be excluded. Head-up tilt-table testing
may be diagnostic.
The role of permanent pacing in refractory neurocardio-
genic syncope associated with significant bradycardia or
asystole remains controversial. Approximately 25% of
patients have a predominant vasodepressor reaction with-
out significant bradycardia. Many patients will have a
mixed vasodepressive/cardioinhibitory cause of their
symptoms. It has been estimated that approximately one
third of patients will have substantial bradycardia or
asystole during head-up tilt testing or during observed and
recorded spontaneous episodes of syncope. Outcomes from
clinical trials have not been consistent. Results from a
randomized controlled trial147 in highly symptomatic pa-
tients with bradycardia demonstrated that permanent pac-
ing increased the time to the first syncopal event. Another
study demonstrated that DDD (a dual-chamber pacemaker
that senses/paces in the atrium/ventricle and is inhibited/
triggered by intrinsic rhythm) pacing with a sudden bra-
dycardia response function was more effective than beta
blockade in preventing recurrent syncope in highly symp-
tomatic patients with vasovagal syncope and relative
bradycardia during tilt-table testing.148 In VPS (Vasovagal
Pacemaker Study),149 the actuarial rate of recurrent syn-
cope at 1 year was 18.5% for pacemaker patients and
59.7% for control patients. However, in VPS-II (Vasovagal
Pacemaker Study II),150 a double-blind randomized trial,
pacing therapy did not reduce the risk of recurrent synco-
pal events. In VPS-II, all patients received a permanent
pacemaker and were randomized to therapy versus no
therapy in contrast to VPS, in which patients were ran-
domized to pacemaker implantation versus no pacemaker.
On the basis of VPS-II and prevailing expert opinion,145
pacing therapy is not considered first-line therapy for most
patients with neurocardiogenic syncope. However, pacing
therapy does have a role for some patients, specifically
those with little or no prodrome before their syncopal
event, those with profound bradycardia or asystole during
a documented event, and those in whom other therapies
have failed. Dual-chamber pacing, carefully prescribed on
the basis of tilt-table test results with consideration of
alternative medical therapy, may be effective in reducing
symptoms if the patient has a significant cardioinhibitory
component to the cause of their symptoms. Although spon-
taneous or provoked prolonged pauses are a concern in this
population, the prognosis without pacing is excellent.151
The evaluation of patients with syncope of undetermined
origin should take into account clinical status and should not
overlook other, more serious causes of syncope, such as
ventricular tachyarrhythmias.
Recommendations for Permanent Pacing in
Hypersensitive Carotid Sinus Syndrome and
Neurocardiogenic Syncope
Class I
1. Permanent pacing is indicated for recurrent syncope caused
by spontaneously occurring carotid sinus stimulation andcarotid sinus pressure that induces ventricular asystole of
more than 3 seconds. (Level of Evidence: C)142,152
Class IIa
1. Permanent pacing is reasonable for syncope without clear,
provocative events and with a hypersensitive cardioinhibitory
response of 3 seconds or longer. (Level of Evidence: C)142
Class IIb
1. Permanent pacing may be considered for significantly
symptomatic neurocardiogenic syncope associated with
bradycardia documented spontaneously or at the time of
tilt-table testing. (Level of Evidence: B)147,148,150,153
Class III
1. Permanent pacing is not indicated for a hypersensitive
cardioinhibitory response to carotid sinus stimulation
without symptoms or with vague symptoms. (Level of
Evidence: C)
2. Permanent pacing is not indicated for situational vasova-
gal syncope in which avoidance behavior is effective and
preferred. (Level of Evidence: C)
2.2. Pacing for Specific Conditions
The following sections on cardiac transplantation, neuromus-
cular diseases, sleep apnea syndromes, and infiltrative and
inflammatory diseases are provided to recognize develop-
ments in these specific areas and new information that has
been obtained since publication of prior guidelines. Some of
the information has been addressed in prior sections but
herein is explored in more detail.
2.2.1. Cardiac Transplantation
The incidence of bradyarrhythmias after cardiac transplanta-
tion varies from 8% to 23%.154–156 Most bradyarrhythmias
are associated with SND and are more ominous after trans-
plantation, when the basal heart rate should be high. Signif-
icant bradyarrhythmias and asystole have been associated
with reported cases of sudden death.157 Attempts to treat the
bradycardia temporarily with measures such as theophyl-
line158 may minimize the need for pacing. To accelerate
rehabilitation, some transplant programs recommend more lib-
eral use of cardiac pacing for persistent postoperative bradycar-
dia, although approximately 50% of patients show resolution of
the bradyarrhythmia within 6 to 12 months.159–161 The role of
prophylactic pacemaker implantation is unknown for patients
who develop bradycardia and syncope in the setting of rejection,
which may be associated with localized inflammation of the
conduction system. Posttransplant patients who have irreversible
SND or AV block with previously stated Class I indications
should have permanent pacemaker implantation, as the benefits
of the atrial rate contribution to cardiac output and to chrono-
tropic competence may optimize the patient’s functional status.
When recurrent syncope develops late after transplantation,
pacemaker implantation may be considered despite repeated
negative evaluations, as sudden episodes of bradycardia are
often eventually documented and may be a sign of transplant
vasculopathy.
Epstein et al ACC/AHA/HRS Guidelines for Device-Based Therapy e363
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 Recommendations for Pacing After Cardiac
Transplantation
Class I
1. Permanent pacing is indicated for persistent inappropriate
or symptomatic bradycardia not expected to resolve and
for other Class I indications for permanent pacing. (Level
of Evidence: C)
Class IIb
1. Permanent pacing may be considered when relative bra-
dycardia is prolonged or recurrent, which limits rehabili-
tation or discharge after postoperative recovery from
cardiac transplantation. (Level of Evidence: C)
2. Permanent pacing may be considered for syncope after
cardiac transplantation even when bradyarrhythmia has
not been documented. (Level of Evidence: C)
2.2.2. Neuromuscular Diseases
Conduction system disease with progression to complete AV
block is a well-recognized complication of several neuromus-
cular disorders, including myotonic dystrophy and Emery-
Dreifuss muscular dystrophy. Supraventricular and ventricu-
lar arrhythmias may also be observed. Implantation of a
permanent pacemaker has been found useful even in asymp-
tomatic patients with an abnormal resting ECG or with HV
interval prolongation during electrophysiological study.162
Indications for pacing have been addressed in previous
sections on AV block.
2.2.3. Sleep Apnea Syndrome
A variety of heart rhythm disturbances may occur in obstruc-
tive sleep apnea. Most commonly, these include sinus brady-
cardia or pauses during hypopneic episodes. Atrial tachyar-
rhythmias may also be observed, particularly during the
arousal phase that follows the offset of apnea. A small
retrospective trial of atrial overdrive pacing in the treatment
of sleep apnea demonstrated a decrease “in episodes of
central or obstructive sleep apnea without reducing the total
sleep time.”163 Subsequent randomized clinical trials have not
validated a role for atrial overdrive pacing in obstructive
sleep apnea.164,165 Furthermore, nasal continuous positive
airway pressure therapy has been shown to be highly effective
for obstructive sleep apnea, whereas atrial overdrive pacing
has not.166,167 Whether cardiac pacing is indicated among
patients with obstructive sleep apnea and persistent episodes
of bradycardia despite nasal continuous positive airway
pressure has not been established.
Central sleep apnea and Cheyne-Stokes sleep-disordered
breathing frequently accompany systolic heart failure and are
associated with increased mortality.168 CRT has been shown
to reduce central sleep apnea and increase sleep quality in
heart failure patients with ventricular conduction delay.169
This improvement in sleep-disordered breathing may be due
to the beneficial effects of CRT on LV function and central
hemodynamics, which favorably modifies the neuroendocrine
reflex cascade in central sleep apnea.2.2.4. Cardiac Sarcoidosis
Cardiac sarcoidosis usually affects individuals aged 20 to 40
years and is associated with noncaseating granulomas with an
affinity for involvement of the AV conduction system, which
results in various degrees of AV conduction block. Myocar-
dial involvement occurs in 25% of patients with sarcoidosis,
as many as 30% of whom develop complete heart block.
Owing to the possibility of disease progression, pacemaker
implantation is recommended even if high-grade or complete
AV conduction block reverses transiently.170–172
Cardiac sarcoidosis can also be a cause of life-threatening
ventricular arrhythmias with sustained monomorphic VT due
to myocardial involvement.173–175 Sudden cardiac arrest may
be the initial manifestation of the condition, and patients may
have few if any manifestations of dysfunction in organ
systems other than the heart.173,174 Although there are no
large randomized trials or prospective registries of patients
with cardiac sarcoidosis, the available literature indicates that
cardiac sarcoidosis with heart block, ventricular arrhythmias,
or LV dysfunction is associated with a poor prognosis.
Therapy with steroids or other immunosuppressant agents
may prevent progression of the cardiac involvement. Brady-
arrhythmias warrant pacemaker therapy, but they are not
effective in preventing or treating life-threatening ventricular
arrhythmias. Sufficient clinical data are not available to
stratify risk of SCD among patients with cardiac sarcoidosis.
Accordingly, clinicians must use the available literature along
with their own clinical experience and judgment in making
management decisions regarding ICD therapy. Consideration
should be given to symptoms such as syncope, heart failure
status, LV function, and spontaneous or induced ventricular
arrhythmias at electrophysiological study to make individu-
alized decisions regarding use of the ICD for primary
prevention of SCD.
2.3. Prevention and Termination of Arrhythmias
by Pacing
Under certain circumstances, an implanted pacemaker may be
useful to treat or prevent recurrent ventricular and SVTs.176–185
Re-entrant rhythms including atrial flutter, paroxysmal re-entrant
SVT, and VT may be terminated by a variety of pacing
techniques, including programmed stimulation and short bursts
of rapid pacing.186,187 Although rarely used in contemporary
practice after tachycardia detection, these antitachyarrhythmia
devices may automatically activate a pacing sequence or re-
spond to an external instruction (e.g., application of a magnet).
Prevention of arrhythmias by pacing has been demon-
strated in certain situations. In some patients with long-QT
syndrome, recurrent pause-dependent VT may be prevented
by continuous pacing.188 A combination of pacing and beta
blockade has been reported to shorten the QT interval and
help prevent SCD.189,190 ICD therapy in combination with
overdrive suppression pacing should be considered in high-
risk patients.
Although this technique is rarely used today given the
availability of catheter ablation and antiarrhythmic drugs,
atrial synchronous ventricular pacing may prevent recur-
rences of reentrant SVT.191 Furthermore, although ventricular
ectopic activity may be suppressed by pacing in other
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 conditions, serious or symptomatic arrhythmias are rarely
prevented.192
Potential recipients of antitachyarrhythmia devices that
interrupt arrhythmias should undergo extensive testing before
implantation to ensure that the devices safely and reliably
terminate the tachyarrhythmias without accelerating the
tachycardia or causing proarrhythmia. Patients for whom an
antitachycardia pacemaker has been prescribed have usually
been unresponsive to antiarrhythmic drugs or were receiving
agents that could not control their cardiac arrhythmias. When
permanent antitachycardia pacemakers detect and interrupt
SVT, all pacing should be done in the atrium because of the
risk of ventricular pacing–induced proarrhythmia.176,193 Per-
manent antitachycardia pacing (ATP) as monotherapy for VT
is not appropriate given that ATP algorithms are available in
tiered-therapy ICDs that have the capability for cardioversion
and defibrillation in cases when ATP is ineffective or causes
acceleration of the treated tachycardia.
Recommendations for Permanent Pacemakers That
Automatically Detect and Pace to Terminate
Tachycardias
Class IIa
1. Permanent pacing is reasonable for symptomatic recurrent
SVT that is reproducibly terminated by pacing when
catheter ablation and/or drugs fail to control the arrhyth-
mia or produce intolerable side effects. (Level of Evidence:
C)177–179,181,182
Class III
1. Permanent pacing is not indicated in the presence of an
accessory pathway that has the capacity for rapid antero-
grade conduction. (Level of Evidence: C)
2.3.1. Pacing to Prevent Atrial Arrhythmias
Many patients with indications for pacemaker or ICD therapy
have atrial tachyarrhythmias that are recognized before or
after device implantation.194 Re-entrant atrial tachyarrhyth-
mias are susceptible to termination with ATP. Additionally,
some atrial tachyarrhythmias that are due to focal automatic-
ity may respond to overdrive suppression. Accordingly, some
dual-chamber pacemakers and ICDs incorporate suites of
atrial therapies that are automatically applied upon detection
of atrial tachyarrhythmias.
The efficacy of atrial ATP is difficult to measure, primarily
because atrial tachyarrhythmias tend to initiate and terminate
spontaneously with a very high frequency. With device-
classified efficacy criteria, approximately 30% to 60% of
atrial tachyarrhythmias may be terminated with atrial ATP in
patients who receive pacemakers for symptomatic bradycar-
dia.195–197 Although this has been associated with a reduction
in atrial tachyarrhythmia burden over time in selected pa-
tients,195,196 the success of this approach has not been
duplicated reliably in randomized clinical trials.197 Similar
efficacy has been demonstrated in ICD patients194,198,199
without compromising detection of VT, ventricular fibrilla-
tion (VF), or ventricular proarrhythmia.200 In either situation,
automatic atrial therapies should not be activated until theatrial lead is chronically stable, because dislodgement into the
ventricle could result in the induction of VT/VF.
2.3.2. Long-QT Syndrome
The use of cardiac pacing with beta blockade for prevention
of symptoms in patients with the congenital long-QT syn-
drome is supported by observational studies.189,201,202 The pri-
mary benefit of pacemaker therapy may be in patients with
pause-dependent initiation of ventricular tachyarrhythmias203 or
those with sinus bradycardia or advanced AV block in associa-
tion with the congenital long-QT syndrome,204,205 which is most
commonly associated with a sodium channelopathy. Benson et
al.206 discuss sinus bradycardia due to a (sodium) channelopa-
thy. Although pacemaker implantation may reduce the incidence
of symptoms in these patients, the long-term survival benefit
remains to be determined.189,201,204
Recommendations for Pacing to Prevent Tachycardia
Class I
1. Permanent pacing is indicated for sustained pause-
dependent VT, with or without QT prolongation. (Level of
Evidence: C)188,189
Class IIa
1. Permanent pacing is reasonable for high-risk patients with
congenital long-QT syndrome. (Level of Evidence:
C)188,189
Class IIb
1. Permanent pacing may be considered for prevention of
symptomatic, drug-refractory, recurrent AF in patients with
coexisting SND. (Level of Evidence: B)31,184,207
Class III
1. Permanent pacing is not indicated for frequent or complex
ventricular ectopic activity without sustained VT in the
absence of the long-QT syndrome. (Level of Evidence:
C)192
2. Permanent pacing is not indicated for torsade de pointes
VT due to reversible causes. (Level of Evidence: A)190,203
2.3.3. Atrial Fibrillation (Dual-Site, Dual-Chamber,
Alternative Pacing Sites)
In some patients with bradycardia-dependent AF, atrial pacing
may be effective in reducing the frequency of recurrences.208 In
MOST, 2010 patients with SND were randomized between
DDDR and VVIR pacing. After a mean follow-up of 33 months,
there was a 21% lower risk of AF (p0.008) in the DDDR
group than in the VVIR group.209 Other trials are under way to
assess the efficacy of atrial overdrive pacing algorithms and
algorithms that react to premature atrial complexes in preventing
AF, but data to date are sparse and inconsistent.197,210 Dual-site
right atrial pacing or alternate single-site atrial pacing from
unconventional sites (e.g., atrial septum or Bachmann’s bundle)
may offer additional benefits to single-site right atrial pacing
from the appendage in patients with symptomatic drug-
refractory AF and concomitant bradyarrhythmias; however,
results from these studies are also contradictory and inconclu-
sive.211,212 Additionally, analysis of the efficacy of pacing
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 prevention algorithms and alternative pacing sites is limited by
short-term follow-up.213 In patients with sick sinus syndrome
and intra-atrial block (P wave more than 180 milliseconds),
biatrial pacing may lower recurrence rates of AF.214
Recommendation for Pacing to Prevent Atrial
Fibrillation
Class III
1. Permanent pacing is not indicated for the prevention of AF
in patients without any other indication for pacemaker
implantation. (Level of Evidence: B)215
2.4. Pacing for Hemodynamic Indications
Although most commonly used to treat or prevent abnormal
rhythms, pacing can alter the activation sequence in the paced
chambers, influencing regional contractility and central he-
modynamics. These changes are frequently insignificant clin-
ically but can be beneficial or harmful in some conditions.
Pacing to decrease symptoms for patients with obstructive
hypertrophic cardiomyopathy (HCM) is discussed separately in
Section 2.4.2, “Obstructive Hypertrophic Cardiomyopathy.”
2.4.1. Cardiac Resynchronization Therapy
Progression of LV dysfunction to heart failure with low
LVEF is frequently accompanied by impaired electro-
mechanical coupling, which may further diminish effective
ventricular systolic function. The most common disruptions
are prolonged AV conduction (first-degree AV block) and
prolonged ventricular conduction, most commonly left
bundle-branch block. Prolonged ventricular conduction
causes regional mechanical delay within the LV that can
result in reduced ventricular systolic function with increased
metabolic costs, functional mitral regurgitation, and adverse
remodeling with increased ventricular dilatation. Prolonga-
tion of the QRS interval occurs in approximately one third of
patients with advanced heart failure216 and has been associ-
ated with ventricular electromechanical delay (“dyssyn-
chrony”) as identified by multiple sophisticated echocardio-
graphic indices. QRS duration and dyssynchrony have both
been identified as predictors of worsening heart failure, SCD,
and total mortality.217
Modification of ventricular electromechanical delay with
multisite ventricular pacing (“biventricular pacing and CRT”)
can improve ventricular systolic function with reduced meta-
bolic costs, ameliorate functional mitral regurgitation, and, in
some patients, induce favorable remodeling with reduction of
cardiac chamber dimensions.218,219 Functional improvement has
been demonstrated for exercise capacity with peak oxygen
consumption in the range of 1 to 2 milliliters per kilogram per
minute and a 50- to 70-meter increase in 6-minute walk distance,
with a 10-point or greater reduction of heart failure symptoms on
the 105-point Minnesota scale.220–222
Meta-analyses of initial clinical experiences and then
larger subsequent trials confirmed an approximately 30%
decrease in hospitalizations and, more recently, a mortality
benefit of 24% to 36%.223 Resynchronization therapy in the
COMPANION (Comparison of Medical Therapy, Pacing,
and Defibrillation in Heart Failure) trial directly comparedpacing with (CRT-D) and without (CRT-P) defibrillation
capability with optimal medical therapy.224 CRT-D reduced
mortality by 36% compared with medical therapy, but there
was insufficient evidence to conclude that CRT-P was inferior
to CRT-D. The CARE-HF (Cardiac Resynchronization in
Heart Failure) trial limited subjects to a QRS greater than 150
milliseconds (89% of patients) or QRS 120 to 150 millisec-
onds with echocardiographic evidence of dyssynchrony (11%
of patients). It was the first study to show a significant (36%)
reduction in death for resynchronization therapy unaccompa-
nied by backup defibrillation compared with optimal medical
therapy.225
In 1 clinical trial, approximately two thirds of patients who
were randomized to CRT showed a clinical response com-
pared with approximately one third of patients in the control
arm.222 It remains difficult to predict and explain the disparity
of clinical response. The prevalence of dyssynchrony has
been documented in more than 40% of patients with dilated
cardiomyopathy (DCM) and QRS greater than 120 millisec-
onds and is higher among patients with QRS greater than 150
milliseconds. The aggregate clinical experience has consis-
tently demonstrated that a significant clinical response to
CRT is greatest among patients with QRS duration greater
than 150 milliseconds, but intraventricular mechanical delay,
as identified by several echocardiographic techniques, may
exist even when the QRS duration is less than 120 millisec-
onds. No large trial has yet demonstrated clinical benefit
among patients without QRS prolongation, even when they
have been selected for echocardiographic measures of dys-
synchrony.226 The observed heterogeneity of response also
may result from factors such as suboptimal lead placement
and inexcitable areas of fibrosis in the paced segments. These
factors may contribute to the finding of worsening clinical
function in some patients after addition of LV stimulation.
Clinical trials of resynchronization almost exclusively
included patients in sinus rhythm with a left bundle-branch
pattern of prolonged ventricular conduction. Limited prospec-
tive experience among patients with permanent AF suggests
that benefit may result from biventricular pacing when the
QRS is prolonged, although it may be most evident in those
patients in whom AV nodal ablation has been performed,
such that right ventricular (RV) pacing is obligate.227,228
There is not sufficient evidence yet to provide specific
recommendations for patients with right bundle-branch block,
other conduction abnormalities, or QRS prolongation due to
frequent RVA pacing. Furthermore, there are insufficient data
to make specific recommendations regarding CRT in patients
with congenital heart disease.229 In addition, patients receiv-
ing prophylactic pacemaker-defibrillators often evolve si-
lently to dominant ventricular pacing, due both to intrinsic
chronotropic incompetence and to the aggressive uptitration of
beta-adrenergic blocking agents.
The major experience with resynchronization derives from
patients with New York Heart Association (NYHA) Class III
symptoms of heart failure and LVEF less than or equal to 35%.
Heart failure symptom status should be assessed after medical
therapy has been optimized for at least 3 months, including
titration of diuretic therapy to maintain normal volume status.
Patients with Class IV symptoms of heart failure have
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 accounted for only 10% of all patients in clinical trials of
resynchronization therapy. These patients were highly se-
lected, ambulatory outpatients who were taking oral medica-
tions and had no history of recent hospitalization.230 Al-
though a benefit has occasionally been described in patients
with more severe acute decompensation that required brief
intravenous inotropic therapy to aid diuresis, resynchroniza-
tion is not generally used as a “rescue therapy” for such
patients. Patients with dependence on intravenous inotropic
therapy, refractory fluid retention, or progressive renal dys-
function represent the highest-risk population for complica-
tions of any procedure and for early mortality after discharge,
and they are also unlikely to receive a meaningful mortality
benefit from concomitant defibrillator therapy.
Those patients with NYHA Class IV symptoms of heart
failure who derive functional benefit from resynchronization
therapy may return to Class III status, in which prevention of
sudden death becomes a relevant goal. Even among the selected
Class IV patients identified within the COMPANION trial,224
there was no difference in 2-year survival between the CRT
patients with and without backup defibrillation, although more
of the deaths in the CRT-P group were classified as sudden
deaths.230
Indications for resynchronization therapy have not been
established for patients who have marked dyssynchrony and
Class I to II symptoms of heart failure in whom device
placement is indicated for other reasons. Ongoing studies are
examining the hypothesis that early use of CRT, before the
development of Class III symptoms that limit daily activity,
may prevent or reverse remodeling caused by prolonged
ventricular conduction. However, it is not known when or
whether CRT should be considered at the time of initial ICD
implantation for patients without intrinsic QRS prolongation
even if frequent ventricular pacing is anticipated. Finally, a
randomized prospective trial by Beshai et al. did not confirm
the utility of dyssynchrony evaluation by echocardiography
to guide CRT implantation, especially when the QRS is not
prolonged.226
Optimal outcomes with CRT require effective placement of
ventricular leads, ongoing heart failure management with
neurohormonal antagonists and diuretic therapy, and, in some
cases, later reprogramming of device intervals. The pivotal
trials demonstrating the efficacy of CRT took place in centers
that provided this expertise both at implantation and during
long-term follow-up. The effectiveness of CRT in improving
clinical function and survival would be anticipated to be
reduced for patients who do not have access to these
specialized care settings.
Recommendations for Cardiac Resynchronization
Therapy in Patients With Severe Systolic Heart Failure
Class I
1. For patients who have LVEF less than or equal to 35%, a
QRS duration greater than or equal to 0.12 seconds, and sinus
rhythm, CRT with or without an ICD is indicated for the
treatment of NYHA functional Class III or ambulatory Class
IV heart failure symptoms with optimal recommended med-
ical therapy. (Level of Evidence: A)222,224,225,231Class IIa
1. For patients who have LVEF less than or equal to 35%, a
QRS duration greater than or equal to 0.12 seconds, and
AF, CRT with or without an ICD is reasonable for the
treatment of NYHA functional Class III or ambulatory
Class IV heart failure symptoms on optimal recommended
medical therapy. (Level of Evidence: B)220,231
2. For patients with LVEF less than or equal to 35% with
NYHA functional Class III or ambulatory Class IV symp-
toms who are receiving optimal recommended medical
therapy and who have frequent dependence on ventricular
pacing, CRT is reasonable. (Level of Evidence: C)231
Class IIb
1. For patients with LVEF less than or equal to 35% with
NYHA functional Class I or II symptoms who are receiv-
ing optimal recommended medical therapy and who are
undergoing implantation of a permanent pacemaker and/or
ICD with anticipated frequent ventricular pacing, CRT
may be considered. (Level of Evidence: C)231
Class III
1. CRT is not indicated for asymptomatic patients with
reduced LVEF in the absence of other indications for
pacing. (Level of Evidence: B)222,224,225,231
2. CRT is not indicated for patients whose functional status
and life expectancy are limited predominantly by chronic
noncardiac conditions. (Level of Evidence: C)231
2.4.2. Obstructive Hypertrophic Cardiomyopathy
Early nonrandomized studies demonstrated a fall in the LV
outflow gradient with dual-chamber pacing and a short AV
delay and symptomatic improvement in some patients with
obstructive HCM.232–235 One long-term study236 in 8 patients
supported the long-term benefit of dual-chamber pacing in
this group of patients. The outflow gradient was reduced even
after cessation of pacing, which suggests that some ventric-
ular remodeling had occurred as a consequence of pacing.
Two randomized trials235,237 demonstrated subjective im-
provement in approximately 50% of study participants, but
there was no correlation with gradient reduction, and a
significant placebo effect was present. A third randomized,
double-blinded trial238 failed to demonstrate any overall
improvement in QOL with pacing, although there was a
suggestion that elderly patients (more than 65 years of age)
may derive more benefit from pacing.
In a small group of patients with symptomatic, hyperten-
sive cardiac hypertrophy with cavity obliteration, VDD pac-
ing with premature excitation statistically improved exercise
capacity, cardiac reserve, and clinical symptoms.239 Dual-
chamber pacing may improve symptoms and LV outflow
gradient in pediatric patients. However, rapid atrial rates,
rapid AV conduction, and congenital mitral valve abnormalities
may preclude effective pacing in some patients.240
There are currently no data available to support the
contention that pacing alters the clinical course of the disease
or improves survival or long-term QOL in HCM. Therefore,
routine implantation of dual-chamber pacemakers should not
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 be advocated in all patients with symptomatic obstructive
HCM. Patients who may benefit the most are those with
significant gradients (more than 30 mm Hg at rest or more
than 50 mm Hg provoked).235,241–243 Complete heart block
can develop after transcoronary alcohol ablation of septal
hypertrophy in patients with HCM and should be treated with
permanent pacing.244
For the patient with obstructive HCM who is at high risk
for sudden death and who has an indication for pacemaker
implantation, consideration should be given to completion of
risk stratification of the patient for SCD and to implantation
of an ICD for primary prevention of sudden death. A single
risk marker of high risk for sudden cardiac arrest may be
sufficient to justify consideration for prophylactic ICD im-
plantation in selected patients with HCM.245
Recommendations for Pacing in Patients With
Hypertrophic Cardiomyopathy
Class I
1. Permanent pacing is indicated for SND or AV block in
patients with HCM as described previously (see Section
2.1.1, “Sinus Node Dysfunction,” and Section 2.1.2, “Ac-
quired Atrioventricular Block in Adults”). (Level of Evi-
dence: C)
Class IIb
1. Permanent pacing may be considered in medically refrac-
tory symptomatic patients with HCM and significant
resting or provoked LV outflow tract obstruction. (Level of
Evidence: A) As for Class I indications, when risk factors
for SCD are present, consider a DDD ICD (see Section 3,
“Indications for Implantable Cardioverter-Defibrillator
Therapy”).233,235,237,238,246,247
Class III
1. Permanent pacemaker implantation is not indicated for
patients who are asymptomatic or whose symptoms are
medically controlled. (Level of Evidence: C)
2. Permanent pacemaker implantation is not indicated for
symptomatic patients without evidence of LV outflow
tract obstruction. (Level of Evidence: C)
2.5. Pacing in Children, Adolescents, and Patients
With Congenital Heart Disease
The most common indications for permanent pacemaker
implantation in children, adolescents, and patients with con-
genital heart disease may be classified as 1) symptomatic
sinus bradycardia, 2) the bradycardia-tachycardia syndromes,
and 3) advanced second- or third-degree AV block, either
congenital or postsurgical. Although the general indications
for pacemaker implantation in children and adolescents (de-
fined as less than 19 years of age)248 are similar to those in
adults, there are several important considerations in young
patients. First, an increasing number of young patients are
long-term survivors of complex surgical procedures for con-
genital heart defects that result in palliation rather than
correction of circulatory physiology. The residua of impaired
ventricular function and abnormal physiology may result insymptoms due to sinus bradycardia or loss of AV synchrony
at heart rates that do not produce symptoms in individuals
with normal cardiovascular physiology.249,250 Hence, the
indications for pacemaker implantation in these patients need
to be based on the correlation of symptoms with relative
bradycardia rather than absolute heart rate criteria. Second,
the clinical significance of bradycardia is age dependent;
whereas a heart rate of 45 bpm may be a normal finding in an
adolescent, the same rate in a newborn or infant indicates
profound bradycardia. Third, significant technical challenges
may complicate device and transvenous lead implantation in
very small patients or those with abnormalities of venous or
intracardiac anatomy. Epicardial pacemaker lead implanta-
tion represents an alternative technique for these patients;
however, the risks associated with sternotomy or thoracotomy
and the somewhat higher incidence of lead failure must be
considered when epicardial pacing systems are required.251
Fourth, because there are no randomized clinical trials of
cardiac pacing in pediatric or congenital heart disease pa-
tients, the level of evidence for most recommendations is
consensus based (Level of Evidence: C). Diagnoses that
require pacing in both children and adults, such as long-QT
syndrome or neuromuscular diseases, are discussed in spe-
cific sections on these topics in this document.
Bradycardia and associated symptoms in children are often
transient (e.g., sinus arrest or paroxysmal AV block) and
difficult to document.252 Although SND (sick sinus syn-
drome) is recognized in pediatric patients and may be
associated with specific genetic channelopathies,206 it is not
itself an indication for pacemaker implantation. In the young
patient with sinus bradycardia, the primary criterion for
pacemaker implantation is the concurrent observation of a
symptom (e.g., syncope) with bradycardia (e.g., heart rate
less than 40 bpm or asystole more than 3 seconds).53,86,253 In
general, correlation of symptoms with bradycardia is deter-
mined by ambulatory ECG or an implantable loop record-
er.254 Symptomatic bradycardia is an indication for pace-
maker implantation provided that other causes have been
excluded. Alternative causes to be considered include apnea,
seizures, medication effects, and neurocardiogenic mecha-
nisms.255,256 In carefully selected cases, cardiac pacing has
been effective in the prevention of recurrent seizures and
syncope in infants with recurrent pallid breath-holding spells
associated with profound bradycardia or asystole.257
A variant of the bradycardia-tachycardia syndrome, sinus
bradycardia that alternates with intra-atrial re-entrant tachy-
cardia, is a significant problem after surgery for congenital
heart disease. Substantial morbidity and mortality have been
observed in patients with recurrent or chronic intra-atrial
re-entrant tachycardia, with the loss of sinus rhythm an
independent risk factor for the subsequent development of
this arrhythmia.258,259 Thus, both long-term atrial pacing at
physiological rates and atrial ATP have been reported as
potential treatments for sinus bradycardia and the prevention
or termination of recurrent episodes of intra-atrial re-entrant
tachycardia.260,261 The results of either mode of pacing for
this arrhythmia have been equivocal and remain a topic of
considerable controversy.262,263 In other patients, pharmaco-
logical therapy (e.g., sotalol or amiodarone) may be effective
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 in the control of intra-atrial re-entrant tachycardia but also
result in symptomatic bradycardia.264 In these patients, radio-
frequency catheter ablation of the intra-atrial re-entrant tachy-
cardia circuit should be considered as an alternative to
combined pharmacological and pacemaker therapies.265 Sur-
gical resection of atrial tissue with concomitant atrial pacing
has also been advocated for congenital heart disease patients
with intra-atrial re-entrant tachycardia refractory to other
therapies.266
The indications for permanent pacing in patients with
congenital complete AV block continue to evolve on the basis
of improved definition of the natural history of the disease
and advances in pacemaker technology and diagnostic meth-
ods. Pacemaker implantation is a Class I indication in the
symptomatic individual with congenital complete AV block
or the infant with a resting heart rate less than 55 bpm, or less
than 70 bpm when associated with structural heart dis-
ease.267,268 In the asymptomatic child or adolescent with
congenital complete AV block, several criteria (average heart
rate, pauses in the intrinsic rate, associated structural heart
disease, QT interval, and exercise tolerance) must be consid-
ered.208,269 Several studies have demonstrated that pacemaker
implantation is associated with both improved long-term
survival and prevention of syncopal episodes in asymptom-
atic patients with congenital complete AV block.270,271 How-
ever, periodic evaluation of ventricular function is required in
patients with congenital AV block after pacemaker implan-
tation, because ventricular dysfunction may occur as a con-
sequence of myocardial autoimmune disease at a young age
or pacemaker-associated dyssynchrony years or decades after
pacemaker implantation.272,273 The actual incidence of ven-
tricular dysfunction due to pacemaker-related chronic ven-
tricular dyssynchrony remains undefined.
A very poor prognosis has been established for congenital
heart disease patients with permanent postsurgical AV block
who do not receive permanent pacemakers.209 Therefore,
advanced second- or third-degree AV block that persists for
at least 7 days and that is not expected to resolve after cardiac
surgery is considered a Class I indication for pacemaker
implantation.274 Conversely, patients in whom AV conduc-
tion returns to normal generally have a favorable progno-
sis.275 Recent reports have emphasized that there is a small
but definite risk of late-onset complete AV block years or
decades after surgery for congenital heart disease in patients
with transient postoperative AV block.276,277 Limited data
suggest that residual bifascicular conduction block and pro-
gressive PR prolongation may predict late-onset AV block.278
Because of the possibility of intermittent complete AV block,
unexplained syncope is a Class IIa indication for pacing in
individuals with a history of temporary postoperative com-
plete AV block and residual bifascicular conduction block
after a careful evaluation for both cardiac and noncardiac
causes.
Additional details that need to be considered in pacemaker
implantation in young patients include risk of paradoxical
embolism due to thrombus formation on an endocardial lead
system in the presence of residual intracardiac defects and the
lifelong need for permanent cardiac pacing.279 Decisions
about pacemaker implantation must also take into account theimplantation technique (transvenous versus epicardial), with
preservation of vascular access at a young age a primary
objective.280
Recommendations for Permanent Pacing in Children,
Adolescents, and Patients With Congenital
Heart Disease
Class I
1. Permanent pacemaker implantation is indicated for ad-
vanced second- or third-degree AV block associated with
symptomatic bradycardia, ventricular dysfunction, or low
cardiac output. (Level of Evidence: C)
2. Permanent pacemaker implantation is indicated for SND
with correlation of symptoms during age-inappropriate
bradycardia. The definition of bradycardia varies with the
patient’s age and expected heart rate. (Level of Evidence:
B)53,86,253,257
3. Permanent pacemaker implantation is indicated for post-
operative advanced second- or third-degree AV block that
is not expected to resolve or that persists at least 7 days
after cardiac surgery. (Level of Evidence: B)74,209
4. Permanent pacemaker implantation is indicated for con-
genital third-degree AV block with a wide QRS escape
rhythm, complex ventricular ectopy, or ventricular dysfunc-
tion. (Level of Evidence: B)271–273
5. Permanent pacemaker implantation is indicated for con-
genital third-degree AV block in the infant with a ventric-
ular rate less than 55 bpm or with congenital heart disease
and a ventricular rate less than 70 bpm. (Level of Evi-
dence: C)267,268
Class IIa
1. Permanent pacemaker implantation is reasonable for pa-
tients with congenital heart disease and sinus bradycardia
for the prevention of recurrent episodes of intra-atrial
reentrant tachycardia; SND may be intrinsic or secondary
to antiarrhythmic treatment. (Level of Evidence:
C)260,261,264
2. Permanent pacemaker implantation is reasonable for con-
genital third-degree AV block beyond the first year of life
with an average heart rate less than 50 bpm, abrupt pauses
in ventricular rate that are 2 or 3 times the basic cycle
length, or associated with symptoms due to chronotropic
incompetence. (Level of Evidence: B)208,270
3. Permanent pacemaker implantation is reasonable for sinus
bradycardia with complex congenital heart disease with a
resting heart rate less than 40 bpm or pauses in ventricular
rate longer than 3 seconds. (Level of Evidence: C)
4. Permanent pacemaker implantation is reasonable for patients
with congenital heart disease and impaired hemodynamics
due to sinus bradycardia or loss of AV synchrony. (Level of
Evidence: C)250
5. Permanent pacemaker implantation is reasonable for un-
explained syncope in the patient with prior congenital
heart surgery complicated by transient complete heart
block with residual fascicular block after a careful evalu-
ation to exclude other causes of syncope. (Level of
Evidence: B)273,276–278
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 Class IIb
1. Permanent pacemaker implantation may be considered for
transient postoperative third-degree AV block that reverts
to sinus rhythm with residual bifascicular block. (Level of
Evidence: C)275
2. Permanent pacemaker implantation may be considered for
congenital third-degree AV block in asymptomatic chil-
dren or adolescents with an acceptable rate, a narrow QRS
complex, and normal ventricular function. (Level of Evi-
dence: B)270,271
3. Permanent pacemaker implantation may be considered for
asymptomatic sinus bradycardia after biventricular repair
of congenital heart disease with a resting heart rate less
than 40 bpm or pauses in ventricular rate longer than 3
seconds. (Level of Evidence: C)
Class III
1. Permanent pacemaker implantation is not indicated for
transient postoperative AV block with return of normal
AV conduction in the otherwise asymptomatic patient.
(Level of Evidence: B)274,275
2. Permanent pacemaker implantation is not indicated for
asymptomatic bifascicular block with or without first-
degree AV block after surgery for congenital heart disease
in the absence of prior transient complete AV block.
(Level of Evidence: C)
3. Permanent pacemaker implantation is not indicated for
asymptomatic type I second-degree AV block. (Level of
Evidence: C)
4. Permanent pacemaker implantation is not indicated for
asymptomatic sinus bradycardia with the longest relative
risk interval less than 3 seconds and a minimum heart rate
more than 40 bpm. (Level of Evidence: C)
2.6. Selection of Pacemaker Device
Once the decision has been made to implant a pacemaker in
a given patient, the clinician must decide among a large
number of available pacemaker generators and leads. Gener-
ator choices include single- versus dual-chamber versus
biventricular devices, unipolar versus bipolar pacing/sensing
configuration, presence and type of sensor for rate response,
advanced features such as automatic capture verification,
atrial therapies, size, and battery capacity. Lead choices
include diameter, polarity, type of insulation material, and
fixation mechanism (active versus passive). Other factors that
importantly influence the choice of pacemaker system com-
ponents include the capabilities of the pacemaker program-
mer, local availability of technical support, and remote
monitoring capabilities.
Even after selecting and implanting the pacing system, the
physician has a number of options for programming the
device. In modern single-chamber pacemakers, programma-
ble features include pacing mode, lower rate, pulse width and
amplitude, sensitivity, and refractory period. Dual-chamber
pacemakers have the same programmable features, as well as
maximum tracking rate, AV delay, mode-switching algo-
rithms for atrial arrhythmias, and others. Rate-responsive
pacemakers require programmable features to regulate therelation between sensor output and pacing rate and to limit
the maximum sensor-driven pacing rate. Biventricular pace-
makers require the LV pacing output to be programmed, and
often the delay between LV and RV pacing must also be
programmed. With the advent of more sophisticated pace-
maker generators, optimal programming of pacemakers has
become increasingly complex and device-specific and re-
quires specialized knowledge on the part of the physician.
Many of these considerations are beyond the scope of this
document. Later discussion focuses primarily on the choice
regarding the pacemaker prescription that has the greatest
impact on procedural time and complexity, follow-up, patient
outcome, and cost: the choice among single-chamber ventric-
ular pacing, single-chamber atrial pacing, and dual-chamber
pacing.
Table 2 summarizes the appropriateness of different pace-
makers for the most commonly encountered indications for
pacing. Figure 1 is a decision tree for selecting a pacing
system for patients with AV block. Figure 2 is a decision tree
for selecting a pacing system for patients with SND.
An important challenge for the physician in selecting a
pacemaker system for a given patient is to anticipate
progression of abnormalities of that patient’s cardiac
automaticity and conduction and then to select a system
that will best accommodate these developments. Thus, it is
reasonable to select a pacemaker with more extensive
capabilities than needed at the time of implantation but that
may prove useful in the future. Some patients with SND
and paroxysmal AF, for example, may develop AV block
in the future (as a result of natural progression of disease,
drug therapy, or catheter ablation) and may ultimately
benefit from a dual-chamber pacemaker with mode-
switching capability.
Similarly, when pacemaker implantation is indicated,
consideration should be given to implantation of a more
capable device (CRT, CRT-P, or CRT-D) if it is thought
likely that the patient will qualify for the latter within a
short time period. For example, a patient who requires a
pacemaker for heart block that occurs in the setting of MI
who also has an extremely low LVEF may be best served
by initial implantation of an ICD rather than a pacemaker.
In such cases, the advantage of avoiding a second upgrade
procedure should be balanced against the uncertainty
regarding the ultimate need for the more capable device.
2.6.1. Major Trials Comparing Atrial or Dual-
Chamber Pacing With Ventricular Pacing
Over the past decade, the principal debate with respect to
choice of pacemaker systems has concerned the relative
merits of dual-chamber pacing, single-chamber ventricular
pacing, and single-chamber atrial pacing. The physiological
rationale for atrial and dual-chamber pacing is preservation of
AV synchrony; therefore, trials comparing these modes have
often combined patients with atrial or dual-chamber pace-
makers in a single treatment arm. There have been 5 major
randomized trials comparing atrial or dual-chamber pacing
with ventricular pacing; they are summarized in Table 3. Of
the 5 studies, 2 were limited to patients paced for SND, 1 was
limited to patients paced for AV block, and 2 included
e370 Circulation May 27, 2008
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 patients paced for either indication. Only the Danish study281
included a true atrial pacing arm; among patients in the
AAI/DDD arm in CTOPP (Canadian Trial of Physiologic
Pacing), only 5.2% had an atrial pacemaker.282 A significant
Table 2. Choice of Pacemaker Generator in Selected Indications
Pacemaker Generator Sinus Node Dysfunction
Single-chamber atrial pacemaker No suspected abnormality of atrioven
conduction and not at increased r
future atrioventricular block
Maintenance of atrioventricular synch
during pacing desired
Single-chamber ventricular
pacemaker
Maintenance of atrioventricular synch
during pacing not necessary
Rate response available if desired
Dual-chamber pacemaker Atrioventricular synchrony during pac
desired
Suspected abnormality of atrioventric
conduction or increased risk for f
atrioventricular block
Rate response available if desired
Single-lead, atrial-sensing
ventricular pacemaker
Not appropriate
Figure 1. Selection of pacemaker systems for patients with atrio
indicate type of pacemaker. AV indicates atrioventricular.limitation of all of these studies is the percentage of patients
(up to 37.6%) who crossed over from 1 treatment arm to
another or otherwise dropped out of their assigned pacing
mode.
cing
Atrioventricular Block
Neurally Mediated Syncope or
Carotid Sinus Hypersensitivity
Not appropriate Not appropriate
Chronic atrial fibrillation or other
atrial tachyarrhythmia or
maintenance of atrioventricular
synchrony during pacing not
necessary
Rate response available if desired
Chronic atrial fibrillation or
other atrial tachyarrhythmia
Rate response available if
desired
Atrioventricular synchrony during
pacing desired
Atrial pacing desired
Rate response available if desired
Sinus mechanism present
Rate response available if
desired
Desire to limit the number of
pacemaker leads
Not appropriate
ular block. Decisions are illustrated by diamonds. Shaded boxesfor Pa
tricular
isk for
rony
rony
ing
ular
utureventric
node
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 An important consideration in the assessment of trials
that compare pacing modes is the percent of pacing among
the study patients. For example, a patient who is paced
only for very infrequent sinus pauses or infrequent AV
block will probably have a similar outcome with ventric-
ular pacing as with dual-chamber pacing, regardless of any
Figure 2. Selection of pacemaker systems for patients with sinus
boxes indicate type of pacemaker. AV indicates atrioventricular.
Table 3. Randomized Trials Comparing Atrium-Based Pacing Wi
Characteristics
Danish
Study281 PASE23
Pacing indication SND SND and AVB
No. of patients randomized 225 407
Mean follow-up (years) 5.5 1.5
Pacing modes AAI vs. VVI DDDR* vs. VVIR*
Atrium-based pacing superior
with respect to:
Quality of life or functional
status
NA SND patients: yes
AVB patients: no
Heart failure Yes No
Atrial fibrillation Yes No
Stroke or
thromboembolism
Yes No
Mortality Yes No
Cross-over or pacing dropout VVI to AAI/DDD: 4%
AAI to DDD: 5%
AAI to VVI: 10%
VVIR* to DDDR*: 26
R*added to pacing mode designation indicates rate-responsive pacema
rate-responsive pacemakers implanted in some patients.
AAI indicates atrial demand; AVB, atrioventricular block; CTOPP, Canadian
Pacemaker Selection in the Elderly; SND, sinus node dysfunction; UK-PACE, United Kdifferential effects between the 2 pacing configurations.
With the exception of the MOST study31 and limited data
in the UK-PACE trial (United Kingdom Pacing and Car-
diovascular Events),283 the trials included in Table 3 do not
include information about the percent of atrial or ventric-
ular pacing in the study patients.
dysfunction. Decisions are illustrated by diamonds. Shaded
ricular Pacing
CTOPP282,284,285 MOST22,31,48,49,286,287 UK-PACE283
SND and AVB SND AVB
2568 2010 2021
6.4 2.8 3
DDD/AAI vs. VVI(R) DDDR vs. VVIR* DDD(R) vs. VVI(R)
No Yes NA
No Marginal No
Yes Yes No
No No No
No No No
VI(R) dropout: 7%
DD/AAI dropout: 25%
VVIR* to DDDR*: 37.6% VVI(R) to DDD(R): 3.1%
DDD(R) dropout: 8.3%
planted in all patients. (R) added to pacing mode designation indicates
Physiologic Pacing; DDD, fully automatic; MOST, Mode Selection Trial; PASE,th Vent
% V
D
kers im
Trial of
ingdom Pacing and Cardiovascular Events; and VVI, ventricular demand.
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 2.6.2. Quality of Life and Functional Status
End Points
Numerous studies have shown significant improvement in
reported QOL and functional status after pacemaker implan-
tation,22,23,285,286 but there is also a well-documented placebo
effect after device implantation.222 This section will focus on
differences between pacing modes with respect to these
outcomes.
In the subset of patients in the PASE (Pacemaker Selection
in the Elderly) study who received implants for SND,
dual-chamber pacing was associated with greater improve-
ment than was ventricular pacing with regard to a minority of
QOL and functional status measures, but there were no such
differences among patients paced for AV block.23 In the
MOST patients, all of whom received implants for SND,
dual-chamber–paced patients had superior outcomes in some
but not all QOL and functional status measures.22,286 CTOPP,
which included patients who received implants for both SND
and AV block, failed to detect any difference between pacing
modes with respect to QOL or functional status in a subset of
269 patients who underwent this evaluation; a breakdown by
pacing indication was not reported.284
Older cross-over studies of dual-chamber versus ventricu-
lar pacing, which allowed for intrapatient comparisons be-
tween the 2 modes, indicate improved functional status and
patient preference for dual-chamber pacing. For instance,
Sulke et al.288 studied 22 patients who received dual-chamber
rate-responsive pacemakers for high-grade AV block and
found improved exercise time, functional status, and symp-
toms with DDDR compared with VVIR pacing, as well as
vastly greater patient preference for DDDR pacing.
2.6.3. Heart Failure End Points
A Danish study showed an improvement in heart failure
status among atrially-paced patients compared with ventricu-
larly paced patients, as measured by NYHA functional class
and diuretic use.281 MOST showed a marginal improvement
in a similar heart failure score with dual-chamber versus
ventricular pacing, as well as a weak association between
dual-chamber pacing and fewer heart failure hospitaliza-
tions.22 None of the other studies listed in Table 3 detected a
difference between pacing modes with respect to new-onset
heart failure, worsening of heart failure, or heart failure
hospitalization. A meta-analysis of the 5 studies listed in
Table 3 did not show a significant difference between
atrially paced- or dual-chamber–paced patients compared
with ventricularly paced patients with respect to heart
failure hospitalization.289
2.6.4. Atrial Fibrillation End Points
The Danish study, MOST, and CTOPP showed significantly
less AF among the atrially paced or dual-chamber–paced
patients than the ventricularly paced patients.22,281,282 In
MOST, the divergence in AF incidence became apparent at 6
months, whereas in CTOPP, the divergence was apparent
only at 2 years. PASE, a much smaller study, did not detect
any difference in AF between its 2 groups.23 The UK-PACE
trial did not demonstrate a significant difference in AFbetween its 2 treatment arms; however, a trend toward less
AF with dual-chamber pacing began to appear at the end of
the scheduled 3-year follow-up period.28 The meta-analysis
of the 5 studies listed in Table 3 showed a significant decrease
in AF with atrial or dual-chamber pacing compared with
ventricular pacing, with a hazard ratio (HR) of 0.80.289
2.6.5. Stroke or Thromboembolism End Points
Of the 5 studies listed in Table 3, only the Danish study
detected a difference between pacing modes with respect to
stroke or thromboembolism.281 However, the meta-analysis
of the 5 studies in Table 3 showed a decrease of borderline
statistical significance in stroke with atrial or dual-chamber
pacing compared with ventricular pacing, with an HR of
0.81.289
2.6.6. Mortality End Points
The Danish study showed significant improvement in both
overall mortality and cardiovascular mortality among the
atrially paced patients compared with the ventricularly paced
patients.281 None of the other studies showed a significant
difference between pacing modes in either overall or cardio-
vascular mortality. The meta-analysis of the 5 studies in
Table 3 did not show a significant difference between atrially
paced or dual-chamber–paced patients compared with ven-
tricularly paced patients with respect to overall mortality.289
Taken together, the evidence from the 5 studies most
strongly supports the conclusion that dual-chamber or atrial
pacing reduces the incidence of AF compared with ventric-
ular pacing in patients paced for either SND or AV block.
There may also be a benefit of dual-chamber or atrial pacing
with respect to stroke. The evidence also supports a modest
improvement in QOL and functional status with dual-
chamber pacing compared with ventricular pacing in patients
with SND. The preponderance of evidence from these trials
regarding heart failure and mortality argues against any
advantage of atrial or dual-chamber pacing for these 2 end
points.
2.6.7. Importance of Minimizing Unnecessary
Ventricular Pacing
In the past 5 years, there has been increasing recognition of
the deleterious clinical effects of RVA pacing, both in patients
with pacemakers48,49,215 and in those with ICDs.50,51,290
Among the patients in MOST with a normal native QRS
duration, the percent of ventricular pacing was correlated
with heart failure hospitalization and new onset of AF.48 It
has been speculated that the more frequent ventricular pacing
in patients randomized to DDDR pacing (90%) compared
with patients randomized to VVIR pacing (58%) may have
negated whatever positive effects may have accrued from the
AV synchrony afforded by dual-chamber pacing in this study.
A possible explanation for the striking benefits of AAI pacing
found in the Danish study281 described above is the obvious
absence of ventricular pacing in patients with single-chamber
atrial pacemakers.281
In a subsequent Danish study, patients with SND were
randomized between AAIR pacing, DDDR pacing with a
long AV delay (300 milliseconds), and DDDR pacing with a
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 short AV delay (less than or equal to 150 milliseconds).45 The
prevalence of ventricular pacing was 17% in the DDDR–
long-AV-delay patients and 90% in the DDDR–short-AV-
delay patients. At 2.9 years of follow-up, the incidence of AF
was 7.4% in the AAIR group, 17.5% in the DDDR–long-AV-
delay group, and 23.3% in the DDDR–short-AV-delay group.
There were also increases in left atrial and LV dimensions
seen in both DDDR groups but not the AAIR group. This
study supports the superiority of atrial over dual-chamber
pacing and indicates that there may be deleterious effects
from even the modest amount of ventricular pacing that
typically occurs with maximally programmed AV delays in
the DDD mode.
Patients included in studies showing deleterious effects of
RV pacing were either specified as having their RV lead
positioned at the RV apex40,43,280 or can be presumed in most
cases to have had the lead positioned there based on prevail-
ing practices of pacemaker and defibrillator implanta-
tion.45,46,277 Therefore, conclusions about deleterious effects
of RV pacing at this time should be limited to patients with
RVA pacing. Studies are currently under way that compare
the effects of pacing at alternative RV sites (septum, outflow
tract) with RVA pacing.
Despite the appeal of atrium-only pacing, there remains
concern about implanting single-chamber atrial pacemakers
in patients with SND because of the risk of subsequent AV
block. Also, in the subsequent Danish study comparing atrial
with dual-chamber pacing, the incidence of progression to
symptomatic AV block, including syncope, was 1.9% per
year, even with rigorous screening for risk of AV block at the
time of implantation.45 Programming a dual-chamber device
to the conventional DDD mode with a maximally program-
mable AV delay or with AV search hysteresis does not
eliminate frequent ventricular pacing in a significant fraction
of patients.291,292 Accordingly, several pacing algorithms that
avoid ventricular pacing except during periods of high-grade
AV block have been introduced recently.293 These new
modes dramatically decrease the prevalence of ventricular
pacing in both pacemaker and defibrillator patients.294–296 A
recent trial showed the frequency of RV pacing was 9% with
one of these new algorithms compared with 99% with
conventional dual-chamber pacing, and this decrease in RV
pacing was associated with a 40% relative reduction in the
incidence of persistent AF.296 Additional trials are under way
to assess the clinical benefits of these new pacing modes.297
2.6.8. Role of Biventricular Pacemakers
As discussed in Section 2.4.1, “Cardiac Resynchronization
Therapy,” multiple controlled trials have shown biventricular
pacing to improve both functional capacity and QOL and
decrease hospitalizations and mortality for selected patients
with Class III to IV symptoms of heart failure. Although
patients with a conventional indication for pacemaker im-
plantation were excluded from these trials, it is reasonable to
assume that patients who otherwise meet their inclusion
criteria but have QRS prolongation due to ventricular pacing
might also benefit from biventricular pacing.
Regardless of the duration of the native QRS complex,
patients with LV dysfunction who have a conventionalindication for pacing and in whom ventricular pacing is
expected to predominate may benefit from biventricular
pacing. A prospective randomized trial published in 2006
concerning patients with LV enlargement, LVEF less than or
equal to 40%, and conventional indications for pacing
showed that biventricular pacing was associated with im-
proved functional class, exercise capacity, LVEF, and serum
brain natriuretic peptide levels compared with RV pacing.298
It has also been demonstrated that LV dysfunction in the
setting of chronic RV pacing, and possibly as a result of RV
pacing, can be improved with an upgrade to biventricular
pacing.299
Among patients undergoing AV junction ablation for
chronic AF, the PAVE (Left Ventricular-Based Cardiac
Stimulation Post AV Nodal Ablation Evaluation) trial pro-
spectively randomized patients between RVA pacing and
biventricular pacing.300 The patients with RVA pacing had
deterioration in LVEF that was avoided by the patients with
biventricular pacing. The group with biventricular pacing also
had improved exercise capacity compared with the group
with right apical pacing. The advantages of biventricular
pacing were seen predominantly among patients with reduced
LVEF or heart failure at baseline. Other studies have shown
that among AF patients who experience heart failure after AV
junction ablation and RV pacing, an upgrade to biventricular
pacing results in improved symptomatology and improved
LV function.301,302
These findings raise the question of whether patients with
preserved LV function requiring ventricular pacing would
benefit from initial implantation with a biventricular device
(or one with RV pacing at a site with more synchronous
ventricular activation than at the RV apex, such as pacing at
the RV septum, the RV outflow tract,303,304 or the area of the
His bundle).305 Some patients with normal baseline LV
function experience deterioration in LVEF after chronic RV
pacing.47,306 The concern over the effects of long-term RV
pacing is naturally greatest among younger patients who
could be exposed to ventricular pacing for many decades.
Studies have suggested that chronic RVA pacing in young
patients, primarily those with congenital complete heart
block, can lead to adverse histological changes, LV dilation,
and LV dysfunction.41,306,307
There is a role for CRT-P in some patients, especially those
who wish to enhance their QOL without defibrillation
backup. Elderly patients with important comorbidities are
such individuals. Notably, there is an important survival
benefit from CRT-P alone.224,225
2.7. Optimizing Pacemaker Technology and Cost
The cost of a pacemaker system increases with its degree
of complexity and sophistication. For example, the cost of
a dual-chamber pacemaker system exceeds that of a
single-chamber system with respect to the cost of the
generator and the second lead (increased by approximately
$2500287), additional implantation time and supplies (ap-
proximately $160287), and additional follow-up costs (ap-
proximately $550287), per year. A biventricular pacemaker
entails even greater costs, with the hardware alone adding
$5000 to $10 000 to the system cost. With respect to
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 battery life, that of a dual-chamber generator is shorter
than that of a single-chamber generator287,308 and that of a
biventricular device is shorter still. There are also QOL
concerns associated with the more complex systems, in-
cluding increased device size and increased frequency of
follow-up. Against these additional costs are the potential
benefits of the more sophisticated systems with respect to
QOL, morbidity, and mortality. Furthermore, when a
single-chamber system requires upgrading to a dual-
chamber system, the costs are significant; one study
estimated the cost of such an upgrade to be $14 451.287
An analysis of MOST found that the cost-effectiveness of
dual-chamber pacemaker implantation compared with ven-
tricular pacemaker implantation287 was approximately $53
000 per quality-adjusted year of life gained over 4 years of
follow-up. Extended over the expected lifetime of a typical
patient, the calculated cost-effectiveness of dual-chamber
pacing improved to $6800 per quality-adjusted year of life
gained.
It has been estimated that 16% to 24% of pacemaker
implantations are for replacement of generators; of those,
76% are replaced because their batteries have reached their
elective replacement time.309,310 Hardware and software (i.e.,
programming) features of pacemaker systems that prolong
useful battery longevity may improve the cost-effectiveness
of pacing. Leads with steroid elution and/or high pacing
impedance allow for less current drain. Optimal programming
of output voltages, pulse widths, and AV delays can markedly
decrease battery drain; one study showed that expert pro-
gramming of pacemaker generators can have a major impact
on longevity, prolonging it by an average of 4.2 years
compared with nominal settings.311 Generators that automat-
ically determine whether a pacing impulse results in capture
allow for pacing outputs closer to threshold values than
conventional generators. Although these and other features
arguably should prolong generator life, there are other con-
straints on the useful life of a pacemaker generator, including
battery drain not directly related to pulse generation and the
limited life expectancy of many pacemaker recipients; rigor-
ous studies supporting the overall cost-effectiveness of these
advanced pacing features are lacking.
2.8. Pacemaker Follow-Up
After implantation of a pacemaker, careful follow-up and
continuity of care are required. The writing committee
considered the advisability of extending the scope of these
guidelines to include recommendations for follow-up and
device replacement but deferred this decision given other
published statements and guidelines on this topic. These are
addressed below as a matter of information; however, no
endorsement is implied. The HRS has published a series of
reports on antibradycardia pacemaker follow-up.312,313 The
Canadian Working Group in Cardiac Pacing has also pub-
lished a consensus statement on pacemaker follow-up.314 In
addition, the Centers for Medicare and Medicaid Services has
established guidelines for monitoring of patients covered by
Medicare who have antibradycardia pacemakers, although these
have not been updated for some time.315Many of the same considerations are relevant to follow-up
of pacemakers, ICDs, and CRT systems. Programming un-
dertaken at implantation should be reviewed before discharge
and changed accordingly at subsequent follow-up visits as
indicated by interrogation, testing, and patient needs. With
careful attention to programming pacing amplitude, pulse
width, and diagnostic functions, battery life can be enhanced
significantly without compromising patient safety. Taking
advantage of programmable options also allows optimization
of pacemaker function for the individual patient.
The frequency and method of follow-up are dictated by
multiple factors, including other cardiovascular or medical
problems managed by the physician involved, the age of the
pacemaker, and geographic accessibility of the patient to
medical care. Some centers may prefer to use remote moni-
toring with intermittent clinic evaluations, whereas others
may prefer to do the majority or all of the patient follow-up
in a clinic.
For many years, the only “remote” follow-up was trans-
telephonic monitoring (TTM). Available for many years,
TTM provides information regarding capture of the cham-
ber(s) being paced and battery status. TTM may also provide
the caregiver with information regarding appropriate sensing.
However, in recent years, the term “remote monitoring” has
evolved to indicate a technology that is capable of providing
a great deal of additional information. Automatic features,
such as automatic threshold assessment, have been incorpo-
rated increasingly into newer devices and facilitate follow-up
for patients who live far from follow-up clinics.316 However,
these automatic functions are not universal and need not and
cannot supplant the benefits of direct patient contact, partic-
ularly with regard to history taking and physical examination.
A more extensive clinic follow-up usually includes assess-
ment of the clinical status of the patient, battery status, pacing
threshold and pulse width, sensing function, and lead integ-
rity, as well as optimization of sensor-driven rate response
and evaluation of recorded events, such as mode switching
for AF detection and surveillance and ventricular tachyar-
rhythmia events. The schedule for clinic follow-up should be
at the discretion of the caregivers who are providing pace-
maker follow-up. As a guideline, the 1984 Health Care
Financing Administration document suggests the following:
for single-chamber pacemakers, twice in the first 6 months
after implantation and then once every 12 months; for
dual-chamber pacemakers, twice in the first 6 months, then
once every 6 months.315
Regulations regarding TTM have not been revised since
1984.315 Guidelines that truly encompass remote monitoring
of devices have not yet been endorsed by any of the major
professional societies. The Centers for Medicare and Medi-
caid Services have not provided regulations regarding the use
of this technology but have provided limited direction regard-
ing reimbursement. The Centers for Medicare and Medicaid
Services have published a statement that physicians should
use the existing current procedural terminology codes for
in-office pacemaker and ICD interrogation codes for remote
monitoring of cardiac devices.317 Clearly stated guidelines
from professional societies are necessary and should be
written in such a way as to permit remote monitoring that
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 achieves specific clinical goals. Guidelines are currently in
development given the rapid advancement in remote moni-
toring technology.
Appropriate clinical goals of remote monitoring should be
identified and guidelines developed to give caregivers the
ability to optimize the amount of clinical information that can
be derived from this technology. Appropriate clinical goals of
TTM should be divided into those pieces of information
obtainable during nonmagnet (i.e., free-running) ECG assess-
ment and assessment of the ECG tracing obtained during
magnet application. The same goals should be achieved
whether the service is being provided by a commercial or
noncommercial monitoring service.
Goals of TTM nonmagnet ECG assessment are as follows:
• Determine whether the patient displays intrinsic rhythm or
is being intermittently or continuously paced at the pro-
grammed settings.
• Characterize the patient’s underlying atrial mechanism, for
example, sinus versus AF, atrial tachycardia, etc.
• If intrinsic rhythm is displayed, determine that normal
(appropriate) sensing is present for 1 or both chambers
depending on whether it is a single- or dual-chamber
pacemaker and programmed pacing mode.
Goals of TTM ECG assessment during magnet application
are as follows:
• Verify effective capture of the appropriate chamber(s)
depending on whether it is a single- or dual-chamber
pacemaker and verify the programmed pacing mode.
• Assess magnet rate. Once magnet rate is determined, the
value should be compared with values obtained on previ-
ous transmissions to determine whether any change has
occurred. The person assessing the TTM should also be
aware of the magnet rate that represents elective replace-
ment indicators for that pacemaker.
• If the pacemaker is one in which pulse width is 1 of the
elective replacement indicators, the pulse width should
also be assessed and compared with previous values.
• If the pacemaker has some mechanism to allow transtele-
phonic assessment of threshold (i.e., Threshold Margin
Test [TMT™]) and that function is programmed “on,” the
results of this test should be demonstrated and analyzed.
• If a dual-chamber pacemaker is being assessed and magnet
application results in a change in AV interval during
magnet application, that change should be demonstrated
and verified.
2.8.1. Length of Electrocardiographic Samples
for Storage
It is important that the caregiver(s) providing TTM assess-
ment be able to refer to a paper copy or computer-archived
copy of the transtelephonic assessment for subsequent care.
The length of the ECG sample saved should be based on the
clinical information that is required (e.g., the points listed
above). It is the experience of personnel trained in TTM that
a carefully selected ECG sample of 6 to 9 seconds can
demonstrate all of the points for each of the categories listedabove (i.e., a 6- to 9-second strip of nonmagnet and 6- to
9-second strip of magnet-applied ECG tracing).
2.8.2. Frequency of Transtelephonic Monitoring
The follow-up schedule for TTM varies among centers, and
there is no absolute schedule that need be mandated. Regard-
less of the schedule to which the center may adhere, TTM
may be necessary at unscheduled times if, for example, the
patient experiences symptoms that potentially reflect an
alteration in rhythm or device function.
The majority of centers with TTM services follow the
schedule established by the Health Care Financing Adminis-
tration (now the Centers for Medicare and Medicaid Ser-
vices). In the 1984 Health Care Financing Administration
guidelines, there are 2 broad categories for follow-up (as
shown in Table 4): Guideline I, which was thought to apply
to the majority of pacemakers in use at that time, and
Guideline II, which would apply to pacemaker systems for
which sufficient long-term clinical information exists to
ensure that they meet the standards of the Inter-Society
Commission for Heart Disease Resources for longevity and
end-of-life decay. The standards to which they referred are
90% cumulative survival at 5 years after implantation and an
end-of-life decay of less than a 50% drop in output voltage
and less than a 20% deviation in magnet rate, or a drop of 5
bpm or less, over a period of 3 months or more. As of 2000,
it appears that most pacemakers would meet the specifica-
Table 4. Device Monitoring Times Postimplantation: Health
Care Financing Administration 1984 Guidelines for
Transtelephonic Monitoring
Postimplantation Milestone
Monitoring
Time
Guideline I
Single chamber
1st month Every 2 weeks
2nd to 36th month Every 8 weeks
37th month to failure Every 4 weeks
Dual chamber
1st month Every 2 weeks
2nd to 6th month Every 4 weeks
7th to 36th month Every 8 weeks
37th month to failure Every 4 weeks
Guideline II
Single chamber
1st month Every 2 weeks
2nd to 48th month Every 12 weeks
49th month to failure Every 4 weeks
Dual chamber
1st month Every 2 weeks
2nd to 30th month Every 12 weeks
31st to 48th month Every 8 weeks
49th month to failure Every 4 weeks
Modified from the U.S. Department of Health and Human Services.315 In the
public domain.tions in Guideline II.
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 Note that there is no federal or clinical mandate that these
TTM guidelines be followed. The ACC, AHA, and HRS have
not officially endorsed the Health Care Financing Adminis-
tration guidelines. Nevertheless, they may be useful as a
framework for TTM. An experienced center may choose to
do less frequent TTM and supplement it with in-clinic
evaluations as stated previously.
Goals of contemporary remote monitoring are as follows:
• Review all programmed parameters
• Review stored events (e.g., counters, histograms, and
electrograms)
• If review of programmed parameters or stored events
suggests a need for reprogramming or a change in therapy,
arrange a focused in-clinic appointment.
3. Indications for Implantable Cardioverter-
Defibrillator Therapy
Indications for ICDs have evolved considerably from initial
implantation exclusively in patients who had survived 1 or
more cardiac arrests and failed pharmacological therapy.318
Multiple clinical trials have established that ICD use results
in improved survival compared with antiarrhythmic agents
for secondary prevention of SCD.16,319–326 Large prospective,
randomized, multicenter studies have also established that
ICD therapy is effective for primary prevention of sudden
death and improves total survival in selected patient popula-
tions who have not previously had a cardiac arrest or
sustained VT.16–19,327–331
We acknowledge that the “ACC/AHA/ESC 2006 Guide-
lines for Management of Patients With Ventricular Arrhyth-
mias and the Prevention of Sudden Cardiac Death”16 used an
LVEF of less than 40% as a critical point to justify ICD
implantation for primary prevention of SCD. The LVEF used
in clinical trials assessing the ICD for primary prevention of
SCD ranged from less than or equal to 40% in MUSTT
(Multicenter Unsustained Ventricular Tachycardia Trial) to
less than or equal to 30% in MADIT II (Multicenter Auto-
matic Defibrillator Implantation Trial II).329,332 Two trials,
MADIT I (Multicenter Automatic Defibrillator Implantation
Trial I)327 and SCD-HeFT (Sudden Cardiac Death in Heart
Failure Trial),333 used LVEFs of less than or equal to 35% as
entry criteria. The present writing committee reached the
consensus that it would be best to have ICDs offered to
patients with clinical profiles as similar to those included in
the trials as possible. Having given careful consideration to
the issues related to LVEF for these updated ICD guidelines, we
have written these indications for ICDs based on the specific
inclusion criteria for LVEF in the trials. Because of this, there
may be some variation from previously published guidelines.16
We also acknowledge that the determination of LVEF
lacks a “gold standard” and that there may be variation among
the commonly used clinical techniques of LVEF determination.
All clinical methods of LVEF determination lack precision, and
the accuracy of techniques varies amongst laboratories and
institutions. Given these considerations, the present writing
committee recommends that the clinician use the LVEF deter-mination that they believe is the most clinically accurate and
appropriate in their institution.
Patient selection, device and lead implantation, follow-up,
and replacement are parts of a complex process that requires
familiarity with device capabilities, adequate case volume,
continuing education, and skill in the management of ven-
tricular arrhythmias, thus mandating appropriate training and
credentialing. Training program requirements for certification
programs in clinical cardiac electrophysiology that include
ICD implantation have been established by the American
Board of Internal Medicine and the American Osteopathic
Board of Internal Medicine. Individuals with basic certifica-
tion in pediatric cardiology and cardiac surgery may receive
similar training in ICD implantation. In 2004, requirements
for an “alternate training pathway” for those with substantial
prior experience in pacemaker implantation were proposed by
the HRS with a scheduled expiration for this alternate
pathway in 2008.11,12 Fifteen percent of physicians who
implanted ICDs in 2006 reported in the national ICD registry
that they had no formal training (electrophysiology fellow-
ship, cardiac surgical training, or completion of the alternate
pathway recommendation).11,12,334
The options for management of patients with ventricular
arrhythmias include antiarrhythmic agents, catheter ablation,
and surgery. The “ACC/AHA/ESC 2006 Guidelines for
Management of Patients With Ventricular Arrhythmias and
the Prevention of Sudden Cardiac Death” have been pub-
lished with a comprehensive review of management options,
including antiarrhythmic agents, catheter ablation, surgery,
and ICD therapy.16
3.1. Secondary Prevention of Sudden Cardiac
Death
3.1.1. Implantable Cardioverter-Defibrillator
Therapy for Secondary Prevention of Cardiac Arrest
and Sustained Ventricular Tachycardia
Secondary prevention refers to prevention of SCD in those
patients who have survived a prior sudden cardiac arrest or
sustained VT.16 Evidence from multiple randomized con-
trolled trials supports the use of ICDs for secondary preven-
tion of sudden cardiac arrest regardless of the type of
underlying structural heart disease. In patients resuscitated
from cardiac arrest, the ICD is associated with clinically and
statistically significant reductions in sudden death and total
mortality compared with antiarrhythmic drug therapy in
prospective randomized controlled trials.16,319–326
Trials of the ICD in patients who have been resuscitated
from cardiac arrest demonstrate survival benefits with ICD
therapy compared with electrophysiologically guided drug
therapy with Class I agents, sotalol, and empirical amioda-
rone therapy.320,323 A large prospective, randomized second-
ary prevention trial comparing ICD therapy with Class III
antiarrhythmic drug therapy (predominantly empirical amio-
darone) demonstrated improved survival with ICD thera-
py.319 Unadjusted survival estimates for the ICD group and
the antiarrhythmic drug group, respectively, were 89.3%
versus 82.3% at 1 year, 81.6% versus 74.7% at 2 years, and
75.4% versus 64.1% at 3 years (p0.02). Estimated relative
risk reduction with ICD therapy was 39% (95% CI 19% to
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 59%) at 1 year, 27% (95% CI 6% to 48%) at 2 years, and 31%
(95% CI 10% to 52%) at 3 years. Two other reports of large
prospective trials in similar patient groups have shown
similar results.322,323
The effectiveness of ICDs on outcomes in the recent large,
prospective secondary prevention trials—AVID (Antiar-
rhythmics Versus Implantable Defibrillators),319 CASH (Car-
diac Arrest Study Hamburg),321 and CIDS (Canadian Im-
plantable Defibrillator Study)322—were consistent with prior
investigations.320 Specifically, the ICD was associated with a
50% relative risk reduction for arrhythmic death and a 25%
relative risk reduction for all-cause mortality.324 Thus, the
secondary prevention trials have been robust and have shown
a consistent effect of improved survival with ICD therapy
compared with antiarrhythmic drug therapy across studies.324
Some individuals are resuscitated from cardiac arrest due
to possible transient reversible causes. In such patients,
myocardial revascularization may be performed when appro-
priate to reduce the risk of recurrent sudden death, with
individualized decisions made with regard to the need for
ICD therapy.16 Sustained monomorphic VT with prior MI is
unlikely to be affected by revascularization.16 Myocardial
revascularization may be sufficient therapy in patients surviv-
ing VF in association with myocardial ischemia when ven-
tricular function is normal and there is no history of an MI.16
Unless electrolyte abnormalities are proven to be the sole
cause of cardiac arrest, survivors of cardiac arrest in whom
electrolyte abnormalities are discovered in general should be
treated in a manner similar to that of cardiac arrest survivors
without electrolyte abnormalities.16 Patients who experience
sustained monomorphic VT in the presence of antiarrhythmic
drugs or electrolyte abnormalities should also be evaluated
and treated in a manner similar to patients with VT or VF
without electrolyte abnormalities or antiarrhythmic drugs.16
3.1.2. Specific Disease States and Secondary
Prevention of Cardiac Arrest or Sustained
Ventricular Tachycardia
The majority of patients included in prior prospective ran-
domized trials of patients resuscitated from cardiac arrest
have had coronary artery disease with impaired ventricular
function.320,322,323,325,326 Patients with other types of struc-
tural heart disease constitute a minority of patients in the
secondary prevention trials. However, supplemental observa-
tional and registry data support the ICD as the preferred
strategy over antiarrhythmic drug therapy for secondary
prevention for patients resuscitated from cardiac arrest due to
VT or fibrillation with coronary artery disease and other
underlying structural heart disease.
3.1.3. Coronary Artery Disease
Patients with coronary artery disease represent the majority of
patients receiving devices in prior reports of patients surviv-
ing cardiac arrest. Evidence strongly supports a survival
benefit in such patients with an ICD compared with other
therapy options.319,322,323 Between 73% and 83% of patients
enrolled in the AVID, CASH, and CIDS trials had underlying
coronary artery disease.319,321,322 The mean LVEF ranged
from 32% to 45% in these trials, which indicates prior MI inthe majority of patients.319,322,323 Multiple analyses have
supported the notion that patients with reduced LV function
may experience greater benefit with ICD therapy than with
drug therapy.320,335–338 All patients undergoing evaluation for
ICD therapy should be given optimum medical treatment for
their underlying cardiovascular condition.16
Patients experiencing cardiac arrest due to VF that occurs
more than 48 hours after an MI may be at risk for recurrent
cardiac arrest.16 It is recommended that such patients be
evaluated and optimally treated for ischemia.16 If there is
evidence that directly and clearly implicates ischemia imme-
diately preceding the onset of VF without evidence of a prior
MI, the primary therapy should be complete coronary revas-
cularization.16 If coronary revascularization is not possible
and there is evidence of significant LV dysfunction, the
primary therapy for patients resuscitated from VF should be
the ICD.16
Patients with coronary artery disease who present with
sustained monomorphic VT or VF and low-level elevations
of cardiac biomarkers of myocyte injury/necrosis should be
treated similarly to patients who have sustained VT and no
documented rise in biomarkers.16 Prolonged episodes of
sustained monomorphic VT or VF may be associated with a
rise in cardiac troponin and creatine phosphokinase levels due
to myocardial metabolic demands that exceed supply in
patients with coronary artery disease. Evaluation for ischemia
should be undertaken in such patients.16 However, when
sustained VT or VF is accompanied by modest elevations of
cardiac enzymes, it should not be assumed that a new MI was
the cause of the sustained VT.16 Without other clinical data to
support the occurrence of a new MI, it is reasonable to
consider that such patients are at risk for recurrent sustained
VT or VF.16 With these considerations in mind, these patients
should be treated for this arrhythmia in the same manner as
patients without biomarker release accompanying VT.16
3.1.4. Nonischemic Dilated Cardiomyopathy
Patients with nonischemic DCM and prior episodes of VF
or sustained VT are at high risk for recurrent cardiac arrest.
Empirical antiarrhythmic therapy or drug therapy guided
by electrophysiological testing has not been demonstrated
to improve survival in these patients. The ICD has been
shown to be superior to amiodarone for secondary preven-
tion of VT and VF in studies in which the majority of patients
had coronary artery disease,322,323,336 but the subgroups with
nonischemic DCM in these studies benefited similarly319,322,323
or more than the group with ischemic heart failure.324 On the
basis of these data, the ICD is the preferred treatment for patients
with nonischemic DCM resuscitated from prior cardiac arrest
from VF or VT.
3.1.5. Hypertrophic Cardiomyopathy
HCM is an inherited heart muscle disease that affects approx-
imately 1 of every 500 persons in the general population and
is the most common cause of cardiac arrest in individuals
younger than 40 years of age.339 HCM should be suspected as
the cause of cardiac arrest in young individuals during
exertion, because exercise increases the risk of life-
threatening ventricular arrhythmias with this condition.339
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 Sudden death may also be the first manifestation of the
disease in a previously asymptomatic individual. A history of
prior cardiac arrest indicates a substantial risk of future VT or
VF with this condition.339 Prospective randomized trials of
ICD versus pharmacological therapy for patients with prior
cardiac arrest and HCM have not been performed; however,
registry data and observational trials are available.339,340
In those patients with HCM resuscitated from prior cardiac
arrest, there is a high frequency of subsequent ICD therapy
for life-threatening ventricular arrhythmias.339 On the basis of
these data, the ICD is the preferred therapy for such patients
with HCM resuscitated from prior cardiac arrest.339,340
3.1.6. Arrhythmogenic Right Ventricular Dysplasia/
Cardiomyopathy
Arrhythmogenic RV dysplasia/cardiomyopathy (ARVD/C) is a
genetic condition characterized by fibrofatty infiltration of the
RV and less commonly the LV. It usually manifests clinically
with sustained monomorphic VT with left bundle morphol-
ogy in young individuals during exercise. There are no
prospective randomized trials of pharmacological therapy
versus ICD therapy in patients with ARVD/C for secondary
prevention of SCD; however, observational reports from
multiple centers consistently demonstrate a high frequency of
appropriate ICD use for life-threatening ventricular arrhyth-
mias and a very low rate of arrhythmic death in patients with
ARVD/C treated with an ICD.341–348
3.1.7. Genetic Arrhythmia Syndromes
Genetic syndromes that predispose to sustained VT or VF
include the long- and short-QT syndromes, Brugada syn-
drome, idiopathic VF, and catecholaminergic polymorphic
VT.338,349–356 These primary electrical conditions typically
exist in the absence of any underlying structural heart disease
and predispose to cardiac arrest. Although controversy still
exists with regard to risk factors for sudden death with these
conditions, there is consensus that those with prior cardiac
arrest or syncope are at very high risk for recurrent arrhyth-
mic events. On the basis of the absence of any clear or
consistent survival benefit of pharmacological therapy for
those individuals with these genetic arrhythmia syndromes,
the ICD is the preferred therapy for those with prior episodes
of sustained VT or VF and may also be considered for
primary prevention for some patients with a very strong
family history of early mortality (see Sections 3.2.4, “Hyper-
trophic Cardiomyopathy,” and 3.2.7, “Primary Electrical
Disease”).
3.1.8. Syncope With Inducible Sustained
Ventricular Tachycardia
Patients with syncope of undetermined origin in whom
clinically relevant VT/VF is induced at electrophysiological
study should be considered candidates for ICD therapy. In
these patients, the induced arrhythmia is presumed to be the
cause of syncope.341,357–366 In patients with hemodynami-
cally significant and symptomatic inducible sustained VT,
ICD therapy can be a primary treatment option. Appropriate
ICD therapy of VT and VF documented by stored electro-grams lends support to ICD therapy as a primary treatment for
DCM patients with syncope.341,367
3.2. Primary Prevention of Sudden Cardiac Death
Primary prevention of SCD refers to the use of ICDs in
individuals who are at risk for but have not yet had an episode
of sustained VT, VF, or resuscitated cardiac arrest. Clinical
trials have evaluated the risks and benefits of the ICD in
prevention of sudden death and have improved survival in
multiple patient populations, including those with prior MI
and heart failure due to either coronary artery disease or
nonischemic DCM. Prospective registry data are less robust
but still useful for risk stratification and recommendations for
ICD implantation in selected other patient populations, such
as those with HCM, ARVD/C, and the long-QT syndrome. In
less common conditions (e.g., Brugada syndrome, cat-
echolaminergic polymorphic VT, cardiac sarcoidosis, and LV
noncompaction), clinical reports and retrospectively analyzed
series provide less rigorous evidence in support of current
recommendations for ICD use, but this constitutes the best
available evidence for these conditions.
3.2.1. Coronary Artery Disease
There now exists a substantial body of clinical trial data that
support the use of ICDs in patients with chronic ischemic
heart disease. A variety of risk factors have been used to
identify a high-risk population for these studies. MADIT I327
and MUSTT329 required a history of MI, spontaneous non-
sustained VT, inducible VT at electrophysiological study, and
a depressed LVEF (less than or equal to 35% or less than or
equal to 40%, respectively) to enter the study. MADIT I
showed a major relative risk reduction of 54% with the ICD.
MUSTT was not specifically a trial of ICD therapy, because
it compared no therapy with electrophysiologically guided
therapy, but in the group randomized to electrophysiologi-
cally guided therapy, benefit was seen only among those who
received an ICD.
MADIT II332 enrolled 1232 patients with ischemic cardio-
myopathy and an LVEF less than or equal to 30%. No
spontaneous or induced arrhythmia was required for enroll-
ment. All-cause mortality was 20% in the control group and
14.2% in the ICD group (relative risk 31%; p0.016).
SCD-HeFT included patients with both ischemic and non-
ischemic cardiomyopathies, an LVEF less than or equal to
35%, and NYHA Class II or III congestive heart failure.333
Among the 1486 patients with ischemic heart disease ran-
domized to either placebo or ICD therapy, the 5-year event
rates were 0.432 and 0.359, respectively (HR 0.79; p0.05).
Two recent meta-analyses of these trials have supported the
overall conclusion that ICD therapy in high-risk individuals
with coronary artery disease results in a net risk reduction for
total mortality of between 20% and 30%.325,368
Two trials, however, have failed to show improved sur-
vival with ICD therapy in patients either at the time of
surgical revascularization or within 40 days of an acute MI. In
the CABG-Patch (Coronary Artery Bypass Graft-Patch) tri-
al,328 routine ICD insertion did not improve survival in
patients with coronary artery disease undergoing bypass
surgery who were believed to be at high risk of sudden death
al.
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 on the basis of an abnormal signal-averaged ECG and severe
LV dysfunction (LVEF less than or equal to 35%). Similar
data about the effects of percutaneous revascularization are
not available. In DINAMIT (Defibrillator in Acute Myocar-
dial Infarction Trial),331 674 patients with a recent MI (within
6 to 40 days), reduced LV function (LVEF less than or equal
to 35%), and impaired cardiac autonomic function (depressed
heart rate variability or elevated average heart rate) were
randomized to either ICD therapy or no ICD therapy. Al-
though arrhythmic death was reduced in the ICD group, there
was no difference in total mortality (18.7% versus 17.0%; HR
for death in the ICD group 1.08; p0.66). See Table 5 for
further information.
3.2.2. Nonischemic Dilated Cardiomyopathy
Multiple randomized prospective trials now supplement the
available observational studies that have reported on the role
of the ICD in primary prevention of SCD in patients with
nonischemic DCM.16,224,333,369 –379 Observational studies
suggest that up to 30% of deaths in patients with DCM are
sudden.380 Mortality in medically treated patients with DCM
and a prior history of syncope may exceed 30% at 2 years,
whereas those treated with an ICD experience a high fre-
quency of appropriate ICD therapy.16,372,373
CAT (Cardiomyopathy Trial) enrolled patients with re-
cently diagnosed DCM with randomization to medical ther-
apy versus medical therapy with an ICD.377 The study was
terminated before the primary end point was reached because
of a lower-than-expected incidence of all-cause mortality.377
There was no statistical probability of finding a significant
Table 5. Major Implantable Cardioverter-Defibrillator Trials for P
Trial Year
Patients
(n)
Inclusion Criterion:
LVEF % Less Than or
Equal to
MADIT I327 1996 196 35
MADIT II332 2002 1232 30
CABG-Patch328 1997 900 36
DEFINITE369 2004 485 35
DINAMIT331 2004 674 35
SCD-HeFT333 2005 1676 35
AVID319 1997 1016 40
CASH†323 2000 191 M: 4518 at baseline
CIDS322 2000 659 35
*Hazard ratios for death due to any cause in the implantable cardioverter-de
†Includes only implantable cardioverter-defibrillator and amiodarone patients
‡Upper bound of 97.5% confidence interval.
§One-tailed.
AVID indicates Antiarrhythmics Versus Implantable Defibrillators; CABG, coro
Implantable Defibrillator Study; DEFINITE, Defibrillators in Nonischemic Cardio
Trial; EP, electrophysiological study; HRV, heart rate variability; LVD, left ventric
Defibrillator Implantation Trial I; MADIT II, Multicenter Automatic Defibrillator I
cardiomyopathy; NS, not statistically significant; NSVT, nonsustained ventric
electrocardiogram; and SCD-HeFT, Sudden Cardiac Death in Heart Failure Trisurvival advantage with either strategy. With 50 patients inthe ICD arm and 54 in the control group, the study was
underpowered to find a difference in survival with ICD
therapy. At the time of 5-year follow-up, there were fewer
deaths in the ICD group than in the control group (13 versus
17, respectively).377
Another inconclusive trial was the AMIOVIRT (Amioda-
rone Versus Implantable Defibrillator in Patients with Non-
ischemic Cardiomyopathy and Asymptomatic Nonsustained
Ventricular Tachycardia) study.378 The trial randomized 103
patients with DCM, LVEF less than or equal to 35%, and
nonsustained VT to amiodarone or ICD. The study was
stopped prematurely due to statistical futility in reaching the
primary end point of reduced total mortality.378 The DEFI-
NITE (Defibrillators in Nonischemic Cardiomyopathy Treat-
ment Evaluation) trial randomized 458 patients with nonisch-
emic cardiomyopathy, NYHA Class I to III heart failure,
LVEF less than or equal to 35%, and more than 10 premature
ventricular complexes per hour or nonsustained VT to opti-
mal medical therapy with or without an ICD.369 With a
primary end point of all-cause mortality, statistical signifi-
cance was not reached, but there was a strong trend toward
reduction of mortality with ICD therapy (p0.08). After 2
years, mortality was 14.1% in the standard therapy group
versus 7.9% among those receiving an ICD, which resulted in
a 6.2% absolute reduction and a 35% relative risk reduction
with ICD implantation.369 The results were consistent and
comparable to those of other similar trials.16,333,379
SCD-HeFT compared amiodarone, ICD, and optimal med-
ical therapy in 2521 patients with coronary artery disease or
ion of Sudden Cardiac Death
Other Inclusion
Criteria
Hazard
Ratio*
95% Confidence
Interval p
SVT and positive
EP
0.46 0.26 to 0.82 0.009
rior MI 0.69 0.51 to 0.93 0.016
ositive SAECG and
CABG
1.07 0.81 to 1.42 0.64
ICM, PVCs, or NSVT 0.65 0.40 to 1.06 0.08
to 40 days after
MI and impaired
HRV
1.08 0.76 to 1.55 0.66
rior MI or NICM 0.77 0.62 to 0.96 0.007
rior cardiac arrest 0.62 0.43 to 0.82 0.02
rior cardiac arrest 0.77 1.112‡ 0.081§
rior cardiac arrest,
syncope
0.82 0.60 to 1.10 NS
r group compared with the non-implantable cardioverter-defibrillator group.
SH.
ry bypass graft surgery; CASH, Cardiac Arrest Study Hamburg; CIDS, Canadian
y Treatment Evaluation; DINAMIT, Defibrillator in Acute Myocardial Infarction
function; LVEF, left ventricular ejection fraction; MADIT I, Multicenter Automatic
tion Trial II; MI, myocardial infarction; NA, not applicable; NICM, nonischemic
hycardia; PVCs, premature ventricular complexes; SAECG, signal-averagedrevent
N
P
P
N
6
P
P
P
P
fibrillato
from CA
nary arte
myopath
ular dys
mplanta
ular tacnonischemic cardiomyopathy with NYHA functional Class II
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 or III heart failure and LVEF less than or equal to 35%.333
The amiodarone treatment group received the drug by way of
a double-blinded, placebo-controlled design.333 The median
follow-up was 45.5 months. The absolute mortality decrease
in the medical group was 7.2% after 5 years in the overall
population. The ICD group experienced a decreased risk of
death of 23% compared with the placebo group (HR 0.77,
97.5% CI 0.62 to 0.96), and total mortality in the medical
group was 7.2% per year, with a risk reduction of 23% in the
ICD group versus placebo (95% CI 0.62 to 0.96; p0.007).
Relative risk reduction was comparable for the group with
LV dysfunction due to prior MI and the nonischemic group,
but absolute mortality was lower in the nonischemic group.
This resulted in a greater number needed to treat per life
saved among ischemic patients. There was no mortality
difference between the amiodarone and placebo groups.
Further risk stratification may decrease the number of indi-
viduals needed to undergo ICD implantation to save a life in
this population.
With the exception of DEFINITE (25% in the ICD arm),
trials assessing ICD therapy in primary prophylaxis of DCM
have not generally included asymptomatic patients in NYHA
functional Class I; therefore, the efficacy of ICDs in this
population is not fully known. Because mortality may be low
in this subgroup, the benefit of ICD therapy is moderate at
best.369
The COMPANION trial randomized patients with Class III
or IV heart failure, ischemic or nonischemic DCM, and QRS
duration greater than 120 milliseconds in a 1:2:2 ratio to
receive optimal pharmacological therapy alone or in combi-
nation with CRT with either a pacemaker or a pacemaker-
defibrillator.224 Of the 1520 patients randomized in the trial,
903 were allocated to either the medical therapy or defibril-
lator arms; of this subset, 397 (44%) had DCM. Cardiac
resynchronization with an ICD significantly reduced all-cause
mortality compared with pharmacological therapy alone in
patients with DCM (HR for all-cause death 0.50, 95% CI 0.29
to 0.88; p0.015).224
Two studies have evaluated the time dependence of risk for
sudden death relative to the time of diagnosis of nonischemic
DCM.369,381 An analysis of the DEFINITE study demon-
strated that those who have a recent cardiomyopathy diagno-
sis do not benefit less from use of an ICD than those with a
remote diagnosis.369 On the basis of these data, ICD therapy
should be considered in such patients provided that a revers-
ible cause of transient LV function has been excluded and
their response to optimal medical therapy has been assessed.
The optimal time required for this assessment is uncertain;
however, another analysis determined that patients with
nonischemic DCM experienced equivalent occurrences of
treated and potentially lethal arrhythmias irrespective of
diagnosis duration.381 These findings suggest that use of a
time qualifier relative to the time since diagnosis of a
nonischemic DCM may not reliably discriminate patients at
high risk for SCD in this selected population.381 Given these
considerations, physicians should consider the timing of
defibrillator implantation carefully.3.2.3. Long-QT Syndrome
The long-QT syndromes represent a complex spectrum of
electrophysiological disorders characterized by a propensity
for development of malignant ventricular arrhythmias, espe-
cially polymorphic VT.382,383 Because this is a primary
electrical disorder, with most patients having no evidence of
structural heart disease or LV dysfunction, the long-term
prognosis is excellent if arrhythmia is controlled. Long-term
treatment with beta blockers, permanent pacing, or left
cervicothoracic sympathectomy may be helpful.384–386 ICD
implantation is recommended for selected patients with re-
current syncope despite drug therapy, sustained ventricular
arrhythmias, or sudden cardiac arrest.349,351,352,387,388 Fur-
thermore, use of the ICD for primary prevention of SCD
may be considered when there is a strong family history of
SCD or when compliance or intolerance to drugs is a
concern.349,351,352,387,388
The clinical manifestations of a long-QT mutation may be
influenced by the specific gene involved and the functional
consequences of the mutation in that gene. Risk stratification
of patients with long-QT syndrome continues to evolve, with
data from genetic analysis becoming increasingly useful for
clinical decision making.389–394
3.2.4. Hypertrophic Cardiomyopathy
Most individuals with HCM are asymptomatic, and the first
manifestation of the condition may be SCD.245,395–400 SCD in
patients with HCM is generally related to ventricular arrhyth-
mia thought to be triggered by factors such as ischemia,
outflow obstruction, or AF.339 SCD is less frequently due to
bradycardia.16,339 Among selected high-risk patients, the
annual mortality from HCM has been estimated to be as high
as 6% in reports from tertiary centers.245,395–398 However,
community-based studies suggest a more benign disease in
the majority of individuals, with an annual mortality rate in
the range of 1% or less.16,401–403
Risk factors for SCD have been derived from multiple
observational studies and registries.339,404 – 408 A consensus
document on HCM from the ACC and the European
Society of Cardiology categorized known risk factors for
SCD as “major” and “possible” in individual patients.395
The major risk factors include prior cardiac arrest, spon-
taneous sustained VT, spontaneous nonsustained VT, fam-
ily history of SCD, syncope, LV thickness greater than or
equal to 30 mm, and an abnormal blood pressure response
to exercise.395 This consensus document also noted possi-
ble risk factors, which included AF, myocardial ischemia,
LV outflow obstruction, high-risk mutations, and intense
(competitive) physical exertion.395 The severity of other
symptoms, such as dyspnea, chest pain, and effort intoler-
ance, has not been correlated with increased risk of
SCD.16,395 A flat or hypotensive response to upright or
supine exercise testing in patients younger than 40 years
old has been shown to be a risk factor for SCD, although
the positive predictive value of this finding is low.395 A
normal blood pressure response identifies a low-risk
group.16,395 The presence of nonsustained VT on Holter
monitoring has been associated with a higher risk of SCD,
although the positive predictive accuracy is relatively
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 low.395 Recent analyses indicate that in a high-risk HCM
cohort, ICD interventions were frequent and were highly
effective in restoring normal sinus rhythm.245 However, an
important proportion of ICD discharges occur in primary
prevention patients who undergo implantation of the ICD
for a single risk factor. Therefore, a single risk marker of
high risk for sudden cardiac arrest may be sufficient to
justify consideration for prophylactic ICD implantation in
selected patients.245
Although no randomized studies are available, the ICD has
been used in patients with cardiac arrest, sustained VT, or VF,
with a high percentage of patients receiving appropriate ICD
discharge during follow-up at a rate of 11% per year.245,339 In
a nonrandomized study of ICD implantation in HCM, ICD
implantation in a subgroup of patients for primary prophy-
laxis on the basis of perceived high risk for SCD (syncope,
family history of SCD, nonsustained VT, inducible VT, or
septal thickness greater than or equal to 30 mm) resulted in a
lower rate of appropriate discharge of 5% per year.245,339 The
ICD is not indicated in the majority of asymptomatic patients
with HCM, who will have a relatively benign course. Its role
is individualized in the patient considered to be at high risk
for SCD.245,339,395 Although precise risk stratification has not
been validated, patients with multiple risk factors (especially
severe septal hypertrophy, greater than or equal to 30 mm)
and those with SCD (especially multiple SCDs) in close
relatives appear to be at sufficiently high risk to merit
consideration of ICD therapy.16,245
3.2.5. Arrhythmogenic Right Ventricular Dysplasia/
Cardiomyopathy
Selected patients with ARVD/C may be at risk for SCD.
Because clinical series have reported favorable outcomes with
this therapy for primary prevention of SCD in ARVD/C, the
ICD has assumed a larger role in therapy.16,341,342,345–348,409,410
On the basis of the available clinical data from observational
studies, it is reasonable to conclude that the ICD is a reasonable
therapy for secondary prevention of sudden cardiac arrest in
patients with ARVD/C.16,341,342,345–348,409,410
When the ICD is being considered for primary prevention, it
should be kept in mind that predictive markers of SCD in
patients with ARVD/C have not yet been defined in large
prospective studies focusing on survival.16,341,342,345–348,409,410
Risk factors that have clinical utility in identifying patients with
ARVD/C who are at risk for life-threatening ventricular arrhyth-
mias include induction of VT during electrophysiological test-
ing, detection of nonsustained VT on noninvasive monitoring,
male gender, severe RV dilation, and extensive RV involve-
ment.16,341,342,345–348,409,410 Young age at presentation (less than
5 years), LV involvement, prior cardiac arrest, and unexplained
syncope serve as markers of risk.341,342,346–348,411,412 Patients
with genotypes of ARVD/C associated with a high risk for SCD
should be considered for ICD therapy.345
Although the role of ICD therapy for primary prevention of
sudden death in patients with ischemic heart disease and
dilated, nonischemic cardiomyopathy is well established on
the basis of multiple clinical trials with a consistent finding of
benefit, the data supporting ICD use in patients with ARVD/C
are less extensive.16,341,342,345–348,409,410 Some authoritieshave proposed that an ICD should be implanted in patients
with ARVD/C and an increased risk for SCD based on the
presence of a previous cardiac arrest, syncope due to VT,
evidence of extensive RV disease, LV involvement, or
presentation with polymorphic VT and RVA aneurysm,
which is associated with a genetic locus on chromosome
1q42-43.16,341,342,345–348,409,410
It is evident that there is not yet clear consensus on the
specific risk factors that identify those patients with ARVD/C
in whom the probability of SCD is sufficiently high to warrant
an ICD for primary prevention. In the future, the results of
large prospective registries with rigorous enrollment criteria
for patients with ARVD/C in whom ICDs have been placed
for primary prevention will give insights into the optimal risk
stratification techniques for primary prevention. In the
meantime, individualized decisions for primary prevention
of SCD must be based on experience, judgment, and the
available data. In considering this decision, the clinician
should be mindful that in patients with ARVD/C, the ICD
has proved safe and reliable in sensing and terminating
sustained ventricular arrhythmias. Sudden death is rare in
the available clinical series, whereas appropriate ICD
shocks are common.16,341,342,345–348,409,410
3.2.6. Noncompaction of the Left Ventricle
Noncompaction of the LV is a rare congenital cardiomyopa-
thy characterized anatomically by excessive prominent tra-
beculae and deep intertrabecular recesses in the LV without
other major congenital cardiac malfunction.410,413–421 The
origin of the anatomic abnormalities is likely due to an arrest
of normal embryogenesis of the endocardium and epicardium
of the ventricle during development. This leads to suspension
of the normal compaction process of the loose myocardial
meshwork. Diagnosis is difficult and is frequently missed or
delayed owing to lack of knowledge about this uncommon
disease. Echocardiography is considered by many to be the
diagnostic procedure of choice, but some cases are detected
by computed tomography or magnetic resonance imaging.
Abnormalities in the resting ECG, including bundle-branch
block or ST-segment depression, are found in most patients,
but the findings do not have a high degree of sensitivity or
specificity.410,413–421
Ventricular arrhythmias and sudden death are among the
major complications of this disorder. Sudden death can occur
at any age, and there are currently no techniques clinically
useful for risk stratification for life-threatening ventricular
arrhythmias with noncompaction. Although there is no im-
pairment of systolic function, ventricular arrhythmias are
frequent in noncompaction. Approximately 40% of children
with noncompaction demonstrate complex ventricular ar-
rhythmias. Available clinical data indicate that sudden death
is the most common cause of mortality. Although there are no
prospective trials or registry data, there are sufficient obser-
vational data to indicate that placement of an ICD as a
strategy to reduce the risk of sudden death is a reasonable
clinical strategy.410,413–421
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 3.2.7. Primary Electrical Disease (Idiopathic
Ventricular Fibrillation, Short-QT Syndrome,
Brugada Syndrome, and Catecholaminergic
Polymorphic Ventricular Tachycardia)
The Brugada syndrome is characterized by ST-segment
elevation across the right precordial leads in association with
a high risk of SCD.16,422–425 Although the Brugada-pattern
ECG most commonly shows J-point segment elevation in
leads V1 to V3 and right bundle-branch block, the ECG
pattern can be intermittent.16 Less commonly, the J-point
elevation occurs in the inferior leads.16 Patients with the
Brugada syndrome have a structurally normal heart with a
primary channelopathy.16,426 This is transmitted with an
autosomal dominant pattern of inheritance, and more than
90% of those affected are male. The genetic basis for the
Brugada syndrome involves the cardiac sodium channel gene
(SCN5A).16,426
Cardiac events such as syncope or cardiac arrest occur
predominantly in the third and fourth decades of life, al-
though presentation with cardiac arrest in neonates or chil-
dren has been reported.16,422,424 Fever can acutely predispose
to cardiac arrest in the Brugada syndrome.16,422–424
Risk stratification for SCD in patients with the Brugada
syndrome is of clinical importance, because implantation of
an ICD is the only prophylactic measure able to prevent
SCD.16,422–424 As with long-QT syndrome, there are no data
showing that family history predicts cardiac events among
family members with the Brugada syndrome.16 Accordingly,
asymptomatic individuals with the characteristic ECG but
with no family history are not necessarily at low risk.16
Additionally, family members of an individual with SCD due
to Brugada syndrome should not be assumed to be at
increased risk of SCD.16 Patients with a spontaneous Brugada
pattern have a worse prognosis than individuals in whom the
typical ECG is observed only after pharmacological drug
challenge.16,422–424 Patients with syncope and the ECG pat-
tern of spontaneous ST-segment elevation have a 6-fold
higher risk of cardiac arrest than patients without syncope and
the spontaneous ECG pattern.16,422,424
The role of electrophysiological testing remains controver-
sial in the Brugada syndrome. Although some investigators
suggest that electrophysiological testing has a useful role in
risk stratification, others have not confirmed this observation.
Electrophysiological testing had a low positive predictive
value (23%), but over a 3-year follow-up, it had a very high
negative predictive value (93%).16,422,424 By contrast, Priori
et al. reported that electrophysiological testing has a low
accuracy in predicting individuals who will experience car-
diac arrest.16,410 Priori et al. have proposed that noninvasive
risk stratification based on the ECG and symptoms provides
an accurate alternative for risk stratification.16,410
Because only a single gene has been linked to the Brugada
syndrome, there is still insufficient information about the
contribution of genetic defects in predicting clinical
outcome.16,410,426 Specific mutations in the SCN5A gene do
not identify a subset of patients at higher risk of cardiac
events.16,410,426 SCD is caused by rapid polymorphic VT or
VF that frequently occurs at rest or during sleep.16 Patientswith Brugada syndrome usually do not have ventricular
extrasystoles or nonsustained runs of VT at Holter recording.
Therefore, the therapeutic approach for these patients is
centered on the prevention of cardiac arrest.
Catecholaminergic polymorphic VT is characterized by ven-
tricular tachyarrhythmias that develop in relation to physical or
emotional stress in the presence of a resting ECG that shows no
diagnostic abnormalities at rest.16,428–431 The initial symptoms
often manifest during childhood, although late-onset cases have
been described.16,385,410,427–431 Catecholaminergic polymorphic
VT is transmitted by either an autosomal dominant or recessive
inheritance pattern. Approximately one-half of the autosomal
dominant cases are caused by mutations in the gene encoding the
cardiac ryanodine receptor (RyR2).16 This receptor is responsi-
ble for calcium release from the stores of the sarcoplasmic
reticulum.16 Mutations in the gene that encodes calsequestrin
(CASQ2), a calcium buffering protein in the sarcoplasmic
reticulum, have been associated with the recessive form of
catecholaminergic polymorphic VT.16
Risk stratification for SCD in catecholaminergic polymor-
phic VT is not possible given the relatively small number of
patients reported. Most clinical reports indicate that beta
blockers appear to be an effective treatment. Patients who
have had an episode of VF are considered at higher risk and
are usually treated with an ICD in addition to beta-blocker
therapy.16,385,410,431 The recurrence of sustained VT, hemo-
dynamically untolerated VT, or syncope for which causes
other than VT are excluded while the patient is receiving a
beta blocker are similarly considered markers of higher risk.16
In such patients, an ICD is a commonly used and reasonable
approach.16 Furthermore, electrophysiological testing is not
useful in the management of patients with catecholaminergic
polymorphic VT since the arrhythmia is usually not inducible
with programmed ventricular stimulation.16,385,410,431 Both
supraventricular and ventricular arrhythmias are usually re-
producibly induced by exercise stress test.16,385,410,431 Iso-
lated premature ventricular complexes generally precede runs
of nonsustained VT.16 With continued exercise, the runs of
VT typically increase in duration, and VT may become
sustained.16 A beat-to-beat alternating QRS axis that changes
by 180° (“bidirectional VT”) is a typical pattern of cat-
echolaminergic polymorphic VT-related arrhythmias.16 Cat-
echolaminergic polymorphic VT patients can also present
with irregular polymorphic VT or VF.16 Beta blockers are
generally effective in preventing recurrences of syncope even
when arrhythmias can still be elicited during an exercise
stress test.16 If syncope occurs in a patient taking a beta
blocker, implantation of an ICD is recommended.16
VF has been reported in patients with abnormal repolar-
ization due to ion channel mutations that result in a markedly
shortened QT interval.432 Only a few small series of such
patients have been described, and at present, evidence-based
recommendations about management of asymptomatic indi-
viduals with a short QT interval cannot be made. Some
patients who survive a clinical episode of VF have no
identifiable structural heart disease, no documented transient
cause for arrhythmia, and no known ion channel defect. In
such patients, VF is termed “idiopathic.” ICD therapy is
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 appropriate for secondary prevention in patients with the
short-QT syndrome and idiopathic VF.
3.2.8. Idiopathic Ventricular Tachycardias
Monomorphic VT may be seen in individuals with structur-
ally normal hearts who have no known ion channelopathies.
The most common sites of origin are the RV outflow tract, the
fascicular region of the LV, structures in the LV outflow tract,
and the mitral annular region. The risk for sudden death
related to these arrhythmias is low.433
3.2.9. Advanced Heart Failure and Cardiac
Transplantation
Patients with moderate to severe heart failure face the twin
risks of terminal heart failure decompensation and death due
to unanticipated ventricular tachyarrhythmias. When ICD or
CRT-D implantation is discussed with these patients, the
likelihood of both life-saving and inappropriate shocks
should be placed in the context of the overall anticipated
mortality with heart failure, the expected duration of life
prolongation after effective therapies, and the likely evolution
to limiting symptoms and ultimately death due to pump
failure.434 The relative contribution of preventable sudden
death to mortality decreases with repeated hospitalizations
and multiple comorbidities, particularly in the setting of
kidney dysfunction or advanced age. These factors, whether
cardiac or noncardiac, also influence the value that patients
place on quality versus length of life remaining. However,
individual preferences cannot be assumed and should be
explored with each patient.
Candidates for transplantation constitute a special case of
severe heart failure because of the likelihood of prolonged
survival after transplantation, with 50% of patients currently
surviving at 10 years after transplantation. The high rate of
sudden death on the transplant waiting list merits ICD
implantation in most candidates with heart failure who are
awaiting transplantation out of the hospital. The ICD has been
highly effective as a bridge to transplantation for these
individuals both with and without a prior history of life-
threatening arrhythmias.
Class IV status itself is a heterogenous and dynamic
state435 in which the absolute incidence of sudden death
increases but the proportion of sudden deaths prevented by
ICDs declines, and heart failure deaths account for a greater
proportion of overall mortality. Once patients have persistent
or frequently recurrent Class IV symptoms despite optimal
management, life expectancy is less than 12 months, and ICD
implantation is not indicated, regardless of patient and family
preferences. Occasionally, patients cannot be weaned from
intravenous inotropic infusions and are discharged with
chronic inotropic infusion therapy for symptom palliation,
with the expectation that death due to heart failure will likely
occur within the next 6 months. Despite the proarrhythmic
potential of inotropic agents, these patients receiving chronic
infusions should not be given an ICD (unless awaiting
transplantation or other definitive therapy).
Often, patients hospitalized with Class IV symptoms will
undergo substantial improvement and can be discharged on
oral therapy with minimal or no symptoms at rest. For thesepatients who can remain stable at 1 month after discharge,
without evidence of recurrent congestion or worsening renal
function, survival is similar to that of other Class III patients
who have not been recently hospitalized. In this situation,
ICD implantation can be discussed and may be expected to
improve survival.
Patients with Class IV symptoms of heart failure with pro-
longed QRS duration and optimal lead placement may return to
Class III status or better for both function and survival, at which
point prevention of sudden death again becomes a relevant goal.
Information on this group is limited because only 10% of the
almost 4000 patients in resynchronization trials have had Class
IV symptoms. In the COMPANION trial,224 there were Class IV
patients for whom resynchronization improved QOL and re-
duced rehospitalization and mortality; however, these patients
had been stable at home before study entry and may not
represent typical Class IV patients. Even in this selected group,
there was no difference in 2-year survival between CRT patients
with and without the defibrillator feature.230 In patients with
Class IV symptoms in whom resynchronization is inadequate to
restore clinical stability, the presence of a defibrillator often
complicates the impending transition to end-of-life care.
Recommendations for Implantable Cardioverter
Defibrillators
Secondary prevention refers to the prevention of SCD in
those patients who have survived a prior cardiac arrest or
sustained VT. Primary prevention refers to the prevention of
SCD in individuals without a history of cardiac arrest or
sustained VT. Patients with cardiac conditions associated
with a high risk of sudden death who have unexplained
syncope that is likely to be due to ventricular arrhythmias are
considered to have a secondary indication.
Recommendations for consideration of ICD therapy, par-
ticularly those for primary prevention, apply only to patients
who are receiving optimal medical therapy and have a
reasonable expectation of survival with a good functional
status for more than 1 year. It is difficult to estimate survival
with heart failure in the general population, for whom
comorbidities and age differ from those in trial populations
from which the predictive models have been derived. Patients
with repeated heart failure hospitalizations, particularly in the
presence of reduced renal function, are at high risk for early
death due to heart failure.436–438 See above for discussion
regarding the use of LVEFs based on trial inclusion criteria.
We acknowledge that the “ACC/AHA/ESC 2006 Guidelines
for Management of Patients With Ventricular Arrhythmias and
the Prevention of Sudden Cardiac Death”16 used the LVEF of
less than 40% as a critical point to justify ICD implantation for
primary prevention of SCD. The LVEF used in clinical trials
assessing the ICD for primary prevention of SCD ranged from
less than or equal to 40% in MUSTT to less than or equal to 30%
in MADIT II.329,332 Two trials, MADIT I18 and SCD-HeFT19
used LVEFs of less than or equal to 35% as entry criteria for the
trial. This writing committee reached consensus that it would
be best to have ICDs offered to patients with clinical profiles
as similar to those included in the trials as possible. Having
given careful consideration to the issues related to LVEF for
these updated ICD guidelines, we have written these indica-
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 tions for ICDs on the basis of the specific inclusion criteria for
LVEF in the trials. Because of this, there may be some
variation from previously published guidelines.16
We also acknowledge that the determination of LVEF
lacks a “gold standard” and that there may be variation
among the commonly used clinical techniques of LVEF
determination. All clinical methods of LVEF determination
lack precision and the accuracy of techniques varies amongst
laboratories and institutions. Based on these considerations,
this writing committee recommends that the clinician use the
LVEF determination that they feel is the most clinically
accurate and appropriate in their institution.
Class I
1. ICD therapy is indicated in patients who are survivors of
cardiac arrest due to VF or hemodynamically unstable
sustained VT after evaluation to define the cause of the
event and to exclude any completely reversible causes.
(Level of Evidence: A)16,319–324
2. ICD therapy is indicated in patients with structural heart
disease and spontaneous sustained VT, whether hemodynam-
ically stable or unstable. (Level of Evidence: B)16,319–324
3. ICD therapy is indicated in patients with syncope of
undetermined origin with clinically relevant, hemodynam-
ically significant sustained VT or VF induced at electro-
physiological study. (Level of Evidence: B)16,322
4. ICD therapy is indicated in patients with LVEF less than
or equal to 35% due to prior MI who are at least 40 days
post-MI and are in NYHA functional Class II or III. (Level
of Evidence: A)16,333
5. ICD therapy is indicated in patients with nonischemic
DCM who have an LVEF less than or equal to 35% and
who are in NYHA functional Class II or III. (Level of
Evidence: B)16,333,369,379
6. ICD therapy is indicated in patients with LV dysfunction
due to prior MI who are at least 40 days post-MI, have an
LVEF less than or equal to 30%, and are in NYHA
functional Class I. (Level of Evidence: A)16,332
7. ICD therapy is indicated in patients with nonsustained VT
due to prior MI, LVEF less than or equal to 40%, and
inducible VF or sustained VT at electrophysiological
study. (Level of Evidence: B)16,327,329
Class IIa
1. ICD implantation is reasonable for patients with unex-
plained syncope, significant LV dysfunction, and nonisch-
emic DCM. (Level of Evidence: C)
2. ICD implantation is reasonable for patients with sustained
VT and normal or near-normal ventricular function. (Level
of Evidence: C)
3. ICD implantation is reasonable for patients with HCM who have
1 or more major† risk factors for SCD. (Level of Evidence: C)
4. ICD implantation is reasonable for the prevention of SCD
in patients with ARVD/C who have 1 or more risk factors
for SCD. (Level of Evidence: C)
†See Section 3.2.4, “Hypertrophic Cardiomyopathy,” for definition of
major risk factors.5. ICD implantation is reasonable to reduce SCD in patients
with long-QT syndrome who are experiencing syncope
and/or VT while receiving beta blockers. (Level of Evi-
dence: B)349–354
6. ICD implantation is reasonable for non hospitalized pa-
tients awaiting transplantation. (Level of Evidence: C)
7. ICD implantation is reasonable for patients with Brugada
syndrome who have had syncope. (Level of Evidence: C)
8. ICD implantation is reasonable for patients with Brugada
syndrome who have documented VT that has not resulted
in cardiac arrest. (Level of Evidence: C)
9. ICD implantation is reasonable for patients with cate-
cholaminergic polymorphic VT who have syncope and/or
documented sustained VT while receiving beta blockers.
(Level of Evidence: C)
10. ICD implantation is reasonable for patients with cardiac
sarcoidosis, giant cell myocarditis, or Chagas disease.
(Level of Evidence: C)
Class IIb
1. ICD therapy may be considered in patients with nonisch-
emic heart disease who have an LVEF of less than or equal
to 35% and who are in NYHA functional Class I. (Level of
Evidence: C)
2. ICD therapy may be considered for patients with
long-QT syndrome and risk factors for SCD. (Level of Evi-
dence: B)16,349–354
3. ICD therapy may be considered in patients with syncope
and advanced structural heart disease in whom thorough
invasive and noninvasive investigations have failed to
define a cause. (Level of Evidence: C)
4. ICD therapy may be considered in patients with a familial
cardiomyopathy associated with sudden death. (Level of
Evidence: C)
5. ICD therapy may be considered in patients with LV
noncompaction. (Level of Evidence: C)
Class III
1. ICD therapy is not indicated for patients who do not have
a reasonable expectation of survival with an acceptable
functional status for at least 1 year, even if they meet ICD
implantation criteria specified in the Class I, IIa, and IIb
recommendations above. (Level of Evidence: C)
2. ICD therapy is not indicated for patients with incessant VT
or VF. (Level of Evidence: C)
3. ICD therapy is not indicated in patients with significant
psychiatric illnesses that may be aggravated by device
implantation or that may preclude systematic follow-up.
(Level of Evidence: C)
4. ICD therapy is not indicated for NYHA Class IV patients
with drug-refractory congestive heart failure who are not
candidates for cardiac transplantation or CRT-D. (Level of
Evidence: C)
5. ICD therapy is not indicated for syncope of undetermined
cause in a patient without inducible ventricular tachyar-
rhythmias and without structural heart disease. (Level of
Evidence: C)
6. ICD therapy is not indicated when VF or VT is amenable
to surgical or catheter ablation (e.g., atrial arrhythmias
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 associated with the Wolff-Parkinson-White syndrome, RV
or LV outflow tract VT, idiopathic VT, or fascicular VT in
the absence of structural heart disease). (Level of Evi-
dence: C)
7. ICD therapy is not indicated for patients with ventricular
tachyarrhythmias due to a completely reversible disorder
in the absence of structural heart disease (e.g., electrolyte
imbalance, drugs, or trauma). (Level of Evidence: B)16
3.3. Implantable Cardioverter-Defibrillators in
Children, Adolescents, and Patients With
Congenital Heart Disease
The indications for ICD implantation in young patients and
those with congenital heart disease have evolved over the past
15 years based on data derived primarily from adult random-
ized clinical trials. Similar to adults, ICD indications have
evolved from the secondary prevention of SCD to the
treatment of patients with sustained ventricular arrhythmias
to the current use of ICDs for primary prevention in patients
with an increased risk of SCD. However, in contrast to adults,
there are minimal prospective data regarding ICD survival
benefit, because fewer than 1% of all ICDs are implanted in
pediatric or congenital heart disease patients.439 Consider-
ations such as the cumulative lifetime risk of SCD in
high-risk patients and the need for decades of antiarrhythmic
therapy make the ICD an important treatment option for
young patients.
SCD in childhood and adolescence is associated with 3
principal forms of cardiovascular disease: 1) congenital heart
disease, 2) cardiomyopathies, and 3) genetic arrhythmia
syndromes.440,441 Prospective identification and treatment of
young patients at risk for sudden death is crucial because
compared with adults, a very low percentage of children
undergoing resuscitation survive to hospital discharge.442
The indications for ICD therapy in pediatric patients who
have been resuscitated or who are at high risk for SCD are
similar to those for adults. Data from nonrandomized studies
provide support for the Class I recommendation that young
patients who have been resuscitated from SCD should un-
dergo ICD implantation after a careful evaluation to exclude
any potentially reversible causes.440,443–445 Spontaneous sus-
tained VT or unexplained syncope with inducible sustained
hypotensive VT in patients with congenital heart disease are
also considered Class I ICD indications when other remedi-
able causes (hemodynamic or arrhythmic) have been exclud-
ed.446 Catheter ablation or surgical therapies may provide an
alternative to use of an ICD in patients with congenital heart
disease and recurrent VT.447
Recommendations regarding ICD implantation for primary
prevention of SCD in young patients are based on limited
clinical experience and extrapolation of data from adult
studies. No randomized clinical trials have been performed to
date, and given the relative infrequency of SCD in young
patients, they are unlikely to be completed in the near future.
Because the risk of unexpected sudden death is greater in
young patients than in adults with genetic diseases such as
HCM or the long-QT syndrome, a family history of sudden
death, possibly with genetic confirmation, may influence the
decision to implant an ICD for primary prevention. Addi-tional risk factors to be considered in these diseases are
discussed in specific sections in this document.354,382,448
With regard to primary prevention of SCD in patients
with congenital heart disease, the marked heterogeneity of
defects precludes generalization of risk stratification. Un-
expected sudden death is reported in 1.2% to 3.0% of
patients per decade after surgical treatment of tetralogy of
Fallot, with risk factors including ventricular dysfunction,
QRS duration, and atrial and ventricular arrhythmias.249 A
significantly greater risk of SCD has been identified for
patients with transposition of the great arteries or aortic
stenosis, with most cases presumed to be due to a malig-
nant ventricular arrhythmia associated with ischemia, ven-
tricular dysfunction, or a rapid ventricular response to
atrial flutter or fibrillation.449 – 451
The risk of SCD associated with systemic ventricular
dysfunction in congenital heart disease patients remains
controversial.452,453 The ability to define the risk associ-
ated with impaired function is complicated by the fact that
right (pulmonary) ventricular dysfunction is more common
than left (systemic) ventricular dysfunction and that a
variety of atrial arrhythmias and conduction blocks may
independently predispose these patients to arrhythmias or
syncope. The lack of prospective and randomized clinical
trials precludes exact recommendations regarding risk
stratification and indications for ICD implantation for
primary prevention of SCD in patients with postoperative
congenital heart disease and ventricular dysfunction. One
other potential ICD indication in young patients, which is
similar to adults, is the patient with congenital coronary
anomalies or coronary aneurysms or stenoses after Ka-
wasaki disease, in which an ischemic substrate for malig-
nant arrhythmias may be present.441
Because of concern about drug-induced proarrhythmia
and myocardial depression, an ICD (with or without CRT)
may be preferable to antiarrhythmic drugs in young pa-
tients with DCM or other causes of impaired ventricular
function who experience syncope or sustained ventricular
arrhythmias. ICDs may also be considered as a bridge to
orthotopic heart transplantation in pediatric patients, par-
ticularly given the longer times to donor procurement in
younger patients.454,455
Recommendations for Implantable Cardioverter-
Defibrillators in Pediatric Patients and Patients With
Congenital Heart Disease
Class I
1. ICD implantation is indicated in the survivor of cardiac arrest
after evaluation to define the cause of the event and to exclude
any reversible causes. (Level of Evidence: B)440,443–445
2. ICD implantation is indicated for patients with symptom-
atic sustained VT in association with congenital heart
disease who have undergone hemodynamic and electro-
physiological evaluation. Catheter ablation or surgical repair
may offer possible alternatives in carefully selected patients.
(Level of Evidence: C)447
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 Class IIa
1. ICD implantation is reasonable for patients with congen-
ital heart disease with recurrent syncope of undetermined
origin in the presence of either ventricular dysfunction or
inducible ventricular arrhythmias at electrophysiological
study. (Level of Evidence: B)18,446
Class IIb
1. ICD implantation may be considered for patients with recur-
rent syncope associated with complex congenital heart dis-
ease and advanced systemic ventricular dysfunction when
thorough invasive and noninvasive investigations have failed
to define a cause. (Level of Evidence: C)451,454
Class III
1. All Class III recommendations found in Section 3, “Indi-
cations for Implantable Cardioverter-Defibrillator Ther-
apy,” apply to pediatric patients and patients with congen-
ital heart disease, and ICD implantation is not indicated in
these patient populations. (Level of Evidence: C)
3.3.1. Hypertrophic Cardiomyopathy
Prior studies of ICD therapy for primary and secondary
prevention of SCD in HCM are discussed in Sections 3.1.5
and 3.2.4; most of these studies have included both pediatric
and adult patients. The indications for ICDs in pediatric
patients with HCM for primary and secondary prevention of
sudden cardiac arrest are the same as those for adults. Clinical
decisions should be based on risks and benefits that may be
unique to pediatric patients. In the pediatric population,
recommendations for ICD therapy should be made with
careful consideration of the risks of device implantation,
which may be increased on the basis of body size. Addition-
ally, consideration should be given to the additional years of
benefit that could potentially result from prevention of SCD
in this population.
3.4. Limitations and Other Considerations
3.4.1. Impact on Quality of Life (Inappropriate
Shocks)
Despite its life-saving potential, the use of ICD therapy
carries a risk for psychological consequences and may lead to
a decrement in QOL, particularly among patients who have
experienced shocks.456 Reports of significant behavioral dis-
orders, including anxiety, device dependence, or social with-
drawal, have been described with ICD implantation.457–459
However, QOL substudies from large, randomized clinical
trials of ICD therapy demonstrated that overall, QOL was no
different or was somewhat better among patients randomized
to ICD therapy than among those in the control groups, with
decreases in physical, emotional, and psychological measures
of health-related QOL concentrated among patients who
experienced ICD shocks.328,367,460 Given the broader indica-
tion for and marked increase in implantation of ICDs for
primary prevention that is being driven by the results of the
SCD-HeFT and MADIT II trials,332,333 understanding the
frequency and causes of inappropriate shocks and devisingmanagement strategies to mitigate both inappropriate thera-
pies and their psychological and QOL consequences will be
important for an increasingly large segment of the population.
A systematic review summarized the frequency of inap-
propriate ICD therapies reported in randomized clinical trials
of primary and secondary prevention.461 In these trials, during
follow-up that ranged from 20 to 45 months, inappropriate
ICD therapy was delivered in 10% to 24% of patients. In the
PainFREE Rx II (Pacing Fast VT Reduces Shock Therapies
II) trial, in which patients were randomized to either ATP or
shocks as first therapy for fast VT, at least 1 inappropriate
detection occurred in 15% of patients during approximately
11 months of follow-up.294 The proportion of detections that
were inappropriate was modestly but not significantly higher
among primary prevention patients than among secondary
prevention patients (46% versus 34%; p0.09). Both older
and more recent registry reports suggest similar rates of
inappropriate therapy in unselected populations.462,463
By far, the leading cause of inappropriate therapy is the
misclassification of SVT, most commonly AF.294,358,462,463
But ICD lead malfunction and other causes, such as over-
sensing of T waves, double counting of prolonged QRS, and
electromagnetic interference, may account for 4% to 30% of
inappropriate therapy.305,367,462,464 Patients with multiple
ICD shocks should be evaluated immediately to determine
the cause of the shocks and to direct urgent management.
Short-term therapy with anxiolytic drugs may be instituted
early for patients after recurrent device firings to minimize
acute and delayed anxiety reactions.
A variety of approaches to reduce the occurrence of
inappropriate shocks are currently available, and selection
depends on the cause of the shocks and the type of device
implanted. Although there has been debate as to the utility of
dual-chamber versus single-chamber devices in reducing
rates of inappropriate ICD therapy, a recently published
randomized trial suggests that optimal programming of dual-
chamber devices can reduce the rate of inappropriate detec-
tions and therapies due to SVTs.465 In the multicenter Detect
Supraventricular Tachycardia Study, 400 patients with a
clinical indication for an ICD received dual-chamber devices
and were randomized in a single-blind fashion to optimal
single- or dual-chamber detection programming. SVT oc-
curred in 34% of subjects (31% in the single-chamber arm
and 37% in the dual-chamber arm). Rates of inappropriate
detection of SVT were substantial in both arms (39.5% in the
single-chamber arm and 30.9% in the dual-chamber arm), but
the adjusted odds ratio of inappropriate detection of SVT in
the dual-chamber arm compared with the single-chamber arm
was 0.53 (95% CI 0.30 to 0.94; p0.03). This reduction in
inappropriate detection translated to a similar reduction in
inappropriate therapy, with no compromise of VT detection,
which makes this trial the first to show superiority of
dual-chamber devices when optimally programmed. Other
areas of active research include the development of enhanced
mathematically modeled detection protocols for evaluation of
internal electrograms to improve discrimination of SVT from
VT and to increase the ability to detect lead failures.466–468
Regardless of the cause of or solution for inappropriate ICD
therapy (particularly shocks), careful attention to a team-
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 based approach that includes the patient and family in emotional
and psychological support is also recommended.456,469
3.4.2. Surgical Needs
Surgically placed epicardial pacing leads are indicated in
selected instances when standard transvenous lead placement
is either not feasible or contraindicated. Examples of such
circumstances include: 1) inability or failure to place an
adequate LV lead in patients requiring biventricular pacing,
2) indications for permanent pacing in certain pediatric
patients and in pediatric or adult patients with tricuspid valve
prostheses or recurrent or prolonged bacteremia, and 3)
congenital acquired venous anomalies that preclude trans-
venous access to the heart.
The reported success rate of coronary venous lead implan-
tation for biventricular pacing ranges from 81% to 99%.470,471
Causes of failed percutaneous lead placement may be ana-
tomic (superior vena cava or coronary sinus obstruction or
inadequate coronary venous anatomy) or technical (failure to
cannulate the coronary sinus, coronary sinus dissection,
inadequately high pacing thresholds with intermittent capture,
diaphragmatic pacing due to proximity of the phrenic nerve to
the target coronary sinus branch, or lead dislodge-
ment).470,472,473 When coronary sinus lead implantation fails,
several nonrandomized studies have demonstrated that surgi-
cal LV lead placement is almost always successful.470–473 In
this setting, the key advantage of surgical lead placement is
access to the entire posterior and lateral walls of the LV,
which enables the choice of the best pacing site.471,474 The
combination of echocardiography with tissue Doppler imag-
ing and electrophysiological measurements may facilitate the
choice of a transthoracically directed LV epicardial pacing
site.473 Implantation of 2 epicardial leads may be considered
to provide backup capability if 1 lead should fail or become
dislodged.475 Steroid-eluting epicardial leads may be prefer-
able to screw-on leads.473
The choice of surgical procedure appears to influence
hospital morbidity. Surgical approaches for placement of LV
epicardial leads include left thoracotomy, left thoracoscopy,
and robotically assisted port-based placement. Thoracotomy
in fragile patients with heart failure has been associated with
bleeding, stroke, hypotension, and arrhythmias.470,476 In con-
trast, thoracoscopic and robotic approaches have been re-
ported to be associated with minimal morbidity and may be
preferred.472,473,475 These less invasive procedures generally
require 60 to 90 minutes of operative time and a mean
hospital stay of 4 to 5 days.472 However, not all patients are
candidates for minimally invasive or robotic procedures.
Subjects who have undergone prior thoracotomy or ster-
notomy operations may have limited pericardial/epicardial
accessibility.
In certain instances, it may be advisable to place an LV
epicardial lead at the time of concomitant cardiac surgery. In
patients who are currently or in the future may be candidates
for CRT who require coronary artery bypass grafting or
mitral valve surgery and have medically refractory, symp-
tomatic heart failure, ischemic cardiomyopathy or DCM,
prolonged QRS interval, LV end-diastolic diameter greaterthan or equal to 55 mm, and LVEF less than or equal to 35%,
the surgeon may elect to place an LV epicardial lead.477 The
lead is tunneled to a prepectoral pocket for intraoperative or
postoperative attachment to an appropriate pacing generator.
This approach is probably not indicated for the patient who is
expected to have substantial improvement in LVEF after
cardiac surgery (e.g., the patient with extensive viable myo-
cardium who is undergoing revascularization). There are
limited data documenting outcomes of this “preemptive”
strategy.
Epicardial leads may be necessary in some pediatric patients.
The most common indications for permanent pacemaker im-
plantation in the pediatric population are SND or AV block after
surgery for congenital heart disease and congenital AV block.478
In most instances, such pacing systems can be placed by
standard transvenous techniques.479 However, epicardial leads
may be needed in children as a result of their small size, the
presence of congenital heart defects with a right-to-left shunt, or
an inability to pace the chamber desired because of anatomic
barriers (e.g., after a Fontan procedure).478–480 In such instances,
steroid-eluting leads provide excellent durability.479
Epicardial leads are suggested in some pediatric or adult
patients who need pacing and who have recurrent or pro-
longed bacteremia.481 For a single episode of device-related
bacteremia, extraction of all hardware followed by reimplan-
tation by the transvenous route at a later date is appropriate.
Implantation of permanent epicardial pacing leads is indi-
cated in the pacemaker-dependent patient undergoing me-
chanical tricuspid valve replacement. A prosthetic mechani-
cal tricuspid valve represents an absolute contraindication to
placement of transvenous RV leads, because such leads will
cross the valve and may interfere with valve function. This
scenario occurs commonly in patients with tricuspid valve
endocarditis and a transvenous pacemaker. At surgery, all
hardware should be removed. If the tricuspid valve is repair-
able, standard transvenous pacing leads can be placed post-
operatively. However, if tricuspid valve replacement is nec-
essary, epicardial ventricular leads should be implanted at the
time of surgery.
3.4.3. Patient Longevity and Comorbidities
Physicians, patients, and their families increasingly will be
faced with decisions about device-based therapies (ICD and
CRT) in elderly patients who meet conventional criteria for
implantation. These decisions require not only evidence of
clinical benefit demonstrated in randomized clinical trials but
also estimates of life expectancy, consideration of comorbidi-
ties and procedural risk, and patient preferences. Although
these factors are important when device implantation is
considered in any age group, they assume greater weight in
clinical decision-making among the elderly.
Unfortunately, few clinical trials of device-based therapy
have enrolled enough elderly patients (age greater than 75
years) to reliably estimate the benefits of device-based ther-
apy in this group. Indeed, patients in device trials have
generally had an average age less than 65 years and little
comorbidity. In contrast, the average patient hospitalized with
heart failure and low LVEF is 75 years old with 2 comor-
bidities. The 1-year mortality rate for this population is in the
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 range of 30% to 50%, with a 2-fold higher risk of death in
patients with estimated creatinine clearance less than 60 ml
per minute.326,482 The presence of chronic pulmonary disease
and dementia further increases the risk for death. Fewer than
10% of deaths in this population could be attributed to
presumed SCD in patients living independently.482 After 3
hospitalizations for heart failure in a community population,
median survival declines to 1 year and would be prolonged by
only 0.3 years even if all presumed SCDs were prevented.5
For all patients, the likelihood of meaningful prolongation of
life by prevention of SCD must be assessed against the
background of other factors that limit patient function and
survival.
Among 204 elderly patients with prior MI and LVEF less
than or equal to 30% enrolled in MADIT II (total n1223),
a trial of primary prevention of SCD with ICD therapy, the
HR for mortality with ICD therapy was 0.56 (95% CI 0.29 to
1.08; p0.08), which was similar to that for younger patients
(HR 0.63, 95% CI 0.45 to 0.88; p0.01).482a Furthermore,
QOL scores were similar among older and younger patients.
Subgroup analyses by age (less than or equal to 65 versus
greater than 65 years) from COMPANION and SCD-HeFT
showed some erosion of benefit among the older group, but
there were no significant treatment interactions with
age.224,333
In a study of 107 consecutive patients greater than 80 years
old (82% with ischemic cardiomyopathy) and 241 consecu-
tive patients 60 to 70 years of age (80% with ischemic
cardiomyopathy), life expectancy after device implantation
(predominantly ICD alone) among the octogenarians was 4.2
years compared with 7 years among those 60 to 70 years
old.483 Thus, although survival after implantation is shorter
among the elderly than among younger groups, survival is
substantial, and age itself should not be the predominant
consideration in the use of device-based therapy among the
elderly.
The presence and number of noncardiac comorbidities are
another important consideration in the decision to proceed
with device-based therapy in the elderly. In one registry,
although age greater than 75 years and heart failure were
important predictors of death at 1 and 2 years of follow-up,
after adjustment for age, heart failure, and patient sex, the
number of noncardiac comorbidities was statistically signif-
icantly associated with survival among 2467 patients who
received ICD therapy.484 The presence of 3 or more noncar-
diac comorbidities was associated with a nearly 3-fold in-
crease in the hazard for mortality (HR 2.98, 95% CI 1.74 to
5.10). Therefore, as much as age, the presence and number of
noncardiac comorbidities are critical considerations in the
decision to use device-based therapy.
A meta-analysis of secondary prevention trials (AVID,
CASH, and CIDS) revealed that although ICD therapy
reduced all-cause and arrhythmic death among patients less
than 75 years old, among 252 patients older than 75 years, the
HR for all-cause mortality (predominantly due to progressive
heart failure) was 1.06 (95% CI 0.69 to 1.64; p0.79), and
for arrhythmic death, it was 0.90 (95% CI 0.42 to 1.95;
p0.79).485 The interaction p value was 0.09, which suggeststhat the elderly may derive less benefit from ICD therapy in
secondary prevention than younger patients.
In summary, these data suggest that although age is an
important predictor of outcome after ICD therapy, mean
survival of more than 4 years may be expected even among
octogenarians, and age alone should not be used as a sole
criterion to withhold device-based therapy. However, impor-
tant considerations in the decision to use device-based ther-
apy should include the indication for device implantation (for
ICDs, primary versus secondary prevention), the number of
comorbidities, and patient preferences.
Considerations specific to elderly patients are also relevant
to pacing, CRT, and ICD therapies. Similar to enrollment in
ICD trials, few patients older than 75 years have been
enrolled in trials of CRT. However, subgroup analyses from
CARE-HF (age less than 66.4 versus greater than or equal to
66.4 years) and COMPANION (age less than or equal to 65
versus greater than 65 years) suggest that older patients
derive similar benefit from CRT as younger patients.224,225
The “ACC/AHA/ESC 2006 Guidelines for Management of
Patients With Ventricular Arrhythmias and the Prevention of
Sudden Cardiac Death” addressed ICD implantation in the
elderly.16 Many of those considerations are relevant to other
types of device implantation. Because of underrepresentation
of the elderly in clinical trials, much of the rationale for
implanting devices in these patients rests on subgroup anal-
yses that were not prespecified and is therefore relatively
weak. Furthermore, not only relative efficacy but also proce-
dural complication rates in older versus younger patients are
largely unexplored. These unknowns must be balanced
against the fact that many elderly patients remain functional
until shortly before death and reasonably deserve similar
treatment options as younger patients in many cases. The
ethical principles of autonomy, beneficence (“do good and
avoid evil”), and nonmaleficence (“do no harm”) must always
prevail.
3.4.4. Terminal Care
In the United States, the withholding and withdrawal of
life-sustaining treatments (e.g., cardiopulmonary resuscita-
tion, mechanical ventilation, or hemodialysis) from termi-
nally ill patients who do not want the treatments is ethical and
legal.486 Honoring these requests is an integral aspect of
patient-centered care and should not be regarded as
physician-assisted suicide or euthanasia.
When terminally ill patients (or their surrogates) request
pacemaker, ICD, or CRT deactivation, questions related to
the ethics of device deactivation may arise. Questions com-
monly asked include: Are implantable devices life-sustaining
treatments? Is deactivation the same as physician-assisted
suicide or euthanasia? Is deactivation ethical? Is it legal?
Under what conditions (e.g., code status) should deactivation
be performed? Who should carry out deactivation? What
documentation should exist?
The prevalence of implantable devices in patients dying of
noncardiac diseases makes this an increasingly encountered
clinical issue. Patients and families fear that devices will
prolong the dying process, and some dying patients with
ICDs fear uncomfortable defibrillations. In fact, investigators
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 have found that some patients with ICDs experience uncom-
fortable defibrillations throughout the dying process, includ-
ing moments before death. Cardiologists who implant devices
do not commonly have discussions with patients about
end-of-life issues and device deactivation. Furthermore, pub-
lished experience with deactivation of devices is limited.487
There is general consensus regarding the ethical and legal
permissibility of deactivating ICDs in dying patients who
request deactivation.488 However, caregivers involved in
device management generally make a distinction between
deactivating a pacemaker and deactivating an ICD or CRT
device. Given the clinical context, all 3 can be considered
life-sustaining treatments. Notably, all of these devices may
be refused by patients, and to impose them on patients who do
not want them is unethical and illegal (battery). Furthermore,
ethics and law make no distinction between withholding and
withdrawing treatments.
An approach to dying patients who request pacemaker,
ICD, or CRT deactivation should include the following:
• A dying patient (or, if the patient lacks decision-making
capacity, the patient’s surrogate decision maker) who
requests device deactivation should be fully informed of
the consequences and alternatives to device deactivation,
and a summary of the conversation should be recorded in
the medical record.
• An order for device deactivation should be accompanied
by a do-not-resuscitate (DNR) order; these orders should
be recorded in the patient’s medical record.
• Psychiatric consultation should be sought in any situation
in which a dying patient who requests device deactivation
is thought to have impaired decision-making capacity.
• Ethics consultation should be sought in any situation in
which the clinician or clinicians disagree, based on their
clinical judgment, with a request for device deactivation.
• If the clinician asked to deactivate a device has personal
beliefs that prohibit him or her from carrying out device
deactivation (conscientious objection), then the patient
should be referred to another clinician.
• If the patient is remote from the implanting medical center,
the clinician who is responsible for the patient’s care at the
local site should document the information noted above in
the medical record, and someone capable of programming
the device to “inactive” status should be recruited to
reprogram the device under the direction of the local
physician.
Clinicians involved in device education at the time of
implantation may need to provide more comprehensive in-
formation with regard to end-of-life issues. For example,
clinicians should encourage patients undergoing device im-
plantation to complete advanced directives and specifically
address the matter of device management and deactivation if
the patient is terminally ill.
3.5. Cost-Effectiveness of Implantable
Cardioverter-Defibrillator Therapy
Long-term follow-up studies have consistently demonstrated
that cumulative medical costs are increased substantially
among patients receiving an ICD.17–19,489–491 Several studieshave attempted to weigh whether these added costs are
worthwhile in light of the potential for improved survival
among patients receiving ICD therapy.492 These studies
calculate a cost-effectiveness ratio that is defined as the
difference in the total cost of patients receiving an ICD and
patients receiving alternative therapy, divided by the
additional life-years of survival provided by an ICD
compared with alternative therapy. A benchmark for com-
parison is provided by renal dialysis, which costs approx-
imately $50 000 to add 1 life-year of survival. Cost-
effectiveness, like other outcome measures in clinical
research studies, must be interpreted in light of the
characteristics of the study populations and the length of
follow-up available.
The early studies of ICD cost-effectiveness were based on
mathematical models and relied on nonrandomized studies to
estimate clinical efficacy and cost. These studies found cost-
effectiveness ratios of $17 000,493 $18 100,494 and $29 200 per
year of life saved.495 Another model incorporated costs of
nonthoracotomy ICDs and efficacy estimates based on random-
ized trials and found ICD cost-effectiveness was between
$27 300 and $54 000 per life-year gained, which corresponded
to risk reductions of 40% and 20%, respectively.496
Several randomized clinical trials have measured both cost
and clinical outcomes and thus can directly estimate ICD
cost-effectiveness. MADIT found a 54% reduction in total
mortality and a cost-effectiveness ratio of $27 000 per life-
year added.18 In contrast, CIDS found a 20% reduction in
total mortality and a cost-effectiveness ratio of $139 000 per
life-year added.322,490 The cost-effectiveness ratio from the
AVID trial was $66 677 per life-year added.491 MADIT II
found a 32% reduction in total mortality and $39 200 higher
costs among ICD-assigned patients than among those treated
with conventional therapy.17 The cost-effectiveness ratio in
MADIT II was measured as $235 000 per year of life added
at 2 years of follow-up but was projected to be between
$78 600 and $114 000 per year of life added by 12 years of
follow-up. SCD-HeFT reported that total mortality was re-
duced by 23% and costs increased by $19 000 over 5 years of
follow-up in patients assigned to ICDs compared with pa-
tients assigned to placebo.19 SCD-HeFT estimated the life-
time cost-effectiveness ratio of the ICD strategy was $38 400
per year of life added. This range of results from randomized
studies is primarily due to different estimates of the effective-
ness of the ICD in reducing mortality, because all showed
similar increases in the cost of care among ICD recipients.
When the results of all clinical trials were used in a model that
used a consistent framework to project the full gain in life
expectancy and lifetime costs in each trial,497 the cost-
effectiveness of the ICD ranged from $25 300 to $50 700 per
life-year added in the randomized trials in which the ICD
reduced mortality. In the CABG-Patch trial and DINAMIT,
however, patients assigned to an ICD had lower survival and
higher costs than patients assigned to conventional therapy,
and the ICD strategy was not cost-effective. The evidence
suggests that proper patient selection is necessary for ICD
implantation to be cost-effective; when ICD implantation is
restricted to appropriately selected patients, it has a cost-
effectiveness ratio similar to other accepted cardiovascular
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 therapies and compares well to the standard benchmark of
renal dialysis ($30 000 to $50 000 per year of life saved). In
principle, ICD implantation will be more cost-effective when
used for patients at high risk of arrhythmic death and at low
risk of other causes of death. Additional risk stratification of
patients with a reduced LVEF may improve patient selection
for the ICD and thereby enhance its cost-effectiveness.498
Cost-effectiveness of the ICD would also be improved by
lowering the cost of the device itself and further improving its
reliability and longevity.
The cost-effectiveness of CRT has not been evaluated
extensively. A CRT-P device reduces hospitalization for
heart failure patients, and these cost savings partially offset
the initial cost of device implantation. CRT-P devices are
also effective in improving QOL and may improve sur-
vival. The cost-effectiveness of CRT-P devices versus
medical therapy appears to be favorable. There are few
data on the cost-effectiveness of CRT-D compared with CRT-P
devices.
3.6. Selection of Implantable Cardioverter-
Defibrillator Generators
A single RV lead for sensing and defibrillation is mandatory
for all currently available ICD systems. Single-chamber ICD
systems are capable of bradycardia support in the ventricle
and ATP. Dual-chamber ICD systems (right atrial and RV
leads) are additionally capable of AV sequential pacing.
Triple-chamber ICD systems (right atrial, RV, and LV leads)
are capable of CRT (CRT-D). Despite these increasing
complexities, the optimal hardware system for ICD indica-
tions derived from mortality studies has not been fully
evaluated. There is increasing evidence that choice of hard-
ware may affect important outcomes in ICD patients. This
relates primarily to 2 considerations: 1) management of
ventricular pacing and 2) pain associated with high-voltage
shocks. Conventional ICD therapy in any form may be
associated with worsening heart failure, VT, VF, and noncar-
diac death that can be related to the adverse effects of RVA
pacing.50,51 This is consistent with the increased risks of AF
and heart failure attributable to RVA pacing in pacemaker
trials.45,48 The issue of QOL in the ICD patient population has
been evaluated extensively.460,499–502 Although ICD therapy
is generally well tolerated by most patients, approximately
30% to 50% experience some degree of psychological dis-
tress after implantation.503 One of the principal limitations of
ICD therapy is the discomfort associated with high-voltage
shocks. Several studies have noted a direct correlation be-
tween poor QOL scores and the experience of ICD
shocks.460,499–501
Any hardware system that increases unnecessary ventric-
ular pacing from any site may increase the risk of heart
failure, particularly in patients with poor cardiac ventricular
systolic function.293 The risk of heart failure is increased even
in hearts with initially normal ventricular systolic function
and with part-time ventricular pacing. RVA pacing creates
abnormal contraction, reduced ventricular systolic function,
hypertrophy, and ultrastructural abnormalities. The magni-
tude of the effect relates to the frequency of ventricular pacing
and the degree of pacing-induced mechanical dyssynchronyrather than the hardware system.49 Although these effects have
been demonstrated most clearly during RVA pacing, biventricu-
lar or LV pacing may also induce dyssynchrony in hearts with
normal ventricular conduction504 and can reduce LV systolic
function in patients with no baseline dyssynchrony.505
In patients with no AV block and no intraventricular
conduction abnormalities, ventricular pacing should be
avoided as much as possible. For many ICD patients who do
not have an indication for bradycardia support, this can be
achieved by programming a very low backup ventricular
pacing rate (i.e., 30 to 40 bpm). The optimal management of
cardiac pacing in ICD patients in whom bradycardia support
is required, desired, or emerges is unknown. For ICD patients
with SND in whom bradycardia support is required or
desired, ventricular pacing may be minimized by use of
newer techniques specifically designed to promote intrinsic
conduction.292,506 In patients with AV block, alternate single-
site RV or LV pacing or biventricular pacing (CRT-P/
CRT-D) may be superior to RVA pacing. Efforts to optimize
pacing mode or site should be greater in patients with longer
expected duration of pacing, poorer cardiac function, and
larger mechanical asynchrony. Awareness of the problem of
dyssynchrony should also lead to more regular monitoring of
cardiac ventricular systolic function and mechanical asyn-
chrony in any patient with ventricular pacing.
ATP refers to the use of pacing stimulation techniques for
termination of tachyarrhythmias. Tachycardias that require
reentry to persist are susceptible to termination with pacing.
The most common mechanism of VT in ICD patients is
scar-related reentry. The sine qua non of a re-entrant arrhyth-
mia is the ability to reproducibly initiate and terminate the
tachycardia by critically timed extrastimuli.124 Therefore, the
possibility of successful termination of tachycardias with
pacing can be anticipated on the basis of the mechanism.
Such techniques can be applied automatically with ICDs and
offer the potential for painless termination of VT.
Adjudicated analysis of stored electrograms has revealed
that the majority (approximately 85% to 90%) of spontaneous
ventricular tachyarrhythmias in ICD patients are due to VT
and fast VT, whereas only approximately 10% are due to
VF.507,508 Numerous older studies have consistently demon-
strated that ATP can reliably terminate approximately 85% to
90% of slow VTs (cycle lengths less than 300 milliseconds to
320 milliseconds) with a low risk of acceleration (1% to
5%).509–511 More recently, similarly high rates of success and
low acceleration and syncope rates for fast VTs (average
cycle length 240 milliseconds to 320 milliseconds) have been
demonstrated.507,508 These observations have repositioned the
ICD as primarily an ATP device with defibrillation backup
only as needed. Reduction in painful shocks may improve
patient QOL508 and extend ICD pulse-generator longevity. It
is not yet clear whether important differences in optimal
application of ATP exist in different ICD patient populations.
In general, secondary prevention patients have a greater
frequency of spontaneous ventricular arrhythmia than pri-
mary prevention patients. However, differences in the inci-
dence of specific ventricular rhythms (VT, fast VT, and VF),
response to therapy (ATP or shocks), and susceptibility to
spurious therapies due to SVT are incompletely character-
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 ized.294,512 Differences in substrate may be important as well.
Monomorphic VT associated with chronic ischemic heart
disease is most commonly due to classic reentry and is
therefore susceptible to termination by ATP. Monomorphic
VT is less commonly due to reentry and occurs with lower
frequency in nonischemic DCM.
3.7. Implantable Cardioverter-Defibrillator
Follow-Up
All patients with ICDs require periodic and meticulous
follow-up to ensure safety and optimal device performance, as
well as to monitor a patient’s clinical status.513 The goals of ICD
follow-up include monitoring of device system function; opti-
mization of performance for maximal clinical effectiveness and
system longevity; minimization of complications; anticipation of
replacement of system components and tracking devices under
advisory; ensuring timely intervention for clinical problems;
patient tracking, education, and support; and maintenance of
ICD system records. The importance of device surveillance and
management should be discussed with patients before ICD
implantation. Compliance with device follow-up is an important
element in the evaluation of appropriate candidates for device
therapy and to obtain the best long-term result.
ICD follow-up is best achieved in an organized program
analogous to pacemaker follow-up at outpatient clinics.312
Physicians and institutions performing implantation of these
devices should maintain follow-up facilities for inpatient and
outpatient use. Such facilities should obtain and maintain
implantation and follow-up support devices for all ICDs used
at that facility. The facility should be staffed or supported by
a cardiologist and/or electrophysiologist, who may work in
conjunction with trained associated professionals.312,514,515
Continuous access to these services should be available as
much as feasible on both a regularly scheduled and more
emergent basis. The implantation and/or follow-up facility
should be able to locate and track patients who have received
ICDs or who have entered the follow-up program.
3.7.1. Elements of Implantable Cardioverter-
Defibrillator Follow-Up
The follow-up of an ICD patient must be individualized in
accordance with the patient’s clinical status and conducted by a
physician fully trained in ICD follow-up12; if this is not a
physician fully trained in all aspects of ICD implantation and
follow-up, then such an individual should be available for any
problems that may develop. Direct patient contact is ideal,
allowing for interval history taking, physical examination of the
implantation site, and device programming changes that may be
warranted. Six-month intervals for device follow-up appear to be
safe,516 but more frequent evaluations may be required depend-
ing on the device characteristics and the patient’s clinical status.
Manufacturers’ guidelines for device follow-up may vary with
individual models and should be available. Device automaticity
has facilitated follow-up,316 as has the implementation of remote
monitoring techniques.513,517 Depending on the manufacturer,
remote device interrogation is achieved through Internet-based
systems or via radiofrequency transmissions from the ICD via a
phone device to a central monitoring center; remote reprogram-
ming of devices is not available currently. Remote monitoringmay lessen the dependence on clinic visits, particularly in
patients who live at a considerable distance from the follow-up
clinic, and may allow for the earlier detection of real or potential
problems associated with the device. Guidelines for remote
monitoring have yet to be established. It should be recognized,
furthermore, that remote monitoring is an adjunct to follow-up
and cannot entirely supplant clinic visits.518,519
In general, device programming is initiated at implantation
and may be reviewed periodically. It is often necessary to
reprogram the initially selected parameters either in the outpa-
tient clinic or during electrophysiological testing. When device
function or concomitant antiarrhythmic therapy is modified,
electrophysiological testing may be warranted to evaluate sens-
ing, pacing, or defibrillation functions of the device. Particular
attention should be given to review of sensing parameters,
programmed defibrillation and pacing therapies, device activa-
tion, and event logs. Technical elements that require review
include battery status, lead system parameters, and elective
replacement indicators. Intervening evaluation of device func-
tion is often necessary. In general, when ICD therapy is
delivered, the device should be interrogated.
After implantation of a device, its performance should be
reviewed, limitations on the patient’s specific physical activities
established, and registration accomplished. Current policies on
driving advise patients with an ICD implanted for secondary
prevention to avoid operating a motor vehicle for 6 months after
the last arrhythmic event if it was associated with loss or near
loss of consciousness to determine the pattern of recurrent
VT/VF.520,521 For patients with ICDs implanted for primary
prevention, avoidance of driving for at least 7 days to allow
healing has been recommended.522 Interactions with electromag-
netic interference sources potentially affect employment. Sports
involvement523 and recommendations regarding safeguards for
future surgical procedures524 should be discussed. There are
currently not enough data to make recommendations regarding
antibiotic prophylaxis for procedures or operations required in
the first 6 months after ICD implantation; physicians must weigh
the risks and benefits of antibiotic prophylaxis and use their
judgment in each case. ICD recipients should be encouraged to
carry proper identification and information about their device at
all times. Patients receiving these devices can experience tran-
sient or sustained device-related anxiety. Education and psycho-
logical support before, during, and after ICD insertion are highly
desirable and can improve the patient’s QOL.457,458
Increasing attention has been paid to the safety and efficacy of
implantable devices. It is incumbent upon the follow-up physi-
cian to be aware of advisories issued in relation to potential
device malfunction.2 Specific recommendations for clinicians
managing such advisories are to consider lead/device replace-
ment if death is a likely result of device malfunction; the
mechanism of device/lead failure is known, potentially recur-
rent, and possibly life-threatening; the patient is pacemaker-
dependent; the risk of replacement is substantially lower than the
risk of device malfunction; or the device is approaching its
elective replacement indicator.3 Complications related to re-
placement of ICD generators under advisory have been well
documented, including infection, the need for reoperation, and
death.525 The estimated device failure rate and the likelihood of
mortality resulting from device failure must be weighed against
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 the risk of procedural morbidity and mortality associated with
device replacement. In general, for pacemaker-dependent pa-
tients, advisory device failure rates in excess of 0.3% warrant
consideration of device replacement; in patients with ICD
generators under advisory, an estimated failure rate of 3% favors
replacement in the majority of cases, decreasing to 1% when
procedural mortality rates are 0.1% or less and/or risk of fatal
arrhythmias increases to 20% per year.526 It is anticipated that
the above general recommendations and estimates will vary as a
function of the specific nature of the advisory, how the malfunc-
tion presents, whether early detection and/or reprogramming
may be employed in addressing the potential device failure, and
whether the lead (versus the generator) is affected. This has been
demonstrated, for example, in the case of a recent lead advisory
associated with spurious shocks attributable to lead fracture,
oversensing, and high impedance; reprogramming to minimize
overdetection of noise, enabling of alert features to detect
changes in impedance, and increasing utilization of remote
monitoring to follow such leads may have an effect on future
rates of invasive lead replacement and/or extraction.527
3.7.2. Focus on Heart Failure After First
Appropriate Implantable Cardioverter-Defibrillator
Therapy
In patients with heart failure who have not previously had a
life-threatening arrhythmia, the first event identifies them as
being at higher risk than before for both sudden death and death
due to heart failure, with the majority of patients surviving less
than 2 years.17,19 It is not known to what extent these herald
events serve as markers or as contributors to progression of
disease. They should trigger reevaluation of treatable causes of
heart failure and of the medical regimen. In addition, the
treatment regimen should be evaluated for interventions that
may decrease the risk of arrhythmia recurrence. Particular care
should be paid to the titration of beta-adrenergic blockers. These
agents have been shown to decrease disease progression and
improve outcomes, but uptitration can lead to heart failure
exacerbation and must be attempted gradually in small dose
increments. Many patients with symptomatic heart failure can-
not tolerate “target doses” of beta-adrenergic blockers, whether
used primarily for the indication of heart failure or to prevent
recurrent arrhythmias. Although patients with heart failure who
have had device therapy would ideally be followed up by
specialists in both arrhythmia management and heart failure
management, most patients do not have routine access to such
settings. To maximize the benefit after a sudden death has been
prevented, it is crucial that the management team evaluate the
heart failure profile, review the medical regimen, and plan for
ongoing care.
4. Areas in Need of Further Research
The ACC/AHA Task Force on Practice Guidelines has
charged writing committees to suggest areas in need of
further research. To this end, the present writing committee
offers the following suggestions. They are presented in
tabular form for ease of readability. Their order does not
imply any order of priority.1. Optimal access to device therapy should be provided to
all eligible populations irrespective of sex and ethnicity.
2. Risk stratification of patients meeting current clinical
indications for primary prevention ICD implantation
should be improved to better target therapy to those most
likely to benefit from it.
3. Identification of patients most likely to benefit from/
respond to CRT must be improved.
4. Identify patients without current pacemaker or ICD
indications among those who may benefit from such
therapies.
5. Indicators should be identified that provide direction
about when it is safe to not replace an ICD that has
reached the end of its effective battery life.
6. The cost-effectiveness of device therapy should be ex-
plored further.
7. Guidelines for remote monitoring should be developed.
8. Ways to improve reliability and longevity of leads and
generators must be found, as well as methods to ensure
discovery of performance issues when they arise.
9. Representation of the elderly in clinical trials should be
increased.
10. The influence of age on procedural complication rates
and the risk/benefit ratio for device implantation should
be defined.
11. The effect (positive, negative, or neutral) of biventricular
or LV stimulation in patients with normal ventricular
function should be determined.
12. The need for pacing after MI in the current era should be
determined.
13. Long-term outcomes and risk factors for patients receiv-
ing ICDs in general practice compared with trial popu-
lations and at academic centers should be identified and
described.
14. Guidelines for device management in patients with ter-
minal illness or other requests to terminate device ther-
apy should be developed.
15. The role of ICDs in primary prevention for children with
genetic channelopathies, cardiomyopathies, and congenital
heart defects should be defined more precisely.
16. The efficacy of biventricular pacing in children with
congenital heart disease and dilated cardiomyopathy
should be determined.
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 Appendix 3. Abbreviations List
ACC  American College of Cardiology
ACCF  American College of Cardiology Foundation
AF  Atrial fibrillation
AHA  American Heart Association
AMI  Acute myocardial infarction
AMIOVIRT  Amiodarone Versus Implantable Defibrillator in Patients with Non
ARVD/C  Arrhythmogenic right ventricular dysplasia/cardiomyopathy
ATP  Antitachycardia pacing
AV  Atrioventricular
AVID  Antiarrhythmics Versus Implantable Defibrillators
CABG-Patch  Coronary Artery Bypass Graft-Patch
CARE-HF  Cardiac Resynchronization in Heart Failure
CASH  Cardiac Arrest Study Hamburg
CAT  Cardiomyopathy Trial
CIDS  Canadian Implantable Defibrillator Study
COMPANION  Comparison of Medical Therapy, Pacing, and Defibrillation in
CRT  Cardiac resynchronization therapy
CRT-D  Cardiac resynchronization therapy device incorporating both pacing
CRT-P  Cardiac resynchronization device providing pacing but not defibrilla
CTOPP  Canadian Trial of Physiologic Pacing
DCM  Dilated cardiomyopathy
DDD  Dual-chamber pacemaker that senses/paces in the atrium/ventricle a
DEFINITE  Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluati
DINAMIT  Defibrillator in Acute Myocardial Infarction Trial
ECG  Electrocardiograph
HCM  Hypertrophic cardiomyopathy
HR  Hazard ratio
HRS  Heart Rhythm Society
ICD  Implantable cardioverter-defibrillator
LV  Left ventricular/left ventricle
LVEF  Left ventricular ejection fraction
MADIT I  Multicenter Automatic Defibrillator Implantation Trial I
MADIT II  Multicenter Automatic Defibrillator Implantation Trial II
MI  Myocardial infarction
MOST  Mode Selection Trial
MUSTT  Antiarrhythmic Drug Therapy in the Multicenter UnSustained Tachy
NYHA  New York Heart Association
PainFREE Rx II  Pacing Fast VT Reduces Shock Therapies Trial II
PASE  Pacemaker Selection in the Elderly
PAVE  Left Ventricular-Based Cardiac Stimulation Post AV Nodal Ablation Ev
QOL  Quality of life
RV  Right ventricular/right ventricle
RVA  Right ventricular apical
SCD  Sudden cardiac death
SCD-HeFT  Sudden Cardiac Death in Heart Failure Trial
SND  Sinus node dysfunction
SVT  Supraventricular tachycardia
TTM  Transtelephonic monitoring
UK-PACE  United Kingdom Pacing and Cardiovascular Events
VF  Ventricular fibrillation
VPS  Vasovagal Pacemaker Study I
VPS-II  Vasovagal Pacemaker Study II
VT  Ventricular tachycardiaischemic Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia
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In the article by Epstein et al, “ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of
Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/
NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia
Devices),” which published ahead of print on May 15, 2008, and appeared in the May 27, 2008,
online issue of the journal (Circulation. 2008;117:e350–e408), several corrections were needed.
1. On page e365, in the second column, the last complete paragraph, the first sentence read,
“The major experience with resynchronization . . . and LVEF less than 35%.” It has been
changed to read, “The major experience with resynchronization . . . and LVEF less than or
equal to 35%.”
2. On page e370, in Table 2, for “Dual-chamber pacemaker,” under the column heading
“Atrioventricular Block,” there was a duplication of “Rate response available if desired.”
The first instance has been deleted.
3. On page e376, in the first column, under the heading “3. Indications for Implantable
Cardioverter-Defibrillator Therapy,” the second paragraph, the second sentence read, “The
LVEF used in clinical trials assessing the ICD for primary prevention of SCD ranged from
less than 40% in MUSTT (Multicenter Unsustained Ventricular Tachycardia Trial) to less
than 30% in MADIT II (Multicenter Automatic Defibrillator Implantation Trial II).329,332 ”
It has been changed to read, “The LVEF used in clinical trials assessing the ICD for
primary prevention of SCD ranged from less than or equal to 40% in MUSTT (Multicenter
Unsustained Ventricular Tachycardia Trial) to less than or equal to 30% in MADIT II
(Multicenter Automatic Defibrillator Implantation Trial II).329,332 ”
4. On page e376, in the first column, under the heading “3. Indications for Implantable
Cardioverter-Defibrillator Therapy,” the second paragraph, the third sentence read, “Two
trials, MADIT I (Multicenter Automatic Defibrillator Implantation Trial I)327 and SCD-
HeFT (Sudden Cardiac Death in Heart Failure Trial),333 used LVEFs of less than 35% as
entry criteria.” It has been changed to read, “Two trials, MADIT I (Multicenter Automatic
Defibrillator Implantation Trial I)327 and SCD-HeFT (Sudden Cardiac Death in Heart
Failure Trial),333 used LVEFs of less than or equal to 35% as entry criteria.”
5. On page e379, in Table 5, the following changes have been made:
● For the CABG-Patch trial,328 the value of p (in the last column) has been changed from 0.63
to 0.64.
● For the AVID trial,319 the value of p (in the last column) has been changed from NS to
0.02.
6. On page e383, in the second column, under the heading “Recommendations for Implant-
able Cardioverter Defibrillators,” the third paragraph, the second sentence read, “The
LVEF used in clinical trials assessing the ICD for primary prevention of SCD ranged from
less than 40% in MUSTT to less than 30% in MADIT II.329,332 ” It has been changed to read,
“The LVEF used in clinical trials assessing the ICD for primary prevention of SCD ranged
from less than or equal to 40% in MUSTT to less than or equal to 30% in MADIT II.329,332 ”
(Circulation. 2009;120:e34-e35.)
© 2009 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org
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Correction
7. On page e383, in the second column, under the heading “Recommendations for Implant-
able Cardioverter Defibrillators,” the third paragraph, the third sentence read, “Two trials,
MADIT I18 and SCD-HeFT19 used LVEFs of less than 35% as entry criteria for the trial.”
It has been changed to read, “Two trials, MADIT I18 and SCD-HeFT19 used LVEFs of less
than or equal to 35% as entry criteria for the trial.”
8. On page e384, in the first column, under the Class I heading, Recommendation 4 read,
“ICD therapy is indicated in patients with LVEF less than 35% due to prior MI . . . .” It has
been changed to read, “ICD therapy is indicated in patients with LVEF less than or equal
to 35% due to prior MI . . . .”
9. On page e384, in the first column, under the Class I heading, Recommendation 6 read,
“ICD therapy is indicated in patients with LV dysfunction due to prior MI who are at least
40 days post-MI, have an LVEF less than 30% . . . .” It has been changed to read, “ICD
therapy is indicated in patients with LV dysfunction due to prior MI who are at least 40
days post-MI, have an LVEF less than or equal to 30% . . . .”
10. On page e384, in the first column, under the Class I heading, Recommendation 7 read,
“ICD therapy is indicated in patients with nonsustained VT due to prior MI, LVEF less than
40% . . . .” It has been changed to read, “ICD therapy is indicated in patients with
nonsustained VT due to prior MI, LVEF less than or equal to 40% . . . .”
11. On page e388, in the first column, the first complete paragraph, the first sentence read,
“Among 204 elderly patients with prior MI and LVEF less than 30% enrolled in MADIT
II . . . .” It has been changed to read, “Among 204 elderly patients with prior MI and LVEF
less than or equal to 30% enrolled in MADIT II . . . .”
These corrections have been made to the current online version of the article, which is available
at http://circ.ahajournals.org/cgi/content/full/117/21/e350.
DOI: 10.1161/CIRCULATIONAHA.109.192622
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